Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
Cameron J. Turtle, … , Stanley R. Riddell, David G. Maloney
Cameron J. Turtle, … , Stanley R. Riddell, David G. Maloney
Published April 25, 2016
Citation Information: J Clin Invest. 2016;126(6):2123-2138. https://doi.org/10.1172/JCI85309.
View: Text | PDF
Clinical Research and Public Health Oncology Article has an altmetric score of 217

CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients

  • Text
  • PDF
Abstract

BACKGROUND. T cells that have been modified to express a CD19-specific chimeric antigen receptor (CAR) have antitumor activity in B cell malignancies; however, identification of the factors that determine toxicity and efficacy of these T cells has been challenging in prior studies in which phenotypically heterogeneous CAR–T cell products were prepared from unselected T cells.

METHODS. We conducted a clinical trial to evaluate CD19 CAR–T cells that were manufactured from defined CD4+ and CD8+ T cell subsets and administered in a defined CD4+:CD8+ composition to adults with B cell acute lymphoblastic leukemia after lymphodepletion chemotherapy.

RESULTS. The defined composition product was remarkably potent, as 27 of 29 patients (93%) achieved BM remission, as determined by flow cytometry. We established that high CAR–T cell doses and tumor burden increase the risks of severe cytokine release syndrome and neurotoxicity. Moreover, we identified serum biomarkers that allow testing of early intervention strategies in patients at the highest risk of toxicity. Risk-stratified CAR–T cell dosing based on BM disease burden decreased toxicity. CD8+ T cell–mediated anti-CAR transgene product immune responses developed after CAR–T cell infusion in some patients, limited CAR–T cell persistence, and increased relapse risk. Addition of fludarabine to the lymphodepletion regimen improved CAR–T cell persistence and disease-free survival.

CONCLUSION. Immunotherapy with a CAR–T cell product of defined composition enabled identification of factors that correlated with CAR–T cell expansion, persistence, and toxicity and facilitated design of lymphodepletion and CAR–T cell dosing strategies that mitigated toxicity and improved disease-free survival.

TRIAL REGISTRATION. ClinicalTrials.gov NCT01865617.

FUNDING. R01-CA136551; Life Science Development Fund; Juno Therapeutics; Bezos Family Foundation.

Authors

Cameron J. Turtle, Laïla-Aïcha Hanafi, Carolina Berger, Theodore A. Gooley, Sindhu Cherian, Michael Hudecek, Daniel Sommermeyer, Katherine Melville, Barbara Pender, Tanya M. Budiarto, Emily Robinson, Natalia N. Steevens, Colette Chaney, Lorinda Soma, Xueyan Chen, Cecilia Yeung, Brent Wood, Daniel Li, Jianhong Cao, Shelly Heimfeld, Michael C. Jensen, Stanley R. Riddell, David G. Maloney

×

Total citations by year

Year: 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2009 Total
Citations: 39 134 138 172 156 163 117 127 86 30 1 1163
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article (1163)

Title and authors Publication Year
Molecular dynamics at immune synapse lipid rafts influence the cytolytic behavior of CAR T cells
Gad AZ, Morris JS, Godret-Miertschin L, Montalvo MJ, Kerr SS, Berger H, Lee JC, Saadeldin AM, Abu-Arja MH, Xu S, Vasileiou S, Brock RM, Fousek K, Sheha MF, Srinivasan M, Li Y, Saeedi A, R. Levental K, Leen AM, Mamonkin M, Carisey A, Varadarajan N, Hegde M, Joseph SK, Levental I, Mukherjee M, Ahmed N
Science Advances 2025
Harnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transition
Glaviano A, Lau HS, Carter LM, Lee EH, Lam HY, Okina E, Tan DJ, Tan W, Ang HL, Carbone D, Yee MY, Shanmugam MK, Huang XZ, Sethi G, Tan TZ, Lim LH, Huang RY, Ungefroren H, Giovannetti E, Tang DG, Bruno TC, Luo P, Andersen MH, Qian BZ, Ishihara J, Radisky DC, Elias S, Yadav S, Kim M, Robert C, Diana P, Schalper KA, Shi T, Merghoub T, Krebs S, Kusumbe AP, Davids MS, Brown JR, Kumar AP
Journal of Hematology & Oncology 2025
Advancements and Future Directions of Dual-Target Chimeric Antigen Receptor T-Cell Therapy in Preclinical and Clinical Studies
Zhang C, Liu H
Journal of Immunology Research 2025
LLT1 overexpression renders allogeneic-NK resistance and facilitates the generation of enhanced universal CAR-T cells
Zhu S, Zuo S, Li C, You X, Jiang E, Feng X, Luo Y
Journal of Experimental & Clinical Cancer Research : CR 2025
A multi-kinase inhibitor screen identifies inhibitors preserving stem-cell-like chimeric antigen receptor T cells
Song F, Tsahouridis O, Stucchi S, Walhart T, Mendell S, Hardy PB, Axtman M, Guduru SK, Gilbert TS, Graves LM, Herring LE, Savoldo B, Ma X, Woodcock M, Milner JJ, Ivanova A, Pearce KH, Xu Y, Dotti G
Nature Immunology 2025
Enforced E-selectin ligand installation enhances homing and efficacy of adoptively transferred T cells
Hou Y, Ye J, Qin K, Cui LA, Chung S, Chapla DG, Wang W, Shi Y, Chen M, Moremen KW, Sackstein R, Wu P
bioRxiv 2025
Taming Variability in T-Cell Mechanosensing
Schultheiss PJ, Pulkundwar A, Li W, Kam LC
Cells 2025
Leveraging Vector-Based Gene Disruptions to Enhance CAR T-Cell Effectiveness
Oliveira BC, Bari S, Melenhorst JJ
Cancers 2025
Scalable intracellular delivery via microfluidic vortex shedding enhances the function of chimeric antigen receptor T-cells
Sytsma BJ, Allain V, Bourke S, Faizee F, Fathi M, Ferreira LM, Brewer WJ, Li L, Pan FL, Rothrock AG, Nyberg WA, Li Z, Wilson LH, Berdeaux R, Eyquem J, Pawell RS
Scientific Reports 2025
CAR‐T Cell Manufacturing for Hematological and Solid Tumors: From the Preclinical to Clinical Point of View
Capolla S, Rasool M, Toffoli G, Dal Bo M
Cancer Medicine 2025
Clinical evidence of immunogenicity of CAR-T cell therapies and its implication in the clinical development of CAR-T drug products
Alfar HR, Chen C, Lachacz E, Tang W, Zhang Y
Frontiers in Immunology 2025
Influence of CAR T-cell therapy associated complications
Umair MM, Lai X, Xue Y, Yao H
Frontiers in Oncology 2025
IFN-gamma and donor leukocyte infusions for relapsed myeloblastic malignancies after allogeneic hematopoietic stem cell transplantation 
Sawa Ito, Emily M Geramita, Kedwin Ventura, Biswas Neupane, Shruti S Bhise, Erika M. Moore, Scott N Furlan, Warren Shlomchik
JCI Insight 2025
Cytokine-mediated increase in endothelial-leukocyte interaction mediates brain capillary plugging during CAR T cell neurotoxicity
Park L, Tsai YT, Lim HK, Faulhaber LD, Burleigh K, Faulhaber EM, Bose M, Shih AY, Hirayama AY, Turtle CJ, Annesley CE, Gardner RA, Gustafson HH, Gust J
bioRxiv 2025
Emerging Frontiers in Colorectal Cancer Therapy: From Targeted Molecules to Immunomodulatory Breakthroughs and Cell-Based Approaches
Fatemi N, Mirbahari SN, Tierling S, Sanjabi F, Shahrivari S, AmeliMojarad M, Amelimojarad M, Mirzaei Rezaei M, Nobaveh P, Totonchi M, Nazemalhosseini Mojarad E
Digestive Diseases and Sciences 2025
The Changing Role of Allogeneic Stem Cell Transplantation in Adult B-ALL in the Era of CAR T Cell Therapy
van den Berg J, Meloni C, Halter J, Passweg JR, Holbro A
Current Oncology 2025
On-demand treatment of metabolic diseases by a synthetic drug-inducible exocytosis system
Si Y, He M, Li Y, Jiang J, Fan Y, Xue S, Qiu X, Xie M
Nature Communications 2025
Two-Stage CD8+ CAR T-Cell Differentiation in Patients with Large B-Cell Lymphoma
Cao G, Hu Y, Pan T, Tang E, Asby N, Althaus T, Wan J, Riedell PA, Bishop MR, Kline JP, Huang J
bioRxiv 2025
CD22 TCR-engineered T cells exert antileukemia cytotoxicity without causing inflammatory responses
Nguyen KA, Liu Z, Davies JS, McIntosh CP, Draper LM, Norberg SM, Rae Z, Achar SR, Altan-Bonnet G, Zhang L, Wu X, Meyer TJ, Kelly MC, Taylor N, Hinrichs CS, Ishii K
Science Advances 2025
New player in CAR-T manufacture field: comparison of umbilical cord to peripheral blood strategies
Rassek K, Misiak J, Ołdak T, Rozwadowska N, Basak G, Kolanowski T
Frontiers in Immunology 2025
Strategies for Altering Delivery Technologies to Optimize CAR Therapy
Cao L, Liu Y, Lin G
International Journal of Molecular Sciences 2025
Phase 1 study of CD19 CAR T-cell therapy harboring a fully human scFv in CAR-naïve adult patients with B-ALL
Gauthier J, Liang EC, Huang JJ, Kimble EL, Hirayama AV, Fiorenza S, Voutsinas JM, Wu Q(, Jaeger-Ruckstuhl CA, Pender BS, Kirchmeier DR, Torkelson A, Braathen K, Basom R, Shadman M, Kopmar NE, Cassaday RD, Riddell SR, Maloney DG, Turtle CJ
Blood Advances 2025
MARC, a novel modular chimeric antigen receptor, improves T cell-based cancer immunotherapies by preventing early T cell exhaustion and enhancing persistence
Tual M, Bellemare-Pelletier A, Moore S, Guipouy D, Farzam-Kia N, Jafarzadeh L, Quenneville J, Barrette B, Saba-El-Leil MK, Delisle JS, Gagnon E
Journal for Immunotherapy of Cancer 2025
Humanizing CAR T-cell therapy in B-ALL
Faramand R, Muffly L
Blood Advances 2025
Novel strategies to manage CAR-T cell toxicity.
Mulvey A, Trueb L, Coukos G, Arber C
Nature reviews. Drug discovery 2025
GPR65 Inactivation in Tumor Cells Drives Antigen-Independent CAR T-cell Resistance via Macrophage Remodeling.
Mavuluri J, Dhungana Y, Jones LL, Bhatara S, Shi H, Yang X, Lim SE, Reyes N, Chi H, Yu J, Geiger TL
Cancer discovery 2025
Two-stage CD8(+) CAR T-cell differentiation in patients with large B-cell lymphoma.
Cao G, Hu Y, Pan T, Tang E, Asby N, Althaus T, Wan J, Riedell PA, Bishop MR, Kline JP, Huang J
Nature communications 2025
Defining immune reset: achieving sustained remission in autoimmune diseases.
Junt T, Calzascia T, Traggiai E, da Costa AN, Gergely P, Schett G, Dörner T, Siegel RM
Nature reviews. Immunology 2025
Cellular Kinetics and Biodistribution of Adoptive T Cell Therapies: from Biological Principles to Effects on Patient Outcomes.
Li R, Grosskopf AK, Joslyn LR, Stefanich EG, Shivva V
The AAPS journal 2025
CAR T or NK cells targeting mismatched HLA-DR molecules in acute myeloid leukemia after allogeneic hematopoietic stem cell transplant.
Ikeda S, Hasegawa K, Kogue Y, Arimori T, Kawamoto R, Wibowo T, Yaga M, Inada Y, Uehara H, Matsubara M, Tachikawa M, Suga M, Kida S, Shibata K, Tsutsumi K, Fukushima K, Fujita J, Ueda T, Kusakabe S, Hino A, Ichii M, Hirose A, Nakamae H, Hino M, Nakao T, Inoue M, Yoshihara K, Yoshihara S, Ueda S, Tachi T, Kuroda H, Murakami K, Kijima N, Kishima H, Igashira E, Murakami M, Takiuchi T, Kimura T, Hiroshima T, Kimura T, Shintani Y, Imai C, Yusa K, Mori R, Ogino T, Eguchi H, Takeda K, Oji Y, Kumanogoh A, Takagi J, Hosen N
Nature cancer 2025
Mitigation and Management of Common Toxicities Associated with the Administration of CAR-T Therapies in Oncology Patients.
Renninger J, Kurz L, Stein H
Drug safety 2025
Revolutionizing Cancer Treatment: Unveiling the Power of CAR T-cell Therapy.
Barjasteh AH, Saebi M, Mahmoudi M, Kheder RK, Hashemy SI, Forouzanfar F, Esmaeili SA
Current pharmaceutical design 2025
An Analysis of Monitoring Solutions for CAR T Cell Production.
Shoshi A, Xia Y, Fieschi A, Baumgarten Y, Gaißler A, Ackermann T, Reimann P, Mitschang B, Weyrich M, Bauernhansl T, Miehe R
Healthcare technology letters 2025
BCMA CAR T cells in a patient with relapsing idiopathic inflammatory myositis after initial and repeat therapy with CD19 CAR T cells.
Müller F, Wirsching A, Hagen M, Völkl S, Tur C, Raimondo MG, Taubmann J, Bucci L, Zhang L, Kretschmann S, Aigner M, Eckstein M, Spörl S, Kharboutli S, Böltz S, Atzinger A, Munoz L, Schett G, Mackensen A, Grieshaber-Bouyer R
Nature medicine 2025
Letetresgene Autoleucel in Advanced/Metastatic Myxoid/Round Cell Liposarcoma
D'Angelo SP, Druta M, Van Tine BA, Liebner D, Schuetze SM, Tap WD, Preston J, Goodison S, D'Souza JW, Kapoor GS, Suchindran S, Zajic S, Bhaskar A, Kaczynski H, Kim J, Klohe E, Corigliano E, Eleftheriadou I, Nathenson MJ, Somaiah N
Journal of Clinical Oncology 2025
High-dimensional temporal mapping of CAR T cells reveals phenotypic and functional remodeling during manufacturing
Cadinanos-Garai A, Flugel CL, Cheung A, Jiang E, Vaissié A, Abou-el-Enein M
Molecular Therapy 2025
Efficacy and safety of a novel CD19, CD22 dual-targeted fully human loop bi-CAR-T for the treatment of relapsed/refractory B cell non-Hodgkin lymphoma
Wang H, Wang G, Li T, Zhang P, Mao Z, Luo H, Zhu X, Li D, Zhou J, Zhou X, Huang L
Journal of Translational Medicine 2025
CAR binders affect CAR T-cell tonic signaling, durability, and sensitivity to target
Shukla D, Gabunia K, McGettigan SE, Patel PR, Christensen S, Fan TJ, Song D, Luo Y, Wang Y, Wang H, Young RM, June CH, Scholler J, Riley JL
Cancer immunology research 2025
Anti-HIV-1 HSPC-based gene therapy with safety kill switch to defend against and attack HIV-1 infection
Guo Q, Parikh K, Zhang J, Brinkley A, Chen G, Jakramonpreeya N, Zhen A, An DS
Molecular Therapy. Methods & Clinical Development 2025
TMIGD2 is a new and effective costimulatory domain in CAR-T cells treating human solid tumors
Christopher Nishimura, Devin Corrigan, Xiang Zheng, Phillip Galbo Jr, Shan Wang, Yao Liu, Yao Wei, Linna Suo, Wei Cui, Nadia Mercado, Deyou Zheng, Chengcheng Zhang, Xingxing Zang
Science Advances 2024
Immune evasion in cell-based immunotherapy: unraveling challenges and novel strategies.
Li YR, Halladay T, Yang L
Journal of biomedical science 2024
Endogenous Signaling Molecule Activating (ESMA) CARs: A Novel CAR Design Showing a Favorable Risk to Potency Ratio for the Treatment of Triple Negative Breast Cancer
Ebbinghaus M, Wittich K, Bancher B, Lebedeva V, Appelshoffer A, Femel J, Helm MS, Kollet J, Hardt O, Pfeifer R
International journal of molecular sciences 2024
CAR T cells for hematological malignancies
Savoldo B, Grover N, Dotti G
Journal of Clinical Investigation 2024
CAR-T Cell Therapy for Follicular Lymphomas.
Testa U, D'Alò F, Pelosi E, Castelli G, Leone G
Mediterranean journal of hematology and infectious diseases 2024
Neutrophil activation and clonal CAR-T re-expansion underpinning cytokine release syndrome during ciltacabtagene autoleucel therapy in multiple myeloma.
Yang S, Xu J, Dai Y, Jin S, Sun Y, Li J, Liu C, Ma X, Chen Z, Chen L, Hou J, Mi JQ, Chen SJ
Nature Communications 2024
Early predictive factors of failure in autologous CAR T-cell manufacturing and/or efficacy in hematologic malignancies.
Baguet C, Larghero J, Mebarki M
Blood Advances 2024
Nonactivated and IL-7 cultured CD19-specific CAR T cells are enriched in stem cell phenotypes and functionally superior.
Wang SY, Scurti GM, Dalheim AV, Quinn S, Stiff PJ, Nishimura MI
Blood Advances 2024
"Digital twins elucidate critical role of T(scm) in clinical persistence of TCR-engineered cell therapy".
Joslyn LR, Huang W, Miles D, Hosseini I, Ramanujan S
npj Systems Biology and Applications 2024
Cancer Nano-Immunotherapy: The Novel and Promising Weapon to Fight Cancer.
García-Domínguez DJ, López-Enríquez S, Alba G, Garnacho C, Jiménez-Cortegana C, Flores-Campos R, de la Cruz-Merino L, Hajji N, Sánchez-Margalet V, Hontecillas-Prieto L
International journal of molecular sciences 2024
Treatment strategies for relapse after CAR T-cell therapy in B cell lymphoma
Negishi S, Girsch JH, Siegler EL, Bezerra ED, Miyao K, Sakemura RL
Frontiers in Pediatrics 2024
Engineered T cells from induced pluripotent stem cells: from research towards clinical implementation
Netsrithong R, Garcia-Perez L, Themeli M
Frontiers in immunology 2024
A CAR-T response prediction model for r/r B-NHL patients based on a T cell subset nomogram
Zhang X, Sun R, Zhang M, Zhao Y, Cao X, Guo R, Zhang Y, Liu X, Lyu C, Zhao M
Cancer Immunology, Immunotherapy 2024
CAR‑T cell therapy: A breakthrough in traditional cancer treatment strategies (Review).
Sun D, Shi X, Li S, Wang X, Yang X, Wan M
Molecular medicine reports 2024
Targeting the mevalonate or Wnt pathways to overcome CAR T-cell resistance in TP53-mutant AML cells.
Mueller J, Schimmer RR, Koch C, Schneiter F, Fullin J, Lysenko V, Pellegrino C, Klemm N, Russkamp N, Myburgh R, Volta L, Theocharides AP, Kurppa KJ, Ebert BL, Schroeder T, Manz MG, Boettcher S
EMBO Molecular Medicine 2024
Liquid biopsy approach to monitor the efficacy and response to CAR-T cell therapy
Shishido SN, Hart O, Jeong S, Moriarty A, Heeke D, Rossi J, Bot A, Kuhn P
Journal for ImmunoTherapy of Cancer 2024
Inhibition of CD38 enzymatic activity enhances CAR-T cell immune-therapeutic efficacy by repressing glycolytic metabolism.
Huang Y, Shao M, Teng X, Si X, Wu L, Jiang P, Liu L, Cai B, Wang X, Han Y, Feng Y, Liu K, Zhang Z, Cui J, Zhang M, Hu Y, Qian P, Huang H
Cell reports. Medicine 2024
GMP-manufactured CRISPR/Cas9 technology as an advantageous tool to support cancer immunotherapy
Caforio M, Iacovelli S, Quintarelli C, Locatelli F, Folgiero V
Journal of experimental & clinical cancer research : CR 2024
Mechanical forces amplify TCR mechanotransduction in T cell activation and function.
Jeffreys N, Brockman JM, Zhai Y, Ingber DE, Mooney DJ
2024
Understanding Mechanisms of Response to CAR T-cell Therapy through Single-Cell Sequencing: Insights and Challenges.
Haradhvala NJ, Maus MV
2024
Disruption of SUV39H1-Mediated H3K9 Methylation Sustains CAR T-cell Function.
Jain N, Zhao Z, Koche RP, Antelope C, Gozlan Y, Montalbano A, Brocks D, Lopez M, Dobrin A, Shi Y, Gunset G, Giavridis T, Sadelain M
Cancer Discovery 2024
CAR T therapies in multiple myeloma: unleashing the future.
Sheykhhasan M, Ahmadieh-Yazdi A, Vicidomini R, Poondla N, Tanzadehpanah H, Dirbaziyan A, Mahaki H, Manoochehri H, Kalhor N, Dama P
Cancer Gene Therapy 2024
Chimeric Antigen Receptor T Cell Therapy for Hepatocellular Carcinoma: Where Do We Stand?
Aggeletopoulou I, Kalafateli M, Triantos C
International journal of molecular sciences 2024
Worldwide research trends on tumor burden and immunotherapy: a bibliometric analysis
Zhang L, Zheng H, Jiang ST, Liu YG, Zhang T, Zhang JW, Lu X, Zhao HT, Sang XT, Xu YY
International journal of surgery (London, England) 2024
Key role of CD4+ T cells in determining CD8 function during CAR-T cell manufacture
Melenhorst JJ, Oliveira BC
Journal for ImmunoTherapy of Cancer 2024
CAR-engineered lymphocyte persistence is governed by a FAS ligand/FAS auto-regulatory circuit
Yi F, Cohen T, Zimmerman N, Dündar F, Zumbo P, Eltilib R, Brophy EJ, Arkin H, Feucht J, Gormally MV, Hackett CS, Kropp KN, Etxeberria I, Chandran SS, Park JH, Hsu KC, Sadelain M, Betel D, Klebanoff CA
2024
Making drugs from T cells: The quantitative pharmacology of engineered T cell therapeutics.
Kirouac DC, Zmurchok C, Morris D
npj Systems Biology and Applications 2024
Early induction of cytokine release syndrome by rapidly generated CAR T cells in preclinical models.
Jamali A, Ho N, Braun A, Adabi E, Thalheimer FB, Buchholz CJ
EMBO Molecular Medicine 2024
Automated manufacture of ΔNPM1 TCR-engineered T cells for AML therapy
Yonezawa Ogusuku IE, Herbel V, Lennartz S, Brandes C, Argiro E, Fabian C, Hauck C, Hoogstraten C, Veld S, Hageman L, Teppert K, Koutsoumpli G, Griffioen M, Mockel-Tenbrinck N, Schaser T, de Groot R, Johnston IC, Lock D
2024
Transient acute kidney injury after chimeric antigen receptor T-cell therapy in patients with hematological malignancies
León-Román J, Iacoboni G, Bermejo S, Carpio C, Bolufer M, García-Carro C, Sánchez-Salinas M, Alonso-Martínez C, Bestard O, Barba P, Soler MJ
Clinical Kidney Journal 2024
Biomarkers for prediction of CAR T therapy outcomes: current and future perspectives
Levstek L, Janžič L, Ihan A, Kopitar AN
Frontiers in immunology 2024
Novel insights into TCR-T cell therapy in solid neoplasms: optimizing adoptive immunotherapy
Shao W, Yao Y, Yang L, Li X, Ge T, Zheng Y, Zhu Q, Ge S, Gu X, Jia R, Song X, Zhuang A
Experimental Hematology and Oncology 2024
Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors
Chen T, Wang M, Chen Y, Liu Y
Cancer Cell International 2024
Self-regulating CAR-T cells modulate cytokine release syndrome in adoptive T-cell therapy
Lin MY, Nam E, Shih RM, Shafer A, Bouren A, Ayala Ceja M, Harris C, Khericha M, Vo KH, Kim M, Tseng CH, Chen YY
Journal of Experimental Medicine 2024
Tumor microenvironment reprogramming by nanomedicine to enhance the effect of tumor immunotherapy
Huang Y, Fan H, Ti H
Asian Journal of Pharmaceutical Sciences 2024
Torque Teno Virus DNA Load in Blood as an Immune Status Biomarker in Adult Hematological Patients: The State of the Art and Future Prospects
Albert E, Giménez E, Hernani R, Piñana JL, Solano C, Navarro D
Viruses 2024
Maintenance therapy for early loss of B-cell aplasia after anti-CD19 CAR T-cell therapy.
Gabelli M, Oporto-Espuelas M, Burridge S, Chu J, Farish S, Hedges E, Ware K, Williams L, Young L, Alajangi R, Ancliff P, Bartram J, Bonney D, Chenchara L, Chiesa R, Cugno C, Hodby K, Jalowiec KA, Lazareva A, Lucchini G, Mirci-Danicar OC, Mullanfiroze K, Pavasovic V, Rao A, Rao K, Riley L, Samarasinghe S, Shenton G, Silva J, Vora A, Hough R, Amrolia PJ, Ghorashian S
Blood Advances 2024
Therapeutic bacteria and viruses to combat cancer: double-edged sword in cancer therapy: new insights for future
Yarahmadi A, Zare M, Aghayari M, Afkhami H, Jafari GA
Cell communication and signaling : CCS 2024
Development of a compact bidirectional promoter-driven dual chimeric antigen receptor (CAR) construct targeting CD19 and CD20 in the Sleeping Beauty (SB) transposon system
Khaniya A, Rad SM, Halpin J, Tawinwung S, McLellan A, Suppipat K, Hirankarn N
Journal for ImmunoTherapy of Cancer 2024
Immunotherapy of Hematological Malignancies of Human B-Cell Origin with CD19 CAR T Lymphocytes
Khvorost D, Kendall B, Jazirehi AR
Cells 2024
In vitro encapsulation and expansion of T and CAR-T cells using 3D synthetic thermo-responsive matrices
Lizana-Vasquez GD, Mendez-Vega J, Cappabianca D, Saha K, Torres-Lugo M
RSC Advances 2024
Autologous HER2-specific CAR T cells after lymphodepletion for advanced sarcoma: a phase 1 trial.
Hegde M, Navai S, DeRenzo C, Joseph SK, Sanber K, Wu M, Gad AZ, Janeway KA, Campbell M, Mullikin D, Nawas Z, Robertson C, Mathew PR, Zhang H, Mehta B, Bhat RR, Major A, Shree A, Gerken C, Kalra M, Chakraborty R, Thakkar SG, Dakhova O, Salsman VS, Grilley B, Lapteva N, Gee A, Dotti G, Bao R, Salem AH, Wang T, Brenner MK, Heslop HE, Wels WS, Hicks MJ, Gottschalk S, Ahmed N
Nature cancer 2024
Targeting senescent cells with NKG2D-CAR T cells
Deng Y, Kumar A, Xie K, Schaaf K, Scifo E, Morsy S, Li T, Ehninger A, Bano D, Ehninger D
Cell Death Discovery 2024
CAR-T cell manufacturing landscape—Lessons from the past decade and considerations for early clinical development
Dias J, Garcia J, Agliardi G, Roddie C
2024
Stealth transgenes enable CAR-T cells to evade host immune responses.
Grauwet K, Berger T, Kann MC, Silva H, Larson R, Leick MB, Bailey SR, Bouffard AA, Millar D, Gallagher K, Turtle CJ, Frigault MJ, Maus MV
Journal for ImmunoTherapy of Cancer 2024
CD20 CAR T cells safely and reversibly ablate B cell follicles in a non-human primate model of HIV persistence.
Bui JK, Starke CE, Poole NH, Rust BJ, Jerome KR, Kiem HP, Peterson CW
Molecular Therapy 2024
Placental circulating T cells: a novel, allogeneic CAR-T cell platform with preserved T-cell stemness, more favorable cytokine profile, and durable efficacy compared to adult PBMC-derived CAR-T
Ruggeri Barbaro N, Drashansky T, Tess K, Djedaini M, Hariri R, He S, van der Touw W, Karasiewicz K
Journal for ImmunoTherapy of Cancer 2024
Deleting the mitochondrial respiration negative regulator MCJ enhances the efficacy of CD8(+) T cell adoptive therapies in pre-clinical studies.
Wu MH, Valenca-Pereira F, Cendali F, Giddings EL, Pham-Danis C, Yarnell MC, Novak AJ, Brunetti TM, Thompson SB, Henao-Mejia J, Flavell RA, D'Alessandro A, Kohler ME, Rincon M
Nature Communications 2024
Engineered CAR‐T cells targeting the non‐functional P2X purinoceptor 7 (P2X7) receptor as a novel treatment for ovarian cancer
Bandara V, Niktaras VM, Willett VJ, Chapman H, Lokman NA, Macpherson AM, Napoli S, Gundsambuu B, Foeng J, Sadlon TJ, Coombs J, McColl SR, Barry SC, Oehler MK, Ricciardelli C
IBMS BoneKEy 2024
Preclinical evaluation of cyclophosphamide and fludarabine combined with CD19 CAR-T in the treatment of B-cell hematologic malignancies in vivo
XIA Z, TIAN M, CHENG Y, YI W, DU Z, LI T, WEN Y, LI L, LIU Y, CHEN C
Oncology research 2024
Chimeric antigen receptor T cell therapy for autoimmune disease.
Chung JB, Brudno JN, Borie D, Kochenderfer JN
Nature reviews. Immunology 2024
The Unprecedented Success of Chimeric Antigen Receptor T-Cell Therapy in the Treatment of Hematological Malignancies
Dhaliwal S, Gill FS, Hamid P
Cureus 2024
qPCR assay for detection of Woodchuck Hepatitis Virus Post-Transcriptional Regulatory Elements from CAR-T and TCR-T cells in fresh and formalin-fixed tissue
Pullarkat S, Black G, Bleakley M, Buenrostro D, Chapuis AG, Hirayama AV, Jaeger-Ruckstuhl CA, Kimble EL, Lee BM, Maloney DG, Radich J, Seaton BW, Specht JM, Turtle CJ, Woolston DW, Wright JH, Yeung CC
PloS one 2024
Feasibility and optimization of 19F MRI on a clinical 3T with a large field-of-view torso coil
Lechuga LM, Cho MM, Vail DM, Captini CM, Fain SB, Begovatz P
Physics in Medicine and Biology 2024
Selective refueling of CAR T cells using ADA1 and CD26 boosts antitumor immunity
Hu Y, Sarkar A, Song K, Michael S, Hook M, Wang R, Heczey A, Song X
Cell reports. Medicine 2024
Chimeric antigen receptor T-cell therapy for T-cell acute lymphoblastic leukemia
Oh BL, Vinanica N, Wong DM, Campana D
Haematologica 2024
Advances in research on factors affecting chimeric antigen receptor T‐cell efficacy
Zhou D, Zhu X, Xiao Y
Cancer Medicine 2024
Evolution of the clinical-stage hyperactive TcBuster transposase as a platform for robust non-viral production of adoptive cellular therapies
Skeate JG, Pomeroy EJ, Slipek NJ, Jones BJ, Wick BJ, Chang JW, Lahr WS, Stelljes EM, Patrinostro X, Barnes B, Zarecki T, Krueger JB, Bridge JE, Robbins GM, McCormick MD, Leerar JR, Wenzel KT, Hornberger KM, Walker K, Smedley D, Largaespada DA, Otto N, Webber BR, Moriarity BS
Molecular Therapy 2024
The role of CD4+ CAR T cells in cancer immunotherapy
Bove C, Maher J, Glover M
Translational cancer research 2024
Overcoming the Challenges of Primary Resistance and Relapse after CAR-T cell Therapy
Dreyzin A, Rankin AW, Luciani K, Gavrilova T, Shah NN
Expert Review of Clinical Immunology 2024
Optimization of In Vitro Th17 Polarization for Adoptive Cell Therapy in Chronic Lymphocytic Leukemia
Gamal W, Mediavilla-Varela M, Uriepero-Palma A, Pinilla-Ibarz J, Sahakian E
International journal of molecular sciences 2024
Late events after anti-CD19 CAR T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma
Cordeiro AC, Durisek G, Batista MV, Schmidt J, de Lima M, Bezerra E
Frontiers in Oncology 2024
Universal CAR 2.0 to overcome current limitations in CAR therapy
Schlegel LS, Werbrouck C, Boettcher M, Schlegel P
Frontiers in immunology 2024
Updates on the mechanisms of toxicities associated with monoclonal antibodies targeting growth factor signaling and immune cells in cancer
Park M, Kim JW
Toxicological Research 2024
A bibliometric and knowledge-map study on the treatment of hematological malignancies with CAR-T cells from 2012 to 2023
Huang Q, Li H, Zhang Y
Human Vaccines & Immunotherapeutics 2024
CXCR4 has a dual role in improving the efficacy of BCMA-redirected CAR-NK cells in multiple myeloma
Moles MW, Erdlei H, Menzel L, Massaro M, Fiori A, Bunse M, Schrimpf M, Gerlach K, Gudipati V, Reiser J, Mathavan K, Goodrich JP, Huppa JB, Krönke J, Valamehr B, Höpken UE, Rehm A
Frontiers in immunology 2024
Streamlined measurement of chimeric antigen receptor T-cell concentration, size, viability and two-color phenotyping during manufacturing
Pajarillo R, Paruzzo L, Carturan A, Ugwuanyi O, White G, Guruprasad P, Ballard HJ, Patel RP, Zhang Y, Lee YG, Hong SJ, Dittami GM, Ruella M
Cytotherapy 2024
Overview of infectious complications among CAR T- cell therapy recipients
Arya S, Shahid Z
Frontiers in Oncology 2024
Optimization of preparation method and specificity verification of cat CD19 monoclonal antibody for disease diagnosis and treatment
Shen L, Yan S, Xu A, Lan D, Jiang X, Peng Y, Wang S, Wang Z, Chen Y
Heliyon 2024
Scalable intracellular delivery via microfluidic vortex shedding enhances the function of chimeric antigen receptor T-cells.
Sytsma BJ, Allain V, Bourke S, Faizee F, Fathi M, Berdeaux R, Ferreira LMR, Brewer WJ, Li L, Pan FL, Rothrock AG, Nyberg WA, Li Z, Wilson LH, Eyquem J, Pawell RS
bioRxiv : the preprint server for biology 2024
Humanization of the antigen-recognition domain does not impinge on the antigen-binding, cytokine secretion, and antitumor reactivity of humanized nanobody-based CD19-redirected CAR-T cells.
Safarzadeh Kozani P, Safarzadeh Kozani P, Rahbarizadeh F
Journal of Translational Medicine 2024
Activated CD4(+) T Cell Proportion in the Peripheral Blood Correlates with the Duration of Cytokine Release Syndrome and Predicts Clinical Outcome after Chimeric Antigen Receptor T Cell Therapy.
Kitamura W, Asada N, Ikegawa S, Fujiwara H, Kamoi C, Ennishi D, Nishimori H, Fujii K, Fujii N, Matsuoka KI, Maeda Y
Internal medicine (Tokyo, Japan) 2024
The Kinetics of Inflammation-Related Proteins and Cytokines in Children Undergoing CAR-T Cell Therapy—Are They Biomarkers of Therapy-Related Toxicities?
Marschollek P, Liszka K, Mielcarek-Siedziuk M, Dachowska-Kałwak I, Haze N, Panasiuk A, Olejnik I, Jarmoliński T, Frączkiewicz J, Gamrot Z, Radajewska A, Bil-Lula I, Kałwak K
Biomedicines 2024
The Spectrum of CAR Cellular Effectors: Modes of Action in Anti-Tumor Immunity
Nguyen NT, Müller R, Briukhovetska D, Weber J, Feucht J, Künkele A, Hudecek M, Kobold S
Cancers 2024
A CAR enhancer increases the activity and persistence of CAR T cells.
Rakhshandehroo T, Mantri SR, Moravej H, Louis BBV, Salehi Farid A, Munaretto L, Regan K, Khan RMM, Wolff A, Farkash Z, Cong M, Kuhnast A, Nili A, Lee UJ, Allen HH, Berland L, Simkova E, Uslu SC, Tavakolpour S, Rowley JE, Codet E, Shahbazian H, Baral J, Pyrdol J, Jacobson CA, Nadeem O, Nia HT, Wucherpfennig KW, Rashidian M
Nature Biotechnology 2024
PD-L1(+) macrophage and tumor cell abundance and proximity to T cells in the pretreatment large B-cell lymphoma microenvironment impact CD19 CAR-T cell immunotherapy efficacy.
Hirayama AV, Wright JH, Smythe KS, Fiorenza S, Shaw AN, Gauthier J, Maloney DG, Naresh KN, Yeung CCS, Turtle CJ
HemaSphere 2024
Bispecific CAR-T cells targeting CD19/20 in patients with relapsed or refractory B cell non-Hodgkin lymphoma: a phase I/II trial.
Wang L, Fang C, Kang Q, Huang W, Chen Z, Zhao W, Wang L, Wang Y, Tan K, Guo X, Xu Y, Wang S, Wang L, Qiao J, Tang Z, Yu C, Xu Y, Li Y, Yu L
Blood Cancer Journal 2024
EphA3-targeted chimeric antigen receptor T cells are effective in glioma and generate curative memory T cell responses.
Lertsumitkul L, Iliopoulos M, Wang SS, McArthur SJ, Ebert LM, Davenport AJ, Endersby R, Hansford JR, Drummond KJ, Cross R, Jenkins MR
Journal for ImmunoTherapy of Cancer 2024
Advanced strategies in improving the immunotherapeutic effect of CAR-T cell therapy.
Wang M, Jia L, Dai X, Zhang X
Molecular Oncology 2024
Absolute lymphocyte count after BCMA CAR-T therapy is a predictor of response and outcomes in relapsed multiple myeloma
Mejia Saldarriaga M, Pan D, Unkenholz C, Mouhieddine TH, Velez-Hernandez JE, Engles K, Fein JA, Monge J, Rosenbaum C, Pearse R, Jayabalan D, Gordillo C, Chan HT, Yamshon S, Thibaud S, Mapara M, Inghirami G, Lentzsch S, Reshef R, Rossi A, Parekh S, Jagannath S, Richard S, Niesvizky R, Bustoros M
Blood Advances 2024
Biomarkers of outcome in patients undergoing CD19 CAR‐T therapy for large B cell lymphoma
Gong IY, Tran D, Saibil S, Laister RC, Kuruvilla J
HemaSphere 2024
Reshaping the tumor immune microenvironment to improve CAR-T cell-based cancer immunotherapy
Xia X, Yang Z, Lu Q, Liu Z, Wang L, Du J, Li Y, Yang DH, Wu S
Molecular Cancer 2024
Acute T-cell lymphoblastic leukemia: chimeric antigen receptor technology may offer a new hope
Jing J, Ma Y, Xie Z, Wang B, Chen Y, Chi E, Wang J, Zhang K, Wang Z, Li S
Frontiers in Immunology 2024
Strategies for Improving CAR T Cell Persistence in Solid Tumors
Wittling MC, Cole AC, Brammer B, Diatikar KG, Schmitt NC, Paulos CM
Cancers 2024
Manufacturing CD20/CD19-targeted iCasp9 regulatable CAR-TSCM cells using a Quantum pBac-based CAR-T engineering system
Chang PS, Chen YC, Hua WK, Hsu JC, Tsai JC, Huang YW, Kao YH, Wu PH, Wang PN, Chang YF, Chang MC, Chang YC, Jian SL, Lai JS, Lai MT, Yang WC, Shen CN, Wen KL, Wu SC
PLOS ONE 2024
Activation of Cell-Intrinsic Signaling in CAR-T Cells via a Chimeric IL7R Domain
Vorri SC, Holl NJ, Leeming M, Apostolova P, Marple A, Ravich JW, Canbaz A, Rahnama R, Choe J, Modi A, Fearnow AD, Walsh ST, Pearce EL, Varadhan R, Bonifant CL
Cancer Research Communications 2024
Unlocking the potential of iPSC-derived immune cells: engineering iNK and iT cells for cutting-edge immunotherapy
Fang M, Allen A, Luo C, Finn JD
Frontiers in Immunology 2024
Human plasma cells engineered to secrete bispecifics drive effective in vivo leukemia killing
Hill TF, Narvekar P, Asher GD, Edelstein JN, Camp ND, Grimm A, Thomas KR, Leiken MD, Molloy KM, Cook PJ, Arlauckas SP, Morgan RA, Tasian SK, Rawlings DJ, James RG
Molecular Therapy 2024
Development of an antigen-based approach to noninvasively image CAR T cells in real time and as a predictive tool
Fröse J, Rowley J, Farid AS, Rakhshandehroo T, Leclerc P, Mak H, Allen H, Moravej H, Munaretto L, Millan-Barea L, Codet E, Glockner H, Jacobson C, Hemann M, Rashidian M
Science Advances 2024
Chick Embryo Chorioallantoic Membrane as a Platform for Assessing the In Vivo Efficacy of Chimeric Antigen Receptor T-cell Therapy in Solid Tumors
Nipper AJ, Warren EA, Liao KS, Liu HC, Michikawa C, Porter CE, Wells GA, Villanueva M, Brasil da Costa FH, Veeramachaneni R, Villanueva H, Suzuki M, Sikora AG
ImmunoHorizons 2024
CAR T-cells for pediatric solid tumors: where to go from here?
Trautmann T, Yakobian N, Nguyen R
Cancer metastasis reviews 2024
Humoral Immunity and Antibody Responses against Diphtheria, Tetanus, and Pneumococcus after Immune Effector Cell Therapies: A Prospective Study
Angelidakis G, Chemaly RF, Sahasrabhojane PV, Morado-Aramburo O, Jiang Y, Bhatti MM, Shpall E, Hosing C, Jain P, Mahadeo KM, Khawaja F, Elhajj P, Wargo JA, Jenq RR, Ajami NJ, Kebriaei P, Ariza-Heredia EJ
Vaccines 2024
Identification of early predictive biomarkers for severe cytokine release syndrome in pediatric patients with chimeric antigen receptor T-cell therapy
Su M, Chen L, Xie L, Fleurie A, Jonquieres R, Cao Q, Li B, Liang J, Tang Y
Frontiers in Immunology 2024
Quantification of circulating TCR-engineered T cells targeting a human endogenous retrovirus post-adoptive transfer using nanoplate digital PCR
Barisic S, Cherkasova E, Nadal R, Tian X, Chen L, Parrizzi A, Reger RN, Scurti GM, Nishimura MI, Childs RW
Molecular Therapy. Methods & Clinical Development 2024
PD1CD28 chimeric molecule enhances EGFRvⅢ specific CAR-T cells in xenograft experiments in mouse models
Chen W, Xian N, Zhao N, Zhang Q, Xu Y
PLOS ONE 2024
Fratricide-resistant CD7-CAR T cells in T-ALL.
Oh BLZ, Shimasaki N, Coustan-Smith E, Chan E, Poon L, Lee SHR, Yeap F, Tan LK, Chai LYA, Le Bert N, Tan N, Bertoletti A, Chen SP, Del Bufalo F, Becilli M, Locatelli F, Yeoh AEJ, Campana D
Nature medicine 2024
Anti-BCMA CAR-T therapy for multiple myeloma with extramedullary disease: A case report and review of the literature.
Shi H, Zhang M, Su Y, Liu J, Guo J, Liu M, Ma Q
Medicine 2024
Scalable intracellular delivery via microfluidic vortex shedding enhances the function of chimeric antigen receptor T-cells.
Sytsma BJ, Allain V, Bourke S, Faizee F, Fathi M, Berdeaux R, Ferreira LMR, Brewer WJ, Li L, Pan FL, Rothrock AG, Nyberg WA, Li Z, Wilson LH, Eyquem J, Pawell RS
Research square 2024
Advancement and Challenges in Monitoring of CAR-T Cell Therapy: A Comprehensive Review of Parameters and Markers in Hematological Malignancies.
Ploch W, Sadowski K, Olejarz W, Basak GW
Cancers 2024
Generation of ex vivo autologous hematopoietic stem cell-derived T lymphocytes for cancer immunotherapy
Maneechai K, Khopanlert W, Noiperm P, Udomsak P, Viboonjuntra P, Julamanee J
Heliyon 2024
The influence of CRS and ICANS on the efficacy of anti-CD19 CAR-T treatment for B-cell acute lymphoblastic leukemia
Ma Y, Zhou H, Zhang J, Zhang Q, Li Y, Xie R, Zhang B, Shen Z, Li P, Liang A, Zhou K, Han L, Hu Y, Xu K, Sang W, Wang X
Frontiers in Immunology 2024
Revolutionizing the treatment for nasopharyngeal cancer: the impact, challenges and strategies of stem cell and genetically engineered cell therapies.
Looi CK, Loo EM, Lim HC, Chew YL, Chin KY, Cheah SC, Goh BH, Mai CW
Frontiers in immunology 2024
Incidence of immune effector cell-associated neurotoxicity among patients treated with CAR T-cell therapy for hematologic malignancies: systematic review and meta-analysis
Han MW, Jeong SY, Suh CH, Park H, Guenette JP, Huang RY, Kim KW, Yoon DH
Frontiers in Neurology 2024
Genetically-modified, redirected T cells target hepatitis B surface antigen-positive hepatocytes and hepatocellular carcinoma lesions in a clinical setting.
Wan X, Wisskirchen K, Jin T, Yang L, Wang X, Wu X, Liu F, Wu Y, Ma C, Pang Y, Li Q, Zhang K, Protzer U, Du S
Clinical and molecular hepatology 2024
Breaking the shield of solid tumors: a combined approach for enhanced efficacy of CAR-T cells.
Khaliulin M, Valiullina A, Petukhov A, Yuan Y, Spada S, Bulatov E
Cancer immunology, immunotherapy : CII 2024
Genetically modified and unmodified cellular approaches to enhance graft versus leukemia effect, without increasing graft versus host disease: the use of allogeneic cytokine-induced killer cells
Rambaldi B, Rizzuto G, Rambaldi A, Introna M
Frontiers in Immunology 2024
Split-design approach enhances the therapeutic efficacy of ligand-based CAR-T cells against multiple B-cell malignancies.
Li S, Shi L, Zhao L, Guo Q, Li J, Liu ZL, Guo Z, Cao YJ
Nature communications 2024
Case study of CD19 CAR T therapy in a subject with immune-mediate necrotizing myopathy treated in the RESET-Myositis phase I/II trial
Volkov J, Nunez D, Mozaffar T, Stadanlick J, Werner M, Vorndran Z, Ellis A, Williams J, Cicarelli J, Lam Q, Furmanak T, Schmitt C, Hadi-Nezhad F, Thompson D, Miller C, Little C, Chang D, Basu S
Molecular Therapy 2024
Graft-versus-host disease after anti-CD19 chimeric antigen receptor T-cell therapy following allogeneic hematopoietic cell transplantation: a transplant complications and paediatric diseases working parties joint EBMT study.
Ortí G, Peczynski C, Boreland W, O'Reilly M, von Bonin M, Balduzzi A, Besley C, Kalwak K, Ryhänen S, Güngör T, Wynn RF, Bader P, Mielke S, Blaise D, Amrolia P, Yakoub-Agha I, Calkoen F, Schubert ML, Potter V, Pichler H, Kröger N, Kwon M, Sengeloev H, Torrent A, Chalandon Y, van Gorkom G, Koenecke C, Graham C, Schoemans H, Moiseev I, Penack O, Peric Z
Leukemia 2024
Identification and Characterization of Fully Human FOLR1-Targeting CAR T Cells for the Treatment of Ovarian Cancer
Bethke M, Abramowski P, Droste M, Felsberger A, Kochsiek L, Kotter B, Plettig L, Antonova K, Baghdo S, Burzan N, Tomszak F, Martinez-Osuna M, Eckardt D, Herbel C
Cells 2024
Combining the induced pluripotent stem cell (iPSC) technology with chimeric antigen receptor (CAR)-based immunotherapy: recent advances, challenges, and future prospects
Alidadi M, Barzgar H, Zaman M, Paevskaya OA, Metanat Y, Khodabandehloo E, Moradi V
Frontiers in Cell and Developmental Biology 2024
Integrative single-cell multi-omics of CD19-CARpos and CARneg T cells suggest drivers of immunotherapy response in B cell neoplasias
Guerrero-Murillo M, Rill-Hinarejos A, Trincado JL, Bataller A, Ortiz-Maldonado V, Benítez-Ribas D, Español-Rego M, González-Navarro EA, Martínez-Cibrián N, Marchese D, Martín-Martín L, Martín García-Sancho A, Rives S, Heyn H, Juan M, Urbano-Ispizúa Á, Delgado J, Orfao A, Mereu E, Bueno C, Menendez P
Cell Reports Medicine 2024
Approaches for bridging therapy prior to chimeric antigen receptor T cells for relapsed/refractory acute lymphoblastic B-lineage leukemia in children and young adults
Feuchtinger T, Bader P, Subklewe M, Breidenbach M, Willier S, Metzler M, Gökbuget N, Hauer J, Müller F, Schlegel PG, Frühwald M, Schmid C, Troeger A, Baldus C, Meisel R, Künkele A, Topp M, Bourquin JP, Cario G, von Stackelberg A, Peters C
Haematologica 2024
Impact of T cell characteristics on CAR-T cell therapy in hematological malignancies
Tao Z, Chyra Z, Kotulová J, Celichowski P, Mihályová J, Charvátová S, Hájek R
Blood Cancer Journal 2024
Advances in Induced Pluripotent Stem Cell-Derived Natural Killer Cell Therapy
Qiao W, Dong P, Chen H, Zhang J
Cells 2024
Cullin-5 deficiency promotes chimeric antigen receptor T cell effector functions potentially via the modulation of JAK/STAT signaling pathway
Adachi Y, Terakura S, Osaki M, Okuno Y, Sato Y, Sagou K, Takeuchi Y, Yokota H, Imai K, Steinberger P, Leitner J, Hanajiri R, Murata M, Kiyoi H
Nature Communications 2024
Chimeric antigen receptor T-cell therapy in autoimmune diseases
Liu J, Zhao Y, Zhao H
Frontiers in Immunology 2024
Breaking barriers: advancing cellular therapies in autoimmune disease management
Fu Y, Feng C, Qin S, Xing Z, Liu C, Liu Z, Yu H
Frontiers in Immunology 2024
肿瘤免疫疗法中细胞来源对治疗效果的影响
Chinese Journal of Hematology 2024
Anti-HIV-1 HSPC-based gene therapy with safety kill switch to defend against and attack HIV-1 infection
Guo Q, Parikh K, Zhang J, Brinkley A, Chen G, Jakramonpreeya N, Zhen A, An DS
bioRxiv 2024
From promise to practice: CAR T and Treg cell therapies in autoimmunity and other immune-mediated diseases
Bulliard Y, Freeborn R, Uyeda MJ, Humes D, Bjordahl R, de Vries D, Roncarolo MG
Frontiers in Immunology 2024
Acute Myeloid Leukaemia and Acute Lymphoblastic Leukaemia Classification and Metabolic Characteristics for Informing and Advancing Treatment
Wemyss C, Jones E, Stentz R, Carding SR
Cancers 2024
Increased functional potency of multi-edited CAR-T cells manufactured by a non-viral transfection system
O\u2019Sullivan A, Case S, McCrudden A, Hackett E, Gallagher L, Martin D, Johnson GP, Mahadik K, Kienzle T, Lim JK, Nashat A, Srinivasan K, Lowdell MW, O\u2019Flynn L, Frankish J
Molecular Therapy. Methods & Clinical Development 2024
How I treat postimmunotherapy relapsed B-ALL
Lamble AJ, Kovach AE, Shah NN
Blood 2024
Universal protection of allogeneic T-cell therapies from natural killer cells via CD300a agonism
Zhang SQ, Thomas F, Fang J, Austgen K, Cowan C, Welstead GG
Blood Advances 2024
Phase I Study of ROR1-Specific CAR-T Cells in Advanced Hematopoietic and Epithelial Malignancies
Jaeger-Ruckstuhl CA, Specht JM, Voutsinas JM, MacMillan HR, Wu Q(, Muhunthan V, Berger C, Pullarkat S, Wright JH, Yeung CC, Hyun TS, Seaton B, Aicher LD, Song X, Pierce RH, Lo Y, Cole GO, Lee SM, Newell EW, Maloney DG, Riddell SR
Clinical Cancer Research 2024
Safety and Tolerability of Letetresgene Autoleucel (GSK3377794): Pilot Studies in Patients with Advanced Non–Small Cell Lung Cancer
Altan M, Lopes G, Hiltermann TJ, Govindan R, Villaruz LC, Calvo E, Edelman MJ, Furqan M, Neal J, Felip E, Carlisle JW, Heymach JV, O\u2019Cearbhaill RE, Zauderer M, Chisamore M, Corigliano E, Eleftheriadou I, Zajic S, Jenkins B, Goodison S, Suchindran S, Ramos-Hernandez N, Tarek N, Schoenfeld AJ
Clinical Cancer Research 2024
Development and validation of predictive models of early immune effector cell–associated hematotoxicity
Liang EC, Huang JJ, Portuguese AJ, Ortiz-Maldonado V, Albittar A, Wuliji N, Basom R, Jeon Y, Wu Q, Torkelson A, Kirchmeier D, Chutnik A, Pender B, Sorror M, Hill JA, Kopmar NE, Banerjee R, Cowan AJ, Green D, Gopal AK, Poh C, Shadman M, Hirayama AV, Till BG, Kimble EL, Iovino L, Chapuis AG, Otegbeye F, Cassaday RD, Milano F, Turtle CJ, Maloney DG, Gauthier J
Blood Advances 2024
Dual-targeting CAR T cells for B-cell acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma
de Oliveira Canedo G, Roddie C, Amrolia PJ
Blood Advances 2024
Bioengineered therapeutic systems for improving antitumor immunity
Cao Y, Yan W, Yi W, Yin Q, Li Y
National Science Review 2024
Development of ALL-Hematotox: predicting post-CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemia
Nair MS, Silbert SK, Rejeski K, Wilson KA, Lamble AJ, Valtis Y, Yates B, Morales Arana A, Shouval R, Curran K, Gardner RA, Shalabi H, Annesley C, Park JH, Subklewe M, Shah NN
Blood 2024
Inconsistent reporting and definitions of time-to-event endpoints in CAR T clinical trials: A review
Grady CB, Li Y, Maude SL, Hexner EO, Frey NV, Porter DL, Hwang WT
Transplantation and cellular therapy 2024
Depletion of Tregs from CD4 + CAR‐T cells enhances the tumoricidal effect of CD8 + CAR‐T cells in anti‐CD19 CAR‐T therapy
Sun Y, Liu J, Zhan D, Wei J, XianShi L, Zhang R, Duan C, Zhang D, Tang X, Lin T, Li L, Lai X
The Febs Journal 2024
Long-term remission following CAR-T therapy in a patient with transformed follicular lymphoma relapse after allogeneic stem cell transplantation.
Kubo R, Onodera K, Onishi Y, Fukuhara N, Harigae H
Annals of hematology 2024
CD4 CAR-T cells targeting CD19 play a key role in exacerbating cytokine release syndrome, while maintaining long-term responses
Bove C, Arcangeli S, Falcone L, Camisa B, El Khoury R, Greco B, De Lucia A, Bergamini A, Bondanza A, Ciceri F, Bonini C, Casucci M
Journal for ImmunoTherapy of Cancer 2023
Development of HIV-Resistant CAR T Cells by CRISPR/Cas-Mediated CAR Integration into the CCR5 Locus
Rothemejer FH, Lauritsen NP, Juhl AK, Schleimann MH, König S, Søgaard OS, Bak RO, Tolstrup M
Viruses 2023
Is CD19-directed chimeric antigen receptor T cell therapy a smart strategy to combat central nervous system lymphoma?
Miyao K, Yokota H, Sakemura RL
Frontiers in Oncology 2023
The frequency of differentiated CD3+CD27-CD28- T cells predicts response to CART cell therapy in diffuse large B-cell lymphoma
Worel N, Grabmeier-Pfistershammer K, Kratzer B, Schlager M, Tanzmann A, Rottal A, Körmöczi U, Porpaczy E, Staber PB, Skrabs C, Herkner H, Gudipati V, Huppa JB, Salzer B, Lehner M, Saxenhuber N, Friedberg E, Wohlfarth P, Hopfinger G, Rabitsch W, Simonitsch-Klupp I, Jäger U, Pickl WF
Frontiers in immunology 2023
CAR-T therapy followed by allogeneic hematopoietic stem cell transplantation for refractory/relapsed acute B lymphocytic leukemia: Long-term follow-up results
Li Z, Yang K, Song Y, Zhao Y, Wu F, Wen X, Li J, Wang X, Xu T, Zheng X, Zheng Q, Wu T
Frontiers in Oncology 2023
Enhancing CAR-T cell functionality in a patient-specific manner
Zhang DK, Adu-Berchie K, Iyer S, Liu Y, Cieri N, Brockman JM, Neuberg D, Wu CJ, Mooney DJ
Nature Communications 2023
Germline T cell receptor exchange results in physiological T cell development and function
Rollins MR, Raynor JF, Miller EA, Butler JZ, Spartz EJ, Lahr WS, You Y, Burrack AL, Moriarity BS, Webber BR, Stromnes IM
Nature Communications 2023
Analysis of causes for poor persistence of CAR-T cell therapy in vivo
Kong Y, Tang L, You Y, Li Q, Zhu X
Frontiers in immunology 2023
Comparison of the efficacy of second and third generation lentiviral vector transduced CAR CD19 T cells for use in the treatment of acute lymphoblastic leukemia both in vitro and in vivo models
Sawaisorn P, Atjanasuppat K, Uaesoontrachoon K, Rattananon P, Treesuppharat W, Hongeng S, Anurathapan U
PloS one 2023
Recent advances and applications of CRISPR-Cas9 in cancer immunotherapy
Liu Z, Shi M, Ren Y, Xu H, Weng S, Ning W, Ge X, Liu L, Guo C, Duo M, Li L, Li J, Han X
Molecular Cancer 2023
Assessment of anti-CD20 antibody pre-treatment for augmentation of CAR-T cell therapy in SIV-infected rhesus macaques
Pampusch MS, Sevcik EN, Quinn ZE, Davey BC, Berg JM, Gorrell-Brown I, Abdelaal HM, Rakasz EG, Rendahl A, Skinner PJ
Frontiers in immunology 2023
Safety and efficacy of autologous and allogeneic humanized CD19-targeted CAR-T cell therapy for patients with relapsed/refractory B-ALL
Song F, Hu Y, Zhang Y, Zhang M, Yang T, Wu W, Huang S, Xu H, Chang AH, Huang H, Wei G
Journal for ImmunoTherapy of Cancer 2023
The role of macrophages-mediated communications among cell compositions of tumor microenvironment in cancer progression
Li M, Jiang P, Wei S, Wang J, Li C
Frontiers in immunology 2023
Comparative Pre-Clinical Analysis of CD20-Specific CAR T Cells Encompassing 1F5-, Leu16-, and 2F2-Based Antigen-Recognition Moieties
Belovezhets T, Kulemzin S, Volkova O, Najakshin A, Taranin A, Gorchakov A
International journal of molecular sciences 2023
A systematic framework for predictive biomarkers in immune effector cell-associated neurotoxicity syndrome
Butt OH, Zhou AY, Ances BM, DiPersio JF, Ghobadi A
Frontiers in neurology 2023
T-cells engineered with a novel VHH-based chimeric antigen receptor against CD19 exhibit comparable tumoricidal efficacy to their FMC63-based counterparts
Nasiri F, Safarzadeh Kozani P, Rahbarizadeh F
Frontiers in immunology 2023
Modeling interaction of Glioma cells and CAR T-cells considering multiple CAR T-cells bindings
Li R, Sahoo P, Wang D, Wang Q, Brown CE, Rockne RC, Cho H
2023
T-cell exhaustion and stemness in antitumor immunity: Characteristics, mechanisms, and implications
Chi X, Luo S, Ye P, Hwang WL, Cha JH, Yan X, Yang WH
Frontiers in immunology 2023
CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naïve/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
Larson SM, Walthers CM, Ji B, Ghafouri SN, Naparstek J, Trent J, Chen JM, Roshandell M, Harris C, Khericha M, Schweppe T, Berent-Maoz B, Gosliner SB, Almaktari A, Ceja MA, Allen-Auerbach MS, Said J, Nawaly K, Mead M, de Vos S, Young PA, Oliai C, Schiller GJ, Timmerman JM, Ribas A, Chen YY
Cancer Discovery 2023
Challenges of Anti-Mesothelin CAR-T-Cell Therapy
Zhai X, Mao L, Wu M, Liu J, Yu S
Cancers 2023
Myeloidcells in the immunosuppressive microenvironment in glioblastoma: The characteristics and therapeutic strategies
Huang B, Zhang J, Zong W, Chen S, Zong Z, Zeng X, Zhang H
Frontiers in immunology 2023
Preclinical proof of concept for VivoVec, a lentiviral-based platform for in vivo CAR T-cell engineering
Michels KR, Sheih A, Hernandez SA, Brandes AH, Parrilla D, Irwin B, Perez AM, Ting HA, Nicolai CJ, Gervascio T, Shin S, Pankau MD, Muhonen M, Freeman J, Gould S, Getto R, Larson RP, Ryu BY, Scharenberg AM, Sullivan AM, Green S
Journal for ImmunoTherapy of Cancer 2023
Human A2-CAR T cells reject HLA-A2+ human islets transplanted into mice without inducing graft versus host disease
Ellis CE, Mojibian M, Ida S, Fung VC, Skovsø S, McIver E, O\u2019Dwyer S, Webber TD, Braam MJ, Saber N, Kieffer TJ, Levings MK
2023
Controlling therapeutic protein expression via inhalation of a butter flavor molecule.
Bertschi A, Stefanov BA, Xue S, Charpin-El Hamri G, Teixeira AP, Fussenegger M
Nucleic Acids Research 2023
Mesenchymal stem cell suppresses the efficacy of CAR-T toward killing lymphoma cells by modulating the microenvironment through stanniocalcin-1.
Zhang R, Liu Q, Zhou S, He H, Zhao M, Ma W
eLife 2023
Combining chemotherapy with CAR-T cell therapy in treating solid tumors
Wang AX, Ong XJ, D\u2019Souza C, Neeson PJ, Zhu JJ
Frontiers in immunology 2023
Current and future concepts for the generation and application of genetically engineered CAR-T and TCR-T cells
Hiltensperger M, Krackhardt AM
Frontiers in immunology 2023
Safety and efficacy of co-administration of CD19 and CD22 CAR-T cells in children with B-ALL relapse after CD19 CAR-T therapy
Li W, Ding L, Shi W, Wan X, Yang X, Yang J, Wang T, Song L, Wang X, Ma Y, Luo C, Tang J, Gu L, Chen J, Lu J, Tang Y, Li B
Journal of Translational Medicine 2023
Advancing CAR T cell therapy through the use of multidimensional omics data.
Yang J, Chen Y, Jing Y, Green MR, Han L
Nature reviews. Clinical oncology 2023
Advances in CAR-T Cell Therapy in Head and Neck Squamous Cell Carcinoma
Wang HQ, Fu R, Man QW, Yang G, Liu B, Bu LL
Journal of Clinical Medicine 2023
The current landscape of CAR T-cell therapy for solid tumors: Mechanisms, research progress, challenges, and counterstrategies
Daei Sorkhabi A, Mohamed Khosroshahi L, Sarkesh A, Mardi A, Aghebati-Maleki A, Aghebati-Maleki L, Baradaran B
Frontiers in immunology 2023
Programming CAR T Cell Tumor Recognition: Tuned Antigen Sensing and Logic Gating
Hamieh M, Mansilla-Soto J, Rivière I, Sadelain M
Cancer Discovery 2023
The peculiar challenge of bringing CAR-T cells into the brain: Perspectives in the clinical application to the treatment of pediatric central nervous system tumors
Del Baldo G, Del Bufalo F, Pinacchio C, Carai A, Quintarelli C, De Angelis B, Merli P, Cacchione A, Locatelli F, Mastronuzzi A
Frontiers in immunology 2023
Long-term outcomes following CAR T cell therapy: what we know so far
Cappell KM, Kochenderfer JN
Nature reviews. Clinical oncology 2023
Predictive short/long-term efficacy biomarkers and resistance mechanisms of CD19-directed CAR-T immunotherapy in relapsed/refractory B-cell lymphomas.
Xu H, Li N, Wang G, Cao Y
Frontiers in immunology 2023
Cytotoxicity of CD19-CAR-NK92 cells is primarily mediated via perforin/granzyme pathway.
Althaus J, Nilius-Eliliwi V, Maghnouj A, Döring S, Schroers R, Hudecek M, Hahn SA, Mika T
Cancer Immunology, Immunotherapy 2023
Immunosuppressive tumor microenvironment contributes to tumor progression in diffuse large B-cell lymphoma upon anti-CD19 chimeric antigen receptor T therapy.
Yan Z, Li L, Fu D, Wu W, Qiao N, Huang Y, Jiang L, Wu D, Hu Y, Zhang H, Xu P, Cheng S, Wang L, Lacin S, Muftuoglu M, Zhao W
Frontiers of Medicine 2023
Characterization of the endotheliopathy, innate-immune activation and hemostatic imbalance underlying CAR-T cell toxicities: laboratory tools for an early and differential diagnosis
Moreno-Castaño AB, Fernández S, Ventosa H, Palomo M, Martinez-Sanchez J, Ramos A, Ortiz-Maldonado V, Delgado J, Fernández de Larrea C, Urbano-Ispizua A, Penack O, Nicolás JM, Téllez A, Escolar G, Carreras E, Fernández-Avilés F, Castro P, Diaz-Ricart M
Journal for ImmunoTherapy of Cancer 2023
Preliminary assessment of cardiotoxicity in chimeric antigen receptor T cell therapy: a systematic review and meta-analysis.
Guo M, Wang X, Xiao S, Liu A, Xu T, Huan C, Wu H, Hu Y, Zhou S, Zhu H, Pan D
Clinical and Experimental Medicine 2023
DC vaccine enhances CAR-T cell antitumor activity by overcoming T cell exhaustion and promoting T cell infiltration in solid tumors.
Zhang M, Wang Y, Chen X, Zhang F, Chen J, Zhu H, Li J, Chen Z, Wang A, Xiao Y, Chen Z, Dong Y, Yin X, Ji F, Liu J, Liang J, Pan F, Guo Z, He L
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2023
Which one is better for refractory/relapsed acute B-cell lymphoblastic leukemia: Single-target (CD19) or dual-target (tandem or sequential CD19/CD22) CAR T-cell therapy?
Liu S, Zhang X, Dai H, Cui W, Yin J, Li Z, Yang X, Yang C, Xue S, Qiu H, Miao M, Chen S, Jin Z, Fu C, Li C, Sun A, Han Y, Wang Y, Yu L, Wu D, Cui Q, Tang X
Blood Cancer Journal 2023
Axicabtagene Ciloleucel in the Management of Follicular Lymphoma: Current Perspectives on Clinical Utility, Patient Selection and Reported Outcomes
Mohty R, Kharfan-Dabaja MA, Chavez JC
Cancer management and research 2023
Mutated Flt3Lg Provides Reduced Flt3 Recycling Compared to Wild-Type Flt3Lg and Retains the Specificity of Flt3Lg-Based CAR T-Cell Targeting in AML Models
Maiorova V, Mollaev MD, Vikhreva P, Chudakov DM, Kibardin A, Maschan MA, Larin S
International journal of molecular sciences 2023
Monitoring of kinetics and exhaustion markers of circulating CAR-T cells as early predictive factors in patients with B-cell malignancies
García-Calderón CB, Sierro-Martínez B, García-Guerrero E, Sanoja-Flores L, Muñoz-García R, Ruiz-Maldonado V, Jimenez-Leon MR, Delgado-Serrano J, Molinos-Quintana Á, Guijarro-Albaladejo B, Carrasco-Brocal I, Lucena JM, García-Lozano JR, Blázquez-Goñi C, Reguera-Ortega JL, González-Escribano MF, Reinoso-Segura M, Briones J, Pérez-Simón JA, Caballero-Velázquez T
Frontiers in immunology 2023
A combination of pre-infusion serum ferritin, CRP and IL-6 predicts outcome in relapsed/refractory multiple myeloma patients treated with CAR-T cells
Liu Y, Jie X, Nian L, Wang Y, Wang C, Ma J, Jiang J, Wu Q, Qiao J, Chen W, Cao J, Yan Z, Shi M, Cheng H, Zhu F, Sang W, Li D, Chen C, Xu K, Li Z
Frontiers in immunology 2023
Deciphering and advancing CAR T-cell therapy with single-cell sequencing technologies
Huang S, Wang X, Wang Y, Wang Y, Fang C, Wang Y, Chen S, Chen R, Lei T, Zhang Y, Xu X, Li Y
Molecular Cancer 2023
Advancing Cell-Based Cancer Immunotherapy Through Stem Cell Engineering
Li YR, Dunn ZS, Yu Y, Li M, Wang P, Yang L
Cell Stem Cell 2023
Rational Alternatives to Fludarabine and Cyclophosphamide-Based Pre-CAR Lymphodepleting Regimens in the Pediatric and Young Adult B-ALL Setting.
Green S, Schultz L
Current Oncology Reports 2023
Prognostic value of prelymphodepletion absolute lymphocyte counts in relapsed/refractory diffuse large B-cell lymphoma patients treated with chimeric antigen receptor T cells
Lu Y, Zhu H, Liu Y, Wang Y, Sun Y, Cheng H, Yan Z, Cao J, Sang W, Zhu F, Li D, Sun H, Zheng J, Xu K, Li Z
Frontiers in immunology 2023
Durable remission related to CAR-T persistence in R/R B-ALL and long-term persistence potential of prime CAR-T
Shiqi L, Jiasi Z, Lvzhe C, Huailong X, Liping H, Lin L, Qianzhen Z, Zhongtao Y, Junjie S, Zucong C, Yingzi Z, Meiling W, Yunyan L, Linling W, Lihua F, Yingnian C, Wei Z, Yu L, Le L, Youcheng W, Dingsong Z, Yancheng D, Ping Y, Lihua Z, Xiaoping L, Xiaozhuang H, Zhongzheng Z, Zhi Y, Cheng Q, Sanbin W
2023
Regulation of CD19 CAR-T cell activation based on an engineered downstream transcription factor
Lainšček D, Golob-Urbanc A, Mikolič V, Pantović-Žalig J, Malenšek Š, Jerala R
2023
The Interplay between T Cells and Cancer: The Basis of Immunotherapy
Chen C, Liu X, Chang CY, Wang HY, Wang RF
Genes & development 2023
CAR T-cell detection scoping review: an essential biomarker in critical need of standardization.
Turicek DP, Giordani VM, Moraly J, Taylor N, Shah NN
Journal for ImmunoTherapy of Cancer 2023
Activation-inducible CAR expression enables precise control over engineered CAR T cell function
Fraessle SP, Tschulik C, Effenberger M, Cletiu V, Gerget M, Schober K, Busch DH, Germeroth L, Stemberger C, Poltorak MP
Communications biology 2023
Strategies for Reducing Toxicity and Enhancing Efficacy of Chimeric Antigen Receptor T Cell Therapy in Hematological Malignancies
Wang H, Tang L, Kong Y, Liu W, Zhu X, You Y
International journal of molecular sciences 2023
A novel polymer-conjugated human IL-15 improves efficacy of CD19-targeted CAR T-cell immunotherapy.
Hirayama AV, Chou CK, Miyazaki T, Steinmetz RN, Di HA, Fraessle SP, Gauthier J, Fiorenza S, Hawkins RM, Overwijk WW, Riddell SR, Marcondes MQ, Turtle CJ
Blood Advances 2023
Insights in the host response towards biomaterial-based scaffolds for cancer therapy
Schluck M, Weiden J, Verdoes M, Figdor CG
Frontiers in Bioengineering and Biotechnology 2023
Novel strategies to prevent and overcome relapse after allogeneic hematopoietic cell transplantation in acute lymphoblastic leukemia
Hodroj MH, Abou Dalle I, Moukalled N, El Cheikh J, Mohty M, Bazarbachi A
Frontiers in immunology 2023
Enhancing Anticancer Efficacy of Chemotherapeutics Using Targeting Ligand-Functionalized Synthetic Antigen Receptor-Mesenchymal Stem Cells
Nethi SK, Li X, Bhatnagar S, Prabha S
Pharmaceutics 2023
Immune Effector Cell associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS)
Hines MR, Knight TE, McNerney KO, Leick MB, Jain T, Ahmed S, Frigault MJ, Hill JA, Jain MD, Johnson WT, Lin Y, Mahadeo KM, Maron GM, Marsh RA, Neelapu SS, Nikiforow S, Ombrello AK, Shah NN, Talleur AC, Turicek D, Vatsayan A, Wong SW, Maus MV, Komanduri KV, Berliner N, Henter JI, Perales MA, Frey NV, Teachey DT, Frank MJ, Shah NN
2023
Multi-Targeted Immunotherapeutics to Treat B Cell Malignancies
Gambles MT, Yang J, Kopeček J
Journal of Controlled Release 2023
Mechanisms of resistance and treatment of relapse after CAR T-cell therapy for large B-cell lymphoma and multiple myeloma
Rejeski K, Jain MD, Smith EL
2023
Current and potential roles of immuno-PET/-SPECT in CAR T-cell therapy
Mulgaonkar A, Udayakumar D, Yang Y, Harris S, Öz OK, Ramakrishnan Geethakumari P, Sun X
Frontiers in Medicine 2023
Fine-Tuning through Generations: Advances in Structure and Production of CAR-T Therapy
Zheng Z, Li S, Liu M, Chen C, Zhang L, Zhou D
Cancers 2023
Acute Lymphoblastic Leukemia Immunotherapy Treatment: Now, Next, and Beyond
Aureli A, Marziani B, Venditti A, Sconocchia T, Sconocchia G
Cancers 2023
Chimeric antigen receptor T-cell therapy for adult B-cell acute lymphoblastic leukemia: state-of-the-(C)ART and the road ahead.
Pasvolsky O, Kebriaei P, Shah BD, Jabbour E, Jain N
Blood Advances 2023
Engineering enhanced chimeric antigen receptor-T cell therapy for solid tumors
Neeser A, Ramasubramanian R, Wang C, Ma L
2023
Treatment of adult ALL patients with third-generation CD19-directed CAR T cells: results of a pivotal trial.
Schubert ML, Schmitt A, Hückelhoven-Krauss A, Neuber B, Kunz A, Waldhoff P, Vonficht D, Yousefian S, Jopp-Saile L, Wang L, Korell F, Keib A, Michels B, Haas D, Sauer T, Derigs P, Kulozik A, Kunz J, Pavel P, Laier S, Wuchter P, Schmier J, Bug G, Lang F, Gökbuget N, Casper J, Görner M, Finke J, Neubauer A, Ringhoffer M, Wolleschak D, Brüggemann M, Haas S, Ho AD, Müller-Tidow C, Dreger P, Schmitt M
Journal of Hematology & Oncology 2023
Complexities in comparing the impact of costimulatory domains on approved CD19 CAR functionality
Smith R, Shen R
Journal of Translational Medicine 2023
Ginsenoside Rg1 improves anti-tumor efficacy of adoptive cell therapy by enhancing T cell effector functions
Liu Y, An L, Yang C, Wang X, Huang R, Zhang X
2023
Immunotherapy in hematologic malignancies: achievements, challenges and future prospects.
Tang L, Huang Z, Mei H, Hu Y
Signal Transduction and Targeted Therapy 2023
Modulation of Radiation Doses and Chimeric Antigen Receptor T Cells: A Promising New Weapon in Solid Tumors—A Narrative Review
Pontoriero A, Critelli P, Chillari F, Ferrantelli G, Sciacca M, Brogna A, Parisi S, Pergolizzi S
Journal of Personalized Medicine 2023
Fully closed cell sorter for immune cell therapy manufacturing
Matsumoto M, Tashiro S, Ito T, Takahashi K, Hashimoto G, Kajihara J, Miyahara Y, Shiku H, Katsumoto Y
2023
Development of a bicistronic anti-CD19/CD20 CAR construct including abrogation of unexpected nucleic acid sequence deletions.
Lam N, Finney R, Yang S, Choi S, Wu X, Cutmore L, Andrade J, Huang L, Amatya C, Cam M, Kochenderfer JN
2023
Strategies for enhancing CAR T cell expansion and persistence in HIV infection
Rothemejer FH, Lauritsen NP, Søgaard OS, Tolstrup M
Frontiers in immunology 2023
Validation of a High-Sensitivity Assay for Detection of Chimeric Antigen Receptor T-Cell Vectors Using Low-Partition Digital PCR Technology.
Arcila ME, Patel U, Momeni-Boroujeni A, Yao J, Chan R, Chan J, Rijo I, Yu W, Chaves N, Patel H, Kakadiya S, Lachhander S, Senechal B, Riviere IC, Wang X, Sadelain M, Nafa K, Salazar P, Palomba L, Curran KJ, Park JH, Daniyan A, Borsu L
The Journal of molecular diagnostics : JMD 2023
Pre-clinical validation of a pan-cancer CAR-T cell immunotherapy targeting nfP2X7.
Bandara V, Foeng J, Gundsambuu B, Norton TS, Napoli S, McPeake DJ, Tyllis TS, Rohani-Rad E, Abbott C, Mills SJ, Tan LY, Thompson EJ, Willet VM, Nikitaras VJ, Zheng J, Comerford I, Johnson A, Coombs J, Oehler MK, Ricciardelli C, Cowin AJ, Bonder CS, Jensen M, Sadlon TJ, McColl SR, Barry SC
Nature Communications 2023
Bridging live-cell imaging and next-generation cancer treatment.
Alieva M, Wezenaar AKL, Wehrens EJ, Rios AC
Nature reviews. Cancer 2023
ICOS and OX40 tandem co-stimulation enhances CAR T-cell cytotoxicity and promotes T-cell persistence phenotype
Moreno-Cortes E, Franco-Fuquen P, Garcia-Robledo JE, Forero J, Booth N, Castro JE
Frontiers in Oncology 2023
Development of a multiscale mechanistic modeling framework integrating differential cellular kinetics of CAR T‐cell subsets and immunophenotypes in cancer patients
Salem AM, Mugundu GM, Singh AP
The Journal of Pathology 2023
A major role for CD4+ T cells in driving cytokine release syndrome during CAR T cell therapy
Boulch M, Cazaux M, Cuffel A, Ruggiu M, Allain V, Corre B, Loe-Mie Y, Hosten B, Cisternino S, Auvity S, Thieblemont C, Caillat-Zucman S, Bousso P
Cell reports. Medicine 2023
Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansion
Rejeski K, Perez A, Iacoboni G, Blumenberg V, Bücklein VL, Völkl S, Penack O, Albanyan O, Stock S, Müller F, Karschnia P, Petrera A, Reid K, Faramand R, Davila ML, Modi K, Dean EA, Bachmeier C, von Bergwelt-Baildon M, Locke FL, Bethge W, Bullinger L, Mackensen A, Barba P, Jain MD, Subklewe M
Science Advances 2023
Innate immune response restarts adaptive immune response in tumors
Li WS, Zhang QQ, Li Q, Liu SY, Yuan GQ, Pan YW
Frontiers in immunology 2023
Lymph node metastasis in cancer progression: molecular mechanisms, clinical significance and therapeutic interventions
Ji H, Hu C, Yang X, Liu Y, Ji G, Ge S, Wang X, Wang M
Signal Transduction and Targeted Therapy 2023
Human A2-CAR T Cells Reject HLA-A2+ Human Islets Transplanted into Mice Without Inducing Graft Versus Host Disease
Ellis CE, Mojibian M, Ida S, Fung VC, Skovsø S, McIver E, O\u2019Dwyer S, Webber TD, Braam MJ, Saber N, Sasaki S, Lynn FC, Kieffer TJ, Levings MK
Transplantation 2023
AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells
Sakemura RL, Hefazi M, Cox MJ, Siegler EL, Sinha S, Hansen MJ, Stewart CM, Feigin JM, Roman CM, Schick KJ, Can I, Tapper EE, Horvei P, Adada MM, Bezerra ED, Fonkoua LA, Ruff MW, Forsman CL, Nevala WK, Boysen JC, Tschumper RC, Grand CL, Kuchimanchi KR, Mouritsen L, Foulks JM, Warner SL, Call TG, Parikh SA, Ding W, Kay NE, Kenderian SS
Cancer immunology research 2023
Cell Granularity Reflects Immune Cell Function and Enables Selection of Lymphocytes with Superior Attributes for Immunotherapy
Wu T, Tan JH, Sin W, Luah YH, Tan SY, Goh M, Birnbaum ME, Chen Q, Cheow LF
Advanced Science 2023
Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T Cell Therapy in Adults with high-risk Relapsed/Refractory ALL
Aldoss I, Khaled SK, Wang X, Palmer J, Wang Y, Wagner JR, Clark MC, Simpson J, Paul J, Vyas V, Chien SH, Stein A, Pullarkat V, Salhotra A, Al Malki MM, Aribi A, Sandhu K, Thomas SH, Budde LE, Marcucci G, Brown CE, Forman SJ
Clinical cancer research 2023
Exploring CAR-T Cell Therapy Side Effects: Mechanisms and Management Strategies
Zhang Y, Qin D, Shou AC, Liu Y, Wang Y, Zhou L
Journal of Clinical Medicine 2023
Prediction of severe CRS and determination of biomarkers in B cell-acute lymphoblastic leukemia treated with CAR-T cells
Wei Z, Xu J, Zhao C, Zhang M, Xu N, Kang L, Lou X, Yu L, Feng W
Frontiers in immunology 2023
Actin cytoskeleton remodeling at the cancer cell side of the immunological synapse: good, bad, or both?
Ockfen E, Filali L, Pereira Fernandes D, Hoffmann C, Thomas C
Frontiers in immunology 2023
Outcomes of Second Anti-CD19 CAR T-Cell Therapy (CART2) in Acute B Lymphoblastic Leukemia and the Impact of Allo-HSCT on Efficacy
Xu Q, Shi Y, Xue L, An F, Xu H, Liu X, Zhu X, Sun Z, Zhai Z, Wang X
Cell transplantation 2023
Complete spectrum of adverse events associated with chimeric antigen receptor (CAR)-T cell therapies
Yang C, Nguyen J, Yen Y
Journal of biomedical science 2023
Novel Approaches to Treatment of Acute Myeloid Leukemia Relapse Post Allogeneic Stem Cell Transplantation
Liberatore C, Di Ianni M
International journal of molecular sciences 2023
Delivery of Plasmid DNA by Ionizable Lipid Nanoparticles to Induce CAR Expression in T Cells
Prazeres PH, Ferreira H, Costa PA, da Silva W, Alves MT, Padilla M, Thatte A, Santos AK, Lobo AO, Sabino A, Del Puerto HL, Mitchell MJ, Guimaraes PP
International Journal of Nanomedicine 2023
CAR T-Cells in Acute Lymphoblastic Leukemia: Current Status and Future Prospects
Almaeen AH, Abouelkheir M
Biomedicines 2023
A High-Throughput Microfluidic Cell Sorter Using a Three-Dimensional Coupled Hydrodynamic-Dielectrophoretic Pre-Focusing Module
Aghaamoo M, Cardenas-Benitez B, Lee AP
Micromachines 2023
Cellular and molecular waypoints along the path of T cell exhaustion
Lan X, Zebley CC, Youngblood B
Science Immunology 2023
Genome Editing in Engineered T Cells for Cancer Immunotherapy
Bonini C, Chapuis AG, Hudecek M, Guedan S, Magnani CF, Qasim W
Human Gene Therapy 2023
Alliance between titans: combination strategies of CAR-T cell therapy and oncolytic virus for the treatment of hematological malignancies.
Gao X, Liu J, Sun R, Zhang J, Cao X, Zhang Y, Zhao M
Annals of Hematology 2023
Insights gained from single-cell analysis of chimeric antigen receptor T-cell immunotherapy in cancer
Tang L, Huang ZP, Mei H, Hu Y
Military Medical Research 2023
Developing Strategies to Improve the Efficacy of CAR-T Therapy for Acute Myeloid Leukemia.
Guo S, Gao X, Sadhana M, Guo R, Liu J, Lu W, Zhao MF
Current Treatment Options in Oncology 2023
The Role of CD4 T Cell Help in CD8 T Cell Differentiation and Function During Chronic Infection and Cancer
Topchyan P, Lin S, Cui W
Immune Network 2023
CAR-T cell therapy for hematological malignancies: History, status and promise
Wang C, Wang J, Che S, Zhao H
Heliyon 2023
CAR+ and CAR− T cells share a differentiation trajectory into an NK-like subset after CD19 CAR T cell infusion in patients with B cell malignancies
Louie RH, Cai C, Samir J, Singh M, Deveson IW, Ferguson JM, Amos TG, McGuire HM, Gowrishankar K, Adikari T, Balderas R, Bonomi M, Ruella M, Bishop D, Gottlieb D, Blyth E, Micklethwaite K, Luciani F
Nature Communications 2023
Harnessing CD3 diversity to optimize CAR T cells
Velasco Cárdenas RM, Brandl SM, Meléndez AV, Schlaak AE, Buschky A, Peters T, Beier F, Serrels B, Taromi S, Raute K, Hauri S, Gstaiger M, Lassmann S, Huppa JB, Boerries M, Andrieux G, Bengsch B, Schamel WW, Minguet S
Nature Immunology 2023
Model‐informed drug development of autologous CAR‐T cell therapy: Strategies to optimize CAR‐T cell exposure leveraging cell kinetic/dynamic modeling
Mc Laughlin AM, Milligan PA, Yee C, Bergstrand M
The Journal of Pathology 2023
Framework humanization optimizes potency of anti-CD72 nanobody CAR-T cells for B-cell malignancies
Temple WC, Nix MA, Naik A, Izgutdina A, Huang BJ, Wicaksono G, Phojanakong P, Serrano JA, Young EP, Ramos E, Salangsang F, Steri V, Xirenayi S, Hermiston M, Logan AC, Stieglitz E, Wiita AP
Journal for ImmunoTherapy of Cancer 2023
Ligand-based targeting of c-kit using engineered γδ T cells as a strategy for treating acute myeloid leukemia
Branella GM, Lee JY, Okalova J, Parwani KK, Alexander JS, Arthuzo RF, Fedanov A, Yu B, McCarty D, Brown HC, Chandrakasan S, Petrich BG, Doering CB, Spencer HT
Frontiers in immunology 2023
CAR-T Cell Therapy in the Treatment of Pediatric Non-Hodgkin Lymphoma
Ostojska M, Nowak E, Twardowska J, Lejman M, Zawitkowska J
Journal of Personalized Medicine 2023
CAR T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia
Saleh K, Pasquier F, Bigenwald C, De Botton S, Ribrag V, Castilla-Llorente C
Journal of Clinical Medicine 2023
Assessment and predictive ability of the absolute neutrophil count in peripheral blood for in vivo CAR T cells expansion and CRS
Zhang M, Long X, Xiao Y, Jin J, Chen C, Meng J, Liu W, Liu A, Chen L
Journal for ImmunoTherapy of Cancer 2023
Factors associated with long-term outcomes of CD19 CAR T-cell therapy for relapsed/refractory CLL.
Liang EC, Albittar A, Huang JJ, Hirayama AV, Kimble EL, Portuguese AJ, Chapuis A, Shadman M, Till BG, Cassaday RD, Milano F, Kiem HP, Riddell SR, Turtle CJ, Maloney DG, Gauthier J
Blood Advances 2023
Has the shortage of fludarabine altered the current paradigm of lymphodepletion in favor of bendamustine?
Filioglou D, Husnain M, Khurana S, Simpson RJ, Katsanis E
Frontiers in immunology 2023
DIALing-up the preclinical characterization of gene-modified adoptive cellular immunotherapies
Giardino Torchia ML, Moody G
Frontiers in immunology 2023
Toxicities of CAR T-cell therapy: a review of current literature
Asghar MS, Ismail Shah SM, Rani A, Kazmi S, Savul IS, Ukrani J, Khan F, Hasan CA, Rathore N, Syed M, Keswani S, Surkasha F, Mal D, Kumar D
Annals of Medicine and Surgery 2023
CAR-T treatment for cancer: prospects and challenges
Chen R, Chen L, Wang C, Zhu H, Gu L, Li Y, Xiong X, Chen G, Jian Z
Frontiers in Oncology 2023
A bibliometric and knowledge-map study of CAR-T cell-related cytokine release syndrome (CRS) from 2012 to 2023.
Li H, Huang Q, Zhang Y
Human Vaccines & Immunotherapeutics 2023
Cyclosporine A-resistant CAR-T cells mediate antitumour immunity in the presence of allogeneic cells.
Zhang Y, Fang H, Wang G, Yuan G, Dong R, Luo J, Lyu Y, Wang Y, Li P, Zhou C, Yin W, Xiao H, Sun J, Zeng X
Nature Communications 2023
Early prediction of cytokine release syndrome by measuring phosphate and magnesium levels following chimeric antigen receptor T cell therapy
Yoshida M, Matsuoka Y, Mitsuyuki S, Yonetani N, Kawai J, Kondo T, Ishikawa T
2023
Building safety into CAR-T therapy.
Peters DT, Savoldo B, Grover NS
Human Vaccines & Immunotherapeutics 2023
Recent advances in cellular immunotherapy for lymphoid malignancies.
Chung H, Cho H
Blood Research 2023
Lymphodepletion – an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle
Lickefett B, Chu L, Ortiz-Maldonado V, Warmuth L, Barba P, Doglio M, Henderson D, Hudecek M, Kremer A, Markman J, Nauerth M, Negre H, Sanges C, Staber PB, Tanzi R, Delgado J, Busch DH, Kuball J, Luu M, Jäger U
Frontiers in immunology 2023
Engineering self-propelled tumor-infiltrating CAR T cells using synthetic velocity receptors.
Johnston AC, Alicea GM, Lee CC, Patel PV, Hanna EA, Vaz E, Forjaz A, Wan Z, Nair PR, Lim Y, Chen T, Du W, Kim D, Nichakawade TD, Rebecca VW, Bonifant CL, Fan R, Kiemen AL, Wu PH, Wirtz D
bioRxiv : the preprint server for biology 2023
γ-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial.
Cowan AJ, Pont MJ, Sather BD, Turtle CJ, Till BG, Libby EN 3rd, Coffey DG, Tuazon SA, Wood B, Gooley T, Wu VQ, Voutsinas J, Song X, Shadman M, Gauthier J, Chapuis AG, Milano F, Maloney DG, Riddell SR, Green DJ
The Lancet Oncology 2023
Current assessment and management of measurable residual disease in patients with acute lymphoblastic leukemia in the setting of CAR-T-cell therapy
Lin M, Zhao X, Chang Y, Zhao X
Chinese Medical Journal 2023
Manufacture of CD22 CAR T cells following positive versus negative selection results in distinct cytokine secretion profiles and γδ T cell output
Song HW, Benzaoui M, Dwivedi A, Underwood S, Shao L, Achar S, Posarac V, Remley VA, Prochazkova M, Cai Y, Jin P, Somerville RP, Stroncek DF, Altan-Bonnet G, Shah NN, Chien CD, Taylor N, Highfill SL
2023
CD19 occupancy with tafasitamab increases therapeutic index of CART19 cell therapy and diminishes severity of CRS
Sakemura RL, Manriquez Roman C, Horvei P, Siegler EL, Girsch JH, Sirpilla OL, Stewart CM, Yun K, Can I, Ogbodo EJ, Adada MM, Bezerra ED, Kankeu Fonkoua LA, Hefazi M, Ruff MW, Kimball BL, Mai LK, Huynh TN, Nevala WK, Ilieva K, Augsberger C, Patra-Kneuer M, Schanzer J, Endell J, Heitmüller C, Steidl S, Parikh SA, Ding W, Kay NE, Nowakowski GS, Kenderian SS
Blood 2023
Timing of anti–PD-L1 antibody initiation affects efficacy/toxicity of CD19 CAR T-cell therapy for large B-cell lymphoma
Hirayama AV, Kimble EL, Wright JH, Fiorenza S, Gauthier J, Voutsinas JM, Wu Q, Yeung CC, Gazeau N, Pender BS, Kirchmeier DR, Torkelson A, Chutnik AN, Cassaday RD, Chapuis AG, Green DJ, Kiem HP, Milano F, Shadman M, Till BG, Riddell SR, Maloney DG, Turtle CJ
Blood Advances 2023
Rapid anti-myeloma activity by T cells expressing an anti-BCMA CAR with a human heavy-chain-only antigen-binding domain
Mikkilineni L, Natrakul DA, Lam N, Manasanch EE, Mann J, Weissler KA, Wong N, Brudno JN, Goff SL, Yang JC, Ganaden M, Patel R, Zheng Z, Gartner JJ, Martin KR, Wang HW, Yuan CM, Lowe T, Maric I, Shao L, Jin P, Stroncek DF, Highfill SL, Rosenberg SA, Kochenderfer JN
Molecular Therapy 2023
Progress and Pitfalls of Chimeric Antigen Receptor T Cell Immunotherapy against T Cell Malignancies.
Angelos MG, Patel RP, Ruella M, Barta SK
2023
Transient responses and significant toxicities of anti-CD30 CAR T cells for CD30+ lymphomas: results of a phase 1 trial
Brudno JN, Natrakul DA, Karrs J, Patel N, Maass-Moreno R, Ahlman MA, Mikkilineni L, Mann J, Stroncek DF, Highfill SL, Fromm GC, Patel R, Pittaluga S, Kochenderfer JN
Blood Advances 2023
Cooperative CAR targeting to selectively eliminate AML and minimize escape.
Haubner S, Mansilla-Soto J, Nataraj S, Kogel F, Chang Q, de Stanchina E, Lopez M, Ng MR, Fraser K, Subklewe M, Park JH, Wang X, Rivière I, Sadelain M
Cancer Cell 2023
Aptamer-Based Chromatographic Methods for Efficient and Economical Separation of Leukocyte Populations
Ling M, Cardle II, Song K, Yan AJ, Kacherovsky N, Jensen MC, Pun SH
ACS Biomaterials Science & Engineering 2023
INSPIRED Symposium Part 1: Clinical Variables Associated with Improved Outcomes for Children and Young Adults treated with Chimeric Antigen Receptor T cells for B cell Acute Lymphoblastic Leukemia.
Myers RM, Jacoby E, Pulsipher MA, Pasquini MC, Grupp SA, Shah NN, Laetsch TW, Curran KJ, Schultz LM
2023
All about blinatumomab: the bispecific T cell engager immunotherapy for B cell acute lymphoblastic leukemia
Mirfakhraie R, Dehaghi BK, Ghorbi MD, Ghaffari-Nazari H, Mohammadian M, Salimi M, Ardakani MT, Parkhideh S
2023
Promises and challenges of a decentralized CAR T-cell manufacturing model
Shah M, Krull A, Odonnell L, de Lima MJ, Bezerra E
2023
INSPIRED Symposium Part 4B: Chimeric Antigen Receptor T Cell Correlative Studies-Established Findings and Future Priorities.
Ligon JA, Ramakrishna S, Ceppi F, Calkoen FGJ, Diorio C, Davis KL, Jacoby E, Gottschalk S, Schultz LM, Capitini CM
Transplantation and cellular therapy 2023
CAR T-cell manufacturing from naive/stem memory T-lymphocytes enhances antitumor responses while curtailing cytokine release syndrome
Silvia Arcangeli, Camilla Bove, Claudia Mezzanotte, Barbara Camisa, Laura Falcone, Francesco Manfredi, Eugenia Bezzecchi, Rita El Khoury, Rossana Norata, Francesca Sanvito, Maurilio Ponzoni, Beatrice Greco, Marta A Moresco, Matteo G. Carrabba, Fabio Ciceri, Chiara Bonini, Attilio Bondanza, Monica Casucci
Journal of Clinical Investigation 2022
Investigation of the Risk Factors to Predict Cytokine Release Syndrome in Relapsed or Refractory Acute B-lymphocytic Leukemia Patients Receiving IL-6 Knocking Down Anti-CD19 Chimeric Antigen Receptor T Cell Therapy
Wen-Jie Gong, Yan Qiu, Ming-Hao Li, Yan-Yan Li, Jing-Qiu Yu, Liqing Kang, Aining Sun, Depei Wu, Lei Yu, Sheng-Li Xue
Frontiers in immunology 2022
Single-cell analysis by mass cytometry reveals CD19 CAR T cell spatiotemporal plasticity in patients
L Goldberg, E Haas, V Vyas, R Urak, S Forman, X Wang
OncoImmunology 2022
Knowns and Unknowns about CAR-T Cell Dysfunction
A Titov, Y Kaminskiy, I Ganeeva, E Zmievskaya, A Valiullina, A Rakhmatullina, A Petukhov, R Miftakhova, A Rizvanov, E Bulatov
Cancers 2022
Highly aminated iron oxide nanoworms for simultaneous manufacturing and labeling of chimeric antigen receptor T cells
W Zhang, H Gaikwad, EV Groman, E Purev, D Simberg, G Wang
Journal of Magnetism and Magnetic Materials 2022
Enhanced Chimeric Antigen Receptor T Cell Therapy through Co-Application of Synergistic Combination Partners
S Stock, A Kluever, S Endres, S Kobold
Biomedicines 2022
Adoptive Cellular Therapy for Multiple Myeloma Using CAR- and TCR-Transgenic T Cells: Response and Resistance
F Füchsl, A Krackhardt
Cells 2022
Engineered T cells and their therapeutic applications in autoimmune diseases
L Bao, X Bo, H Cao, C Qian, Z Wang, B Li
Zoological Research 2022
TCR-T Immunotherapy: The Challenges and Solutions
Y Liu, X Yan, F Zhang, X Zhang, F Tang, Z Han, Y Li
Frontiers in Oncology 2022
PiggyBac Transposon-Mediated CD19 Chimeric Antigen Receptor-T Cells Derived From CD45RA-Positive Peripheral Blood Mononuclear Cells Possess Potent and Sustained Antileukemic Function
M Suematsu, S Yagyu, N Nagao, S Kubota, Y Shimizu, M Tanaka, Y Nakazawa, T Imamura
Frontiers in immunology 2022
A Bibliometric and Knowledge-Map Analysis of CAR-T Cells From 2009 to 2021
L Miao, J Zhang, Z Zhang, S Wang, F Tang, M Teng, Y Li
Frontiers in immunology 2022
Development of CAR T Cell Therapy in Children—A Comprehensive Overview
M Boettcher, A Joechner, Z Li, S Yang, P Schlegel
Journal of Clinical Medicine 2022
Overcome tumor relapse in CAR T cell therapy
C Huo, J Yang, Y Gu, D Wang, X Zhang, Y Li
Clinical & Translational Oncology 2022
A novel and efficient CD22 CAR-T therapy induced a robust antitumor effect in relapsed/refractory leukemia patients when combined with CD19 CAR-T treatment as a sequential therapy
Y Zhang, S Li, Y Wang, Y Lu, Y Xu, Q Rao, H Wang, H Xing, Z Tian, K Tang, L Lv, M Wang, J Wang
Experimental Hematology and Oncology 2022
iNKT: A new avenue for CAR-based cancer immunotherapy
Y Liu, G Wang, D Chai, Y Dang, J Zheng, H Li
Translational oncology 2022
A T-cell independent universal cellular therapy strategy through antigen depletion
D Li, W Wang, S Xie, M Ge, R Wang, Q Xu, Y Sun, J Zhu, H Liu
Theranostics 2022
Reprogramming the tumor microenvironment by genome editing for precision cancer therapy
K Liu, J Cui, Y Zhan, Q Ouyang, Q Lu, D Yang, X Li, J Yin
Molecular Cancer 2022
Harnessing Antitumor CD4+ T Cells for Cancer Immunotherapy
M Khelil, Y Godet, S Abdeljaoued, C Borg, O Adotévi, R Loyon
Cancers 2022
Harnessing the chemokine system to home CAR-T cells into solid tumors
J Foeng, I Comerford, S McColl
Cell reports. Medicine 2022
The differential effects of tumor burdens on predicting the net benefits of ssCART-19 cell treatment on r/r B-ALL patients
M Li, S Xue, X Tang, J Xu, S Chen, Y Han, H Qiu, M Miao, N Xu, J Tan, L Kang, Z Yu, X Lou, Y Xu, J Chen, Z Yan, W Feng, D Wu, L Yu
Scientific Reports 2022
Chimeric Antigen Receptor T-Cell Therapy in Paediatric B-Cell Precursor Acute Lymphoblastic Leukaemia: Curative Treatment Option or Bridge to Transplant?
J Buechner, I Caruana, A Künkele, S Rives, K Vettenranta, P Bader, C Peters, A Baruchel, F Calkoen
Frontiers in Pediatrics 2022
Novel immunotherapies in multiple myeloma
K Ohmine, R Uchibori
International Journal of Hematology 2022
Humanized CD30-Targeted Chimeric Antigen Receptor T Cells Exhibit Potent Preclinical Activity Against Hodgkin’s Lymphoma Cells
J Guo, S He, Y Zhu, W Yu, D Yang, X Zhao
Frontiers in Cell and Developmental Biology 2022
Therapeutic effiacy of T cells expressing chimeric antigen receptor derived from a mesothelin-specific scFv in orthotopic human pancreatic cancer animal models
H Lee, I Kim, U Kim, S Choi, T Kim, D Lee, Y Lee, J Lee, J Jo, Y Lee, H Lee, S Kim, J Ahn
Neoplasia (New York, N.Y.) 2022
Anti-CAIX BBζ CAR4/8 T cells exhibit superior efficacy in a ccRCC mouse model
Y Wang, A Buck, M Grimaud, A Culhane, S Kodangattil, C Razimbaud, D Bonal, Q Nguyen, Z Zhu, K Wei, M O'Donnell, Y Huang, S Signoretti, T Choueiri, G Freeman, Q Zhu, W Marasco
Molecular Therapy — Oncolytics 2022
Feasibility study of a novel preparation strategy for anti-CD7 CAR-T cells with a recombinant anti-CD7 blocking antibody
J Ye, Y Jia, I Tuhin, J Tan, M Monty, N Xu, L Kang, M Li, X Lou, M Zhou, X Fang, J Shao, H Zhu, Z Yan, L Yu
Molecular Therapy — Oncolytics 2022
HLA-independent T cell receptors for targeting tumors with low antigen density
J Mansilla-Soto, J Eyquem, S Haubner, M Hamieh, J Feucht, N Paillon, A Zucchetti, Z Li, M Sjöstrand, P Lindenbergh, M Saetersmoen, A Dobrin, M Maurin, A Iyer, A Angus, M Miele, Z Zhao, T Giavridis, S van der Stegen, F Tamzalit, I Rivière, M Huse, R Hendrickson, C Hivroz, M Sadelain
Nature Medicine 2022
Effectiveness and Safety of Anti-CD19 Chimeric Antigen Receptor-T Cell Immunotherapy in Patients With Relapsed/Refractory Large B-Cell Lymphoma: A Systematic Review and Meta-Analysis
Z Ying, Y Song, J Zhu
Frontiers in pharmacology 2022
CAR T cells redirected to cell surface GRP78 display robust anti-acute myeloid leukemia activity and do not target hematopoietic progenitor cells
N Hebbar, R Epperly, A Vaidya, U Thanekar, S Moore, M Umeda, J Ma, S Patil, D Langfitt, S Huang, C Cheng, J Klco, S Gottschalk, M Velasquez
Nature Communications 2022
Insights into Modern Therapeutic Approaches in Pediatric Acute Leukemias
K Panuciak, M Margas, K Makowska, M Lejman
Cells 2022
Emerging Management Approach for the Adverse Events of Immunotherapy of Cancer
Rahman MM, Behl T, Islam MR, Alam MN, Islam MM, Albarrati A, Albratty M, Meraya AM, Bungau SG
Molecules (Basel, Switzerland) 2022
Optimization of Culture Conditions for the Generation of Canine CD20-CAR-T Cells for Adoptive Immunotherapy.
Sakai O, Yamamoto H, Igase M, Mizuno T
In vivo (Athens, Greece) 2022
Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion.
Amini L, Silbert SK, Maude SL, Nastoupil LJ, Ramos CA, Brentjens RJ, Sauter CS, Shah NN, Abou-El-Enein M
Nature reviews. Clinical oncology 2022
The Past, Present, and Future of Non-Viral CAR T Cells
Moretti A, Ponzo M, Nicolette CA, Tcherepanova IY, Biondi A, Magnani CF
Frontiers in immunology 2022
Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy.
Juluri KR, Wu QV, Voutsinas J, Hou J, Hirayama AV, Mullane E, Miles N, Maloney DG, Turtle CJ, Bar M, Gauthier J
Blood Advances 2022
Development of a Novel Anti-CD19 CAR Containing a Fully Human scFv and Three Costimulatory Domains.
Wutti-In Y, Sujjitjoon J, Sawasdee N, Panya A, Kongkla K, Yuti P, Yongpitakwattana P, Thepmalee C, Junking M, Chieochansin T, Poungvarin N, Yamabhai M, Yenchitsomanus PT
Frontiers in Oncology 2022
Fludarabine exposure predicts outcome after CD19 CAR T-cell therapy in children and young adults with acute leukemia.
Dekker L, Calkoen FG, Jiang Y, Blok H, Veldkamp SR, De Koning C, Spoon M, Admiraal R, Hoogerbrugge P, Vormoor B, Vormoor HJ, Visscher H, Bierings M, Van Der Vlugt M, Van Tinteren H, Nijstad AL, Huitema ADR, Van Der Elst KCM, Pieters R, Lindemans CA, Nierkens S
Blood Advances 2022
Treating CAR-T relapses: check not checkmate.
Spiegel JY, Komanduri KV
Blood 2022
Biomarkers of Response and Resistance to Immunotherapy in Microsatellite Stable Colorectal Cancer: Toward a New Personalized Medicine.
Huyghe N, Benidovskaya E, Stevens P, Van den Eynde M
Cancers 2022
Impact of Manufacturing Procedures on CAR T Cell Functionality
Watanabe N, Mo F, McKenna MK
Frontiers in immunology 2022
Resistance against anti-CD19 and anti-BCMA CAR T cells: Recent advances and coping strategies
Atilla PA, Atilla E
Translational oncology 2022
Targeting of the alphav beta3 integrin complex by CAR-T cells leads to rapid regression of diffuse intrinsic pontine glioma and glioblastoma.
Cobb DA, de Rossi J, Liu L, An E, Lee DW
Journal for ImmunoTherapy of Cancer 2022
Cytopenia after CAR-T Cell Therapy-A Brief Review of a Complex Problem.
Sharma N, Reagan PM, Liesveld JL
Cancers 2022
T cells expressing CD5/CD7 bispecific chimeric antigen receptors with fully human heavy-chain-only domains mitigate tumor antigen escape.
Dai Z, Mu W, Zhao Y, Cheng J, Lin H, Ouyang K, Jia X, Liu J, Wei Q, Wang M, Liu C, Tan T, Zhou J
Signal Transduction and Targeted Therapy 2022
A durable 4-1BB-based CD19 CAR-T cell for treatment of relapsed or refractory non-Hodgkin lymphoma.
Ying Z, He T, Jin S, Wang X, Zheng W, Lin N, Tu M, Xie Y, Ping L, Liu W, Deng L, Ding Y, Hu X, Bu B, Lu X, Song Y, Zhu J
2022
Update for Advance CAR-T Therapy in Solid Tumors, Clinical Application in Peritoneal Carcinomatosis From Colorectal Cancer and Future Prospects.
Qian S, Villarejo-Campos P, Guijo I, Hernández-Villafranca S, García-Olmo D, González-Soares S, Guadalajara H, Jiménez-Galanes S, Qian C
Frontiers in immunology 2022
Advances in Allogeneic Cancer Cell Therapy and Future Perspectives on “Off-the-Shelf” T Cell Therapy Using iPSC Technology and Gene Editing
Furukawa Y, Hamano Y, Shirane S, Kinoshita S, Azusawa Y, Ando J, Nakauchi H, Ando M
Cells 2022
Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing
Dimitri A, Herbst F, Fraietta JA
Molecular Cancer 2022
Prevention and Treatment of Side Effects of Immunotherapy for Bladder Cancer
Lou K, Feng S, Zhang G, Zou J, Zou X
Frontiers in Oncology 2022
Decade-long leukaemia remissions with persistence of CD4+ CAR T cells
Melenhorst JJ, Chen GM, Wang M, Porter DL, Chen C, Collins MA, Gao P, Bandyopadhyay S, Sun H, Zhao Z, Lundh S, Pruteanu-Malinici L, Nobles CL, Maji S, Frey NV, Gill SI, Tian L, Kulikovskaya I, Gupta M, Ambrose DE, Davis MM, Fraietta JA, Brogdon JL, Young RM, Chew A, Levine BL, Siegel DL, Alanio C, Wherry EJ, Bushman FD, Lacey SF, Tan K, June CH
Nature 2022
Immunogenicity of CAR-T Cell Therapeutics: Evidence, Mechanism and Mitigation
Khan AN, Chowdhury A, Karulkar A, Jaiswal AK, Banik A, Asija S, Purwar R
Frontiers in immunology 2022
CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges
Zhang X, Zhu L, Zhang H, Chen S, Xiao Y
Frontiers in immunology 2022
Neurotoxicity of Tumor Immunotherapy: The Emergence of Clinical Attention.
Zhang B, Li X, Yin T, Qin D, Chen Y, Ma Q, Shu P, Wang Y
Journal of Oncology 2022
Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy.
An L, Lin Y, Deng B, Yin Z, Zhao D, Ling Z, Wu T, Zhao Y, Chang AH, Tong C, Liu S
BMC Cancer 2022
Efficacy and safety of CD19 CAR-T cell therapy for acute lymphoblastic leukemia patients relapsed after allogeneic hematopoietic stem cell transplantation.
Cao XY, Li JJ, Lu PH, Liu KY
International Journal of Hematology 2022
Identification of the Predictive Models for the Treatment Response of Refractory/Relapsed B-Cell ALL Patients Receiving CAR-T Therapy
Gu J, Liu S, Cui W, Dai H, Cui Q, Yin J, Li Z, Kang L, Qiu H, Han Y, Miao M, Chen S, Xue S, Wang Y, Jin Z, Zhu X, Yu L, Wu D, Tang X
Frontiers in immunology 2022
IL-6/IFN-γ double knockdown CAR-T cells reduce the release of multiple cytokines from PBMCs in vitro
Zhang H, Lv X, Kong Q, Tan Y
Human Vaccines & Immunotherapeutics 2022
Cytotoxic Efficiency of Human CD8+ T Cell Memory Subtypes
Knörck A, Schäfer G, Alansary D, Richter J, Thurner L, Hoth M, Schwarz EC
Frontiers in immunology 2022
The generation and application of antigen-specific T cell therapies for cancer and viral-associated disease
Hont AB, Powell AB, Sohai DK, Valdez IK, Stanojevic M, Geiger AE, Chaudhary K, Dowlati E, Bollard CM, Cruz CR
Molecular Therapy 2022
Single-cell antigen-specific landscape of CAR T infusion product identifies determinants of CD19-positive relapse in patients with ALL
Bai Z, Woodhouse S, Zhao Z, Arya R, Govek K, Kim D, Lundh S, Baysoy A, Sun H, Deng Y, Xiao Y, Barrett DM, Myers RM, Grupp SA, June CH, Fan R, Camara PG, Melenhorst JJ
Science Advances 2022
CAR-T Cells Shoot for New Targets: Novel Approaches to Boost Adoptive Cell Therapy for B Cell-Derived Malignancies
Marhelava K, Krawczyk M, Firczuk M, Fidyt K
Cells 2022
Selective B cell depletion upon intravenous infusion of replication-incompetent anti-CD19 CAR lentivirus
Rive CM, Yung E, Dreolini L, Brown SD, May CG, Woodsworth DJ, Holt RA
2022
Toward Rapid, Widely Available Autologous CAR-T Cell Therapy – Artificial Intelligence and Automation Enabling the Smart Manufacturing Hospital
Hort S, Herbst L, Bäckel N, Erkens F, Niessing B, Frye M, König N, Papantoniou I, Hudecek M, Jacobs JJ, Schmitt RH
Frontiers in Medicine 2022
Use of CAR T-cell for acute lymphoblastic leukemia (ALL) treatment: a review study.
Sheykhhasan M, Manoochehri H, Dama P
Cancer Gene Therapy 2022
Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy
Fabrizio VA, Boelens JJ, Mauguen A, Baggott C, Prabhu S, Egeler E, Mavroukakis S, Pacenta H, Phillips CL, Rossoff J, Stefanski HE, Talano JA, Moskop A, Margossian SP, Verneris MR, Myers GD, Karras NA, Brown PA, Qayed M, Hermiston M, Satwani P, Krupski C, Keating AK, Wilcox R, Rabik CA, Chinnabhandar V, Kunicki M, Goksenin AY, Mackall CL, Laetsch TW, Schultz LM, Curran KJ
Blood Advances 2022
CRISPR Gene Editing of Human Primary NK and T Cells for Cancer Immunotherapy
Elmas E, Saljoughian N, de Souza Fernandes Pereira M, Tullius BP, Sorathia K, Nakkula RJ, Lee DA, Naeimi Kararoudi M
Frontiers in Oncology 2022
Time to evolve: predicting engineered T cell-associated toxicity with next-generation models
Donnadieu E, Luu M, Alb M, Anliker B, Arcangeli S, Bonini C, De Angelis B, Choudhary R, Espie D, Galy A, Holland C, Ivics Z, Kantari-Mimoun C, Kersten MJ, Köhl U, Kuhn C, Laugel B, Locatelli F, Marchiq I, Markman J, Moresco MA, Morris E, Negre H, Quintarelli C, Rade M, Reiche K, Renner M, Ruggiero E, Sanges C, Stauss H, Themeli M, Van den Brulle J, Hudecek M, Casucci M
Journal for ImmunoTherapy of Cancer 2022
Enabling Allogeneic T Cell-Based Therapies: Scalable Stirred-Tank Bioreactor Mediated Manufacturing
Gatla H, Uth N, Levinson Y, Navaei A, Sargent A, Ramaswamy S, Friedrich Ben-Nun I
2022
Novel Immune-Based treatments for Diffuse Large B-Cell Lymphoma: The Post-CAR T Cell Era
Atallah-Yunes SA, Robertson MJ, Davé UP, Ghione P, Perna F
Frontiers in immunology 2022
Immunotherapy for Pediatric Acute Lymphoblastic Leukemia: Recent Advances and Future Perspectives
Lv M, Liu Y, Liu W, Xing Y, Zhang S
Frontiers in immunology 2022
Targeting an alternate Wilms' tumor antigen 1 peptide bypasses immunoproteasome dependency.
Lahman MC, Schmitt TM, Paulson KG, Vigneron N, Buenrostro D, Wagener FD, Voillet V, Martin L, Gottardo R, Bielas J, McElrath JM, Stirewalt DL, Pogosova-Agadjanyan EL, Yeung CC, Pierce RH, Egan DN, Bar M, Hendrie PC, Kinsella S, Vakil A, Butler J, Chaffee M, Linton J, McAfee MS, Hunter DS, Bleakley M, Rongvaux A, Van den Eynde BJ, Chapuis AG, Greenberg PD
Science Translational Medicine 2022
Tumour immunotherapy: lessons from predator-prey theory.
Hamilton PT, Anholt BR, Nelson BH
Nature reviews. Immunology 2022
Current Status and Perspectives of Dual-Targeting Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Hematological Malignancies
Xie B, Li Z, Zhou J, Wang W
Cancers 2022
CAR T-Cell Therapy Predictive Response Markers in Diffuse Large B-Cell Lymphoma and Therapeutic Options After CART19 Failure
Caballero AC, Escribà-Garcia L, Alvarez-Fernández C, Briones J
Frontiers in immunology 2022
CAR-T Cell Performance: How to Improve Their Persistence?
López-Cantillo G, Urueña C, Camacho BA, Ramírez-Segura C
Frontiers in immunology 2022
Optimized NGFR-derived hinges for rapid and efficient enrichment and detection of CAR T cells in vitro and in vivo
Bister A, Ibach T, Haist C, Gerhorst G, Smorra D, Soldierer M, Roellecke K, Wagenmann M, Scheckenbach K, Gattermann N, Wiek C, Hanenberg H
2022
NY-ESO-1-specific redirected T cells with endogenous TCR knockdown mediate tumor response and cytokine release syndrome
Ishihara M, Kitano S, Kageyama S, Miyahara Y, Yamamoto N, Kato H, Mishima H, Hattori H, Funakoshi T, Kojima T, Sasada T, Sato E, Okamoto S, Tomura D, Nukaya I, Chono H, Mineno J, Kairi MF, Diem Hoang Nguyen P, Simoni Y, Nardin A, Newell E, Fehlings M, Ikeda H, Watanabe T, Shiku H
Journal for ImmunoTherapy of Cancer 2022
Next-day manufacture of a novel anti-CD19 CAR-T therapy for B-cell acute lymphoblastic leukemia: first-in-human clinical study
Yang J, He J, Zhang X, Li J, Wang Z, Zhang Y, Qiu L, Wu Q, Sun Z, Ye X, Yin W, Cao W, Shen L, Sersch M, Lu P
Blood Cancer Journal 2022
Precision medicine: In vivo CAR therapy as a showcase for receptor-targeted vector platforms
Michels A, Ho N, Buchholz CJ
Molecular Therapy 2022
T cells isolated from G-CSF-treated multiple myeloma patients are suitable for the generation of BCMA-directed CAR-T cells
Battram AM, Oliver-Caldés A, Suárez-Lledó M, Lozano M, Bosch i Crespo M, Martínez-Cibrián N, Cid J, Moreno DF, Rodríguez-Lobato LG, Urbano-Ispizua A, Fernández de Larrea C
2022
Influence of Culture Conditions on Ex Vivo Expansion of T Lymphocytes and Their Function for Therapy: Current Insights and Open Questions
Sudarsanam H, Buhmann R, Henschler R
Frontiers in Bioengineering and Biotechnology 2022
Transgenic expression of IL-7 regulates CAR-T cell metabolism and enhances in vivo persistence against tumor cells
Li L, Li Q, Yan ZX, Sheng LS, Fu D, Xu P, Wang L, Zhao WL
Scientific Reports 2022
Modified Manufacturing Process Modulates CD19CAR T-cell Engraftment Fitness and Leukemia-Free Survival in Pediatric and Young Adult Subjects.
Ceppi F, Wilson AL, Annesley C, Kimmerly GR, Summers C, Brand A, Seidel K, Wu QV, Beebe A, Brown C, Mgebroff S, Lindgren C, Rawlings-Rhea SD, Huang W, Pulsipher MA, Wayne AS, Park JR, Jensen MC, Gardner RA
Cancer immunology research 2022
Mapping CAR T-Cell Design Space Using Agent-Based Models.
Prybutok AN, Yu JS, Leonard JN, Bagheri N
Frontiers in Molecular Biosciences 2022
CAR T-Cell-Based gene therapy for cancers: new perspectives, challenges, and clinical developments.
Jogalekar MP, Rajendran RL, Khan F, Dmello C, Gangadaran P, Ahn BC
Frontiers in immunology 2022
In vivo generation of CAR T cells in the presence of human myeloid cells
Ho N, Agarwal S, Milani M, Cantore A, Buchholz CJ, Thalheimer FB
2022
Chimeric Antigen Receptor T-Cells: An Overview of Concepts, Applications, Limitations, and Proposed Solutions
Alnefaie A, Albogami S, Asiri Y, Ahmad T, Alotaibi SS, Al-Sanea MM, Althobaiti H
Frontiers in Bioengineering and Biotechnology 2022
Biological and Molecular Factors Predicting Response to Adoptive Cell Therapies in Cancer
Ferrer G, Álvarez-Errico D, Esteller M
JNCI Journal of the National Cancer Institute 2022
Relative hypercoagulation induced by suppressed fibrinolysis after tisagenlecleucel infusion in malignant lymphoma
Yamasaki-Morita M, Arai Y, Ishihara T, Onishi T, Shimo H, Nakanishi K, Nishiyama Y, Jo T, Hiramatsu H, Mitsuyoshi T, Mizumoto C, Kanda J, Nishikori M, Kitawaki T, Nogami K, Takaori-Kondo A, Nagao M, Adachi S
Blood Advances 2022
The efficacy and safety of chimeric antigen receptor T cells in digestive system cancers: a systematic review and meta-analysis
Zhao Z, Zhang J, Bian J, Lu X
Annals of translational medicine 2022
The safety of blinatumomab in pediatric patients with acute lymphoblastic leukemia: A systematic review and meta-analysis
Marrapodi MM, Mascolo A, di Mauro G, Mondillo G, Pota E, Rossi F
Frontiers in Pediatrics 2022
Clinical Trials for Chimeric Antigen Receptor T-Cell Therapy: Lessons Learned and Future Directions
Schroeder BA, Jess J, Sankaran H, Shah NN
Current Opinion in Hematology 2022
Efficient derivation of chimeric-antigen receptor-modified TSCM cells
Kranz E, Kuhlmann CJ, Chan J, Kim PY, Chen IS, Kamata M
Frontiers in immunology 2022
A novel antibody-TCR (AbTCR) T-cell therapy is safe and effective against CD19-positive relapsed/refractory B-cell lymphoma.
He P, Liu H, Zimdahl B, Wang J, Luo M, Chang Q, Tian F, Ni F, Yu D, Liu H, Chen L, Wang H, Zhang M, Grupp SA, Liu C
Journal of Cancer Research and Clinical Oncology 2022
Development of minimal physiologically-based pharmacokinetic-pharmacodynamic models for characterizing cellular kinetics of CAR T cells following local deliveries in mice.
Tsai CH, Singh AP, Xia CQ, Wang H
Journal of Pharmacokinetics and Pharmacodynamics 2022
The multifaceted mechanisms of malignant glioblastoma progression and clinical implications.
Sun R, Kim AH
Cancer metastasis reviews 2022
Chimeric antigen receptor T cells engineered to recognize the P329G-mutated Fc part of effector-silenced tumor antigen-targeting human IgG1 antibodies enable modular targeting of solid tumors.
Stock S, Benmebarek MR, Kluever AK, Darowski D, Jost C, Stubenrauch KG, Benz J, Freimoser-Grundschober A, Moessner E, Umana P, Subklewe M, Endres S, Klein C, Kobold S
Journal for ImmunoTherapy of Cancer 2022
Chimeric antigen receptor T cell: A cancer immunotherapy
Singh S, Khasbage S, Kaur RJ, Sidhu JK, Bhandari B
Indian journal of pharmacology 2022
人源化CD19 CAR-T细胞治疗儿童及青少年复发难治急性淋巴细胞白血病患者的疗效及安全性
2022
Relapse Mechanism and Treatment Strategy After Chimeric Antigen Receptor T-Cell Therapy in Treating B-Cell Hematological Malignancies
Xie D, Jin X, Sun R, Zhang M, Wang J, Xiong X, Zhang X, Zhao M
Technology in cancer research & treatment 2022
DLL4 and VCAM1 enhance the emergence of T cell–competent hematopoietic progenitors from human pluripotent stem cells
Michaels YS, Edgar JM, Major MC, Castle EL, Zimmerman C, Yin T, Hagner A, Lau C, Hsu HH, Ibañez-Rios MI, Durland LJ, Knapp DJ, Zandstra PW
Science Advances 2022
Stem-like T cells and niches: Implications in human health and disease
Yi L, Yang L
Frontiers in immunology 2022
CAR-T cell development for Cutaneous T cell Lymphoma: current limitations and potential treatment strategies
To V, Evtimov VJ, Jenkin G, Pupovac A, Trounson AO, Boyd RL
Frontiers in immunology 2022
Paving the Way to Solid Tumors: Challenges and Strategies for Adoptively Transferred Transgenic T Cells in the Tumor Microenvironment.
Füchsl F, Krackhardt AM
Cancers 2022
Current Progress of CAR-NK Therapy in Cancer Treatment.
Pang Z, Wang Z, Li F, Feng C, Mu X
Cancers 2022
Combination strategies to optimize the efficacy of chimeric antigen receptor T cell therapy in haematological malignancies.
Xiao X, Wang Y, Zou Z, Yang Y, Wang X, Xin X, Tu S, Li Y
Frontiers in immunology 2022
Automated, scaled, transposon-based production of CAR T cells
Lock D, Monjezi R, Brandes C, Bates S, Lennartz S, Teppert K, Gehrke L, Karasakalidou-Seidt R, Lukic T, Schmeer M, Schleef M, Werchau N, Eyrich M, Assenmacher M, Kaiser A, Prommersberger S, Schaser T, Hudecek M
Journal for ImmunoTherapy of Cancer 2022
CAR-T cell potency: from structural elements to vector backbone components.
Mazinani M, Rahbarizadeh F
Biomarker Research 2022
Comparable outcomes in patients with B-cell acute lymphoblastic leukemia receiving haploidentical hematopoietic stem cell transplantation: Pretransplant minimal residual disease-negative complete remission following chimeric antigen receptor T-cell therapy versus chemotherapy
Yang TT, Meng Y, Kong DL, Wei GQ, Zhang MM, Wu WJ, Shi JM, Luo Y, Zhao YM, Yu J, Jing RR, Zhao MY, Zhao HL, Huang H, Hu YX
Frontiers in immunology 2022
Decitabine enhances targeting of AML cells by NY-ESO-1-specific TCR-T cells and promotes the maintenance of effector function and the memory phenotype.
Kang S, Wang L, Xu L, Wang R, Kang Q, Gao X, Yu L
Oncogene 2022
Applying a clinical lens to animal models of CAR-T cell therapies
Duncan BB, Dunbar CE, Ishii K
2022
Generation and Functional Characterization of PLAP CAR-T Cells against Cervical Cancer Cells
Yekehfallah V, Pahlavanneshan S, Sayadmanesh A, Momtahan Z, Ma B, Basiri M
Biomolecules 2022
Co-Stimulatory Receptor Signaling in CAR-T Cells
Honikel MM, Olejniczak SH
Biomolecules 2022
Recent advances and clinical pharmacology aspects of Chimeric Antigen Receptor (CAR) T‐cellular therapy development
Kast J, Nozohouri S, Zhou D, Yago MR, Chen P, Ahamadi M, Dutta S, Upreti VV
Clinical and Translational Science 2022
The Evolution of Chimeric Antigen Receptor T-Cell Therapy in Children, Adolescents and Young Adults with Acute Lymphoblastic Leukemia
Ragoonanan D, Sheikh IN, Gupta S, Khazal SJ, Tewari P, Petropoulos D, Li S, Mahadeo KM
Biomedicines 2022
Clinical Strategies for Enhancing the Efficacy of CAR T-Cell Therapy for Hematological Malignancies
Liu Q, Liu Z, Wan R, Huang W
Cancers 2022
Rethinking cancer targeting strategies in the era of smart cell therapeutics.
Allen GM, Lim WA
Nature reviews. Cancer 2022
The challenge of selecting tumor antigens for chimeric antigen receptor T-cell therapy in ovarian cancer.
Ding H, Zhang J, Zhang F, Xu Y, Yu Y, Liang W, Li Q
Medical Oncology 2022
Cellular kinetics: A clinical and computational review of CAR-T cell pharmacology.
Qi T, McGrath K, Ranganathan R, Dotti G, Cao Y
Advanced Drug Delivery Reviews 2022
Point-of-care anti-CD19 CAR T-cells for treatment of relapsed and refractory aggressive B cell lymphoma
Kedmi M, Shouval R, Fried S, Bomze D, Fein J, Cohen Z, Danilesko I, Shem-Tov N, Yerushalmi R, Jacoby E, Besser M, Shimoni A, Nagler A, Avigdor A
2022
Humanized CD19-directed CAR-T Cell Therapy in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia With CNSL or Neurological Comorbidity
Zhang N, Shao J, Li H, Zhu J, Xia M, Chen K, Jiang H
Journal of immunotherapy (Hagerstown, Md. : 1997) 2022
The risk factors and early predictive model of hematotoxicity after CD19 chimeric antigen receptor T cell therapy
Wang Y, Song Z, Geng Y, Gao L, Xu L, Tang G, Ni X, Chen L, Chen J, Wang T, Fu W, Feng D, Yu X, Wang L, Yang J
Frontiers in Oncology 2022
Efficacy and safety of universal (TCRKO) ARI-0001 CAR-T cells for the treatment of B-cell lymphoma.
Maldonado-Pérez N, Tristán-Manzano M, Justicia-Lirio P, Martínez-Planes E, Muñoz P, Pavlovic K, Cortijo-Gutiérrez M, Blanco-Benítez C, Castella M, Juan M, Wenes M, Romero P, Molina-Estévez FJ, Marañón C, Herrera C, Benabdellah K, Martin F
Frontiers in immunology 2022
Challenges of chimeric antigen receptor-T/natural killer cell therapy in the treatment of solid tumors: focus on colorectal cancer and evaluation of combination therapies.
Wang H, Pan W
Molecular and Cellular Biochemistry 2022
Chimeric antigen receptor engineered T cells and their application in the immunotherapy of solid tumours.
Mao R, Hussein MS, He Y
Expert Reviews in Molecular Medicine 2022
Adapter-Mediated Transduction with Lentiviral Vectors: A Novel Tool for Cell-Type-Specific Gene Transfer.
Cordes N, Winter N, Kolbe C, Kotter B, Mittelstaet J, Assenmacher M, Cathomen T, Kaiser A, Schaser T
Viruses 2022
Immunotherapy approaches for hematological cancers.
Lanier OL, Pérez-Herrero E, Andrea APD', Bahrami K, Lee E, Ward DM, Ayala-Suárez N, Rodríguez-Méndez SM, Peppas NA
iScience 2022
Impact of conditioning chemotherapy on lymphocyte kinetics and outcomes in LBCL patients treated with CAR T-cell therapy.
Strati P, Jallouk AP, Sun R, Choi J, Das K, Cherng HJ, Ahmed S, Lee HJ, Iyer SP, Nair R, Nastoupil LJ, Steiner RE, Huff CD, Yu Y, Mistry H, Pulsifer B, Noorani M, Saini N, Shpall EJ, Kebriaei P, Flowers CR, Westin JR, Hildebrandt MAT, Neelapu SS
Leukemia 2022
Secondary donor-derived CD19 CAR-T therapy is safe and efficacious in acute lymphoblastic leukemia with extramedullary relapse after first autologous CAR-T therapy.
Kong D, Yang T, Geng J, Jing R, Zhang Q, Wei G, Huang H, Hu Y
Journal of Zhejiang University. Science. B 2022
Genome-wide profiling of retroviral DNA integration and its effect on clinical pre-infusion CAR T-cell products.
Shao L, Shi R, Zhao Y, Liu H, Lu A, Ma J, Cai Y, Fuksenko T, Pelayo A, Shah NN, Kochenderfer JN, Norberg SM, Hinrichs C, Highfill SL, Somerville RP, Panch SR, Jin P, Stroncek DF
Journal of Translational Medicine 2022
Preferential expansion of CD8+ CD19-CAR T cells postinfusion and the role of disease burden on outcome in pediatric B-ALL
Talleur AC, Qudeimat A, Métais JY, Langfitt D, Mamcarz E, Crawford JC, Huang S, Cheng C, Hurley C, Madden R, Sharma A, Suliman A, Srinivasan A, Velasquez MP, Obeng EA, Willis C, Akel S, Karol SE, Inaba H, Bragg A, Zheng W, Zhou SM, Schell S, Tuggle-Brown M, Cullins D, Patil SL, Li Y, Thomas PG, Zebley C, Youngblood B, Pui CH, Lockey T, Geiger TL, Meagher MM, Triplett BM, Gottschalk S
Blood Advances 2022
CD19/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR
Shalabi H, Qin H, Su A, Yates B, Wolters PL, Steinberg SM, Ligon JA, Silbert S, DéDé K, Benzaoui M, Goldberg S, Achar S, Schneider D, Shahani SA, Little L, Foley T, Molina JC, Panch S, Mackall CL, Lee DW, Chien CD, Pouzolles M, Ahlman M, Yuan CM, Wang HW, Wang Y, Inglefield J, Toledo-Tamula MA, Martin S, Highfill SL, Altan-Bonnet G, Stroncek D, Fry TJ, Taylor N, Shah NN
Blood 2022
CD58 loss in tumor cells confers functional impairment of CAR T cells
Yan X, Chen D, Ma X, Wang Y, Guo Y, Wei J, Tong C, Zhu Q, Lu Y, Yu Y, Wu Z, Han W
Blood Advances 2022
Immunotherapy for the treatment of multiple myeloma
Boussi LS, Avigan ZM, Rosenblatt J
Frontiers in immunology 2022
EEG-based grading of immune effector cell-associated neurotoxicity syndrome
Jones DK, Eckhardt CA, Sun H, Tesh RA, Malik P, Quadri S, Firme MS, van Sleuwen M, Jain A, Fan Z, Jing J, Ge W, Nascimento FA, Sheikh IS, Jacobson C, Frigault M, Kimchi EY, Cash SS, Lee JW, Dietrich J, Westover MB
Scientific Reports 2022
Strategies to enhance CAR-T persistence.
Liu Y, An L, Huang R, Xiong J, Yang H, Wang X, Zhang X
Biomarker Research 2022
Thrombosis and lymphocyte subsets of COVID-19 omicron BA.2 variant patients with cancer
Yin J, Cong X, Wang N, Song W, Guan Y, Zhang Y, Li Z, Liu Z
Frontiers in Oncology 2022
Pan-Cancer Analysis Identifies Tumor Cell Surface Targets for CAR-T Cell Therapies and Antibody Drug Conjugates
Li X, Zhou J, Zhang W, You W, Wang J, Zhou L, Liu L, Chen WW, Li H
Cancers 2022
Measurable residual disease in acute lymphoblastic leukemia: methods and clinical context in adult patients
Saygin C, Cannova J, Stock W, Muffly L
Haematologica 2022
Multiple CAR-T cell therapy for acute B-cell lymphoblastic leukemia after hematopoietic stem cell transplantation: A case report
Deng L, Xiaolin Y, Wu Q, Song X, Li W, Hou Y, Liu Y, Wang J, Tian J, Zuo X, Zhou F
Frontiers in immunology 2022
Computational model of CAR T-cell immunotherapy dissects and predicts leukemia patient responses at remission, resistance, and relapse
Liu L, Ma C, Zhang Z, Witkowski MT, Aifantis I, Ghassemi S, Chen W
Journal for ImmunoTherapy of Cancer 2022
Should We Interfere with the Interleukin-6 Receptor During COVID-19: What Do We Know So Far?
Plocque A, Mitri C, Lefèvre C, Tabary O, Touqui L, Philippart F
Drugs 2022
Current updates on generations, approvals, and clinical trials of CAR T-cell therapy
Asmamaw Dejenie T, Tiruneh G\/Medhin M, Dessie Terefe G, Tadele Admasu F, Wale Tesega W, Chekol Abebe E
Human Vaccines & Immunotherapeutics 2022
Harnessing the Potential of Chimeric Antigen Receptor T-Cell Therapy for the Treatment of T-Cell Malignancies: A Dare or Double Dare?
Assi R, Salman H
Cells 2022
Enhancing CAR T-cell therapies against solid tumors: Mechanisms and reversion of resistance
Qin Y, Xu G
Frontiers in immunology 2022
Safety and Efficacy of Humanized Versus Murinized CD19 and CD22 CAR T-Cell Cocktail Therapy for Refractory/Relapsed B-Cell Lymphoma
Huang L, Li J, Yang J, Zhang X, Zhang M, He J, Zhang G, Li W, Wang H, Li J, Lu P
Cells 2022
Dose-response correlation for CAR-T cells: a systematic review of clinical studies.
Rotte A, Frigault MJ, Ansari A, Gliner B, Heery C, Shah B
Journal for ImmunoTherapy of Cancer 2022
Mechanisms of immune effector cell‐associated neurotoxicity syndrome after CAR‐T treatment
Gu T, Hu K, Si X, Hu Y, Huang H
2022
[Three cases of hemodiafiltration for the treatment of CAR-T related grade 3 - 4 cytokine release syndrome after ineffective treatment with IL-6 receptor inhibitors].
Chen SY, Chen WH, Wan XC, Du X, Luo CR, Li XQ, Zhang XH
Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 2022
Cancer immunotherapy with CAR T cells: well-trodden paths and journey along lesser-known routes.
Smole A
Radiology and Oncology 2022
Phenotypic Composition of Commercial Anti-CD19 CAR T Cells Affects In Vivo Expansion and Disease Response in Patients with Large B-cell Lymphoma
Monfrini C, Stella F, Aragona V, Magni M, Ljevar S, Vella C, Fardella E, Chiappella A, Nanetti F, Pennisi M, Dodero A, Guidetti A, Corradini P, Carniti C
Clinical cancer research 2022
Transcriptomic analysis of the innate immune response to in vitro transfection of plasmid DNA
Warga E, Anderson J, Tucker M, Harris E, Elmer J
2022
Chimeric antigen receptor T-cell therapy for multiple myeloma
Wang Z, Chen C, Wang L, Jia Y, Qin Y
Frontiers in immunology 2022
Efficacy and safety of CD22-specific and CD19/CD22-bispecific CAR-T cell therapy in patients with hematologic malignancies: A systematic review and meta-analysis
Li L, Wang L, Liu Q, Wu Z, Zhang Y, Xia R
Frontiers in Oncology 2022
NOTCH1 signaling during CD4+ T-cell activation alters transcription factor networks and enhances antigen responsiveness
Wilkens AB, Fulton EC, Pont MJ, Cole GO, Leung I, Stull SM, Hart MR, Bernstein ID, Furlan SN, Riddell SR
Blood 2022
Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL
Gauthier J, Gazeau N, Hirayama AV, Hill JA, Wu V, Cearley A, Perkins P, Kirk A, Shadman M, Chow VA, Gopal AK, Hodges Dwinal A, Williamson S, Myers J, Chen A, Nagle S, Hayes-Lattin B, Schachter L, Maloney DG, Turtle CJ, Sorror ML, Maziarz RT
Blood 2022
Molecular monitoring of T-cell kinetics and migration in severe neurotoxicity after real-world CD19-specific chimeric antigen receptor T cell therapy
Berger SC, Fehse B, Akyüz N, Geffken M, Wolschke C, Janson D, Gagelmann N, Luther M, Wichmann D, Frenzel C, Thayssen G, Alegiani A, Badbaran A, Zeschke S, Dierlamm J, Kröger N, Ayuk FA
Haematologica 2022
Dual antigen–targeted off-the-shelf NK cells show durable response and prevent antigen escape in lymphoma and leukemia
Cichocki F, Goodridge JP, Bjordahl R, Mahmood S, Davis ZB, Gaidarova S, Abujarour R, Groff B, Witty A, Wang H, Tuininga K, Kodal B, Felices M, Bonello G, Huffman J, Dailey T, Lee TT, Walcheck B, Valamehr B, Miller JS
Blood 2022
Systematic Interrogation of Tumor Cell Resistance to Chimeric Antigen Receptor T-cell Therapy in Pancreatic Cancer
Hagel KR, Arafeh R, Gang S, Arnoff TE, Larson RC, Doench JG, Mathewson ND, Wucherpfennig KW, Maus MV, Hahn WC
Cancer research 2022
Engineered and banked iPSCs for advanced NK- and T-cell immunotherapies
Cichocki F, van der Stegen SJ, Miller JS
Blood 2022
Clinical Pharmacology and Determinants of Response to UCART19, an Allogeneic Anti-CD19 CAR-T Cell Product, in Adult B-cell Acute Lymphoblastic Leukemia
Dupouy S, Marchiq I, Derippe T, Almena-Carrasco M, Jozwik A, Fouliard S, Adimy Y, Geronimi J, Graham C, Jain N, Maus MV, Mohty M, Boissel N, Teshima T, Kato K, Benjamin R, Balandraud S
2022
How I use risk factors for success or failure of CD19 CAR T cells to guide management of children and AYA with B-cell ALL
Myers RM, Shah NN, Pulsipher MA
Blood 2022
Therapeutic targeting of PRAME with mTCRCAR T cells in acute myeloid leukemia
Kirkey DC, Loeb AM, Castro S, McKay CN, Perkins L, Pardo L, Leonti AR, Tang TT, Loken MR, Brodersen LE, Loeb KR, Scheinberg DA, Le Q, Meshinchi S
Blood Advances 2022
A new story for an old challenge: Would flow cytometry beat molecular biology in monitoring chimeric antigen receptor T cell pharmacokinetics?
Lambert C, Ntrivalas E, Sack U
Cytometry Part A 2022
Phase I CAR-T Clinical Trials Review
Bulsara S, Wu M, Wang T
Anticancer research 2022
Chimeric antigen receptor T (CAR‐T) cells: Novel cell therapy for hematological malignancies
Abbasi S, Totmaj MA, Abbasi M, Hajazimian S, Goleij P, Behroozi J, Shademan B, Isazadeh A, Baradaran B
Cancer Medicine 2022
Post-mortem neuropathologic examination of a 6-case series of CAR T-cell treated patients.
Vidal-Robau N, Caballero G, Archilla I, Ladino A, Fernández S, Ortiz-Maldonado V, Rovira M, Gómez-Hernando M, Delgado J, Suárez-Lledó M, Fernández de Larrea C, Balagué O, Frigola G, Muñoz A, Ortiz E, Ribalta T, Martinez MJ, Angeles-Marcos M, Español-Rego M, González A, Benitez-Ribas D, Martinez-Hernandez E, Castro P, Aldecoa I
Free neuropathology 2022
Compromised antigen binding and signaling interfere with bispecific CD19 and CD79a chimeric antigen receptor function
Leung I, Templeton ML, Lo Y, Rajan A, Stull SM, Garrison SM, Salter AI, Smythe KS, Correnti CE, Srivastava S, Yeung CC, Riddell SR
Blood Advances 2022
Genome-edited allogeneic donor “universal” chimeric antigen receptor T cells
Qasim W
Blood 2022
Should All CAR-T Therapy for Acute Lymphoblastic Leukemia Be Consolidated with Allogeneic Stem Cell Transplant?
Marinos A, Heslop HE
Best practice & research. Clinical haematology 2022
Combining CD34+ stem cell selection with prophylactic pathogen and leukemia directed T‐cell immunotherapy to simultaneously reduce graft versus host disease, infection, and leukemia recurrence after allogeneic stem cell transplant
Gottlieb DJ, Sutrave G, Jiang W, Avdic S, Street JA, Simms R, Clancy LE, Antonenas V, Gloss BS, Bateman C, Bishop DC, Micklethwaite KP, Blyth E
American Journal of Hematology 2022
Safety switch optimization enhances antibody-mediated elimination of CAR T cells
Shabaneh TB, Moffett HF, Stull SM, Derezes T, Tait LJ, Park S, Riddell SR, Lajoie MJ
2022
Therapeutic cancer vaccination targeting antigens and adjuvants to lymphoid tissues using genetically modified T cells
Joshua R. Veatch, Naina Singhi, Shivani Srivastava, Julia L Szeto, Brenda Jesernig, Sylvia M. Stull, Matthew Fitzgibbon, Megha Sarvothama, Sushma Yechan-Gunja, Scott E James, Stanley R Riddell
Journal of Clinical Investigation 2021
Leukemic extracellular vesicles induce chimeric antigen receptor T cell dysfunction in chronic lymphocytic leukemia
MJ Cox, F Lucien, R Sakemura, JC Boysen, Y Kim, P Horvei, CM Roman, MJ Hansen, EE Tapper, EL Siegler, C Forsman, SB Crotts, KJ Schick, M Hefazi, MW Ruff, I Can, M Adada, E Bezerra, LA Fonkoua, WK Nevala, E Braggio, W Ding, SA Parikh, NE Kay, SS Kenderian
Molecular Therapy 2021
Immune inactivation of anti-simian immunodeficiency virus chimeric antigen receptor T cells in rhesus macaques
F Haeseleer, Y Fukazawa, H Park, B Varco-Merth, BJ Rust, JV Smedley, K Eichholz, CW Peterson, R Mason, HP Kiem, M Roederer, LJ Picker, AA Okoye, L Corey
Molecular Therapy — Methods & Clinical Development 2021
Composite CD79A/CD40 co-stimulatory endodomain enhances CD19CAR-T cell proliferation and survival
J Julamanee, S Terakura, K Umemura, Y Adachi, K Miyao, S Okuno, E Takagi, T Sakai, D Koyama, T Goto, R Hanajiri, M Hudecek, P Steinberger, J Leitner, T Nishida, M Murata, H Kiyoi
Molecular Therapy 2021
Phase I study of CAR-T cells with PD-1 and TCR disruption in mesothelin-positive solid tumors
Z Wang, N Li, K Feng, M Chen, Y Zhang, Y Liu, Q Yang, J Nie, N Tang, X Zhang, C Cheng, L Shen, J He, X Ye, W Cao, H Wang, W Han
Cellular and Molecular Immunology 2021
Dual-antigen targeted iPSC-derived chimeric antigen receptor-T cell therapy for refractory lymphoma
S Harada, M Ando, J Ando, M Ishii, T Yamaguchi, S Yamazaki, T Toyota, K Ohara, M Ohtaka, M Nakanishi, C Shin, Y Ota, K Nakashima, K Ohshima, C Imai, Y Nakazawa, H Nakauchi, N Komatsu
Molecular Therapy 2021
Metabolic barriers to cancer immunotherapy
K DePeaux, GM Delgoffe
Nature Reviews Immunology 2021
Improving CAR T-Cell Persistence
V Pietrobon, LA Todd, A Goswami, O Stefanson, Z Yang, F Marincola
International journal of molecular sciences 2021
Focused CRISPR-Cas9 genetic screening reveals USO1 as a vulnerability in B-cell acute lymphoblastic leukemia
AK Jaiswal, H Truong, TM Tran, TL Lin, D Casero, MO Alberti, DS Rao
Scientific Reports 2021
Strategies to Overcome Failures in T-Cell Immunotherapies by Targeting PI3K-δ and –γ
S Chandrasekaran, CR Funk, T Kleber, CM Paulos, M Shanmugam, EK Waller
Frontiers in immunology 2021
Peripheral leukemia burden at time of apheresis negatively affects the clinical efficacy of CART19 in refractory or relapsed B-ALL
B Deng, J Pan, Z Liu, S Liu, Y Chen, X Qu, Y Zhang, Y Lin, Y Zhang, X Yu, Z Zhang, X Niu, R Luan, M Ma, X Li, T Liu, , H Niu, AH Chang, C Tong
Molecular Therapy — Methods & Clinical Development 2021
Strategies to Circumvent the Side-Effects of Immunotherapy Using Allogeneic CAR-T Cells and Boost Its Efficacy: Results of Recent Clinical Trials
S Smirnov, A Petukhov, K Levchuk, S Kulemzin, A Staliarova, K Lepik, O Shuvalov, A Zaritskey, A Daks, O Fedorova
Frontiers in immunology 2021
Super-Treg: Toward a New Era of Adoptive Treg Therapy Enabled by Genetic Modifications
L Amini, J Greig, M Schmueck-Henneresse, HD Volk, S Bézie, P Reinke, C Guillonneau, DL Wagner, I Anegon
Frontiers in immunology 2021
Biology and Treatment of Leukemia and Bone Marrow Neoplasms
V Pullarkat, G Marcucci
2021
A Mathematical Description of the Bone Marrow Dynamics during CAR T-Cell Therapy in B-Cell Childhood Acute Lymphoblastic Leukemia
Á Martínez-Rubio, S Chulián, CB Goñi, MR Orellana, AP Martínez, A Navarro-Zapata, C Ferreras, VM Pérez-García, M Rosa
International journal of molecular sciences 2021
Interleukin‐37 improves T‐cell‐mediated immunity and chimeric antigen receptor T‐cell therapy in aged backgrounds
JA Hamilton, MY Lee, R Hunter, RS Ank, JY Story, G Talekar, T Sisroe, DB Ballak, A Fedanov, CC Porter, EZ Eisenmesser, CA Dinarello, SS Raikar, J DeGregori, CJ Henry
Aging Cell 2021
Chimeric Antigen Receptor–Modified T Cells and T Cell–Engaging Bispecific Antibodies: Different Tools for the Same Job
M Schwerdtfeger, MR Benmebarek, S Endres, M Subklewe, V Desiderio, S Kobold
Current Hematologic Malignancy Reports 2021
How Can We Engineer CAR T Cells to Overcome Resistance?
M Glover, S Avraamides, J Maher
Biologics : targets & therapy 2021
A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains
KM Cappell, JN Kochenderfer
Nature Reviews Clinical Oncology 2021
Determinants of Response and Mechanisms of Resistance of CAR T-cell Therapy in Multiple Myeloma
NW van de Donk, M Themeli, SZ Usmani
2021
Clinical and Product Features Associated with Outcome of DLBCL Patients to CD19-Targeted CAR T-Cell Therapy
S Lamure, FV Laethem, DD Verbizier, C Lozano, E Gehlkopf, JJ Tudesq, C Serrand, M Benzaoui, T Kanouni, A Quintard, JD Vos, E Tchernonog, L Platon, X Ayrignac, P Ceballos, A Sirvent, M François, H Guedon, P Quittet, C Mongellaz, A Conte, C Herbaux, C Bret, N Taylor, V Dardalhon, G Cartron
Cancers 2021
BRD4 inhibition boosts the therapeutic effects of epidermal growth factor receptor-targeted chimeric antigen receptor T cells in glioblastoma
L Xia, J Liu, Z Zheng, Y Chen, J Ding, Y Hu, G Hu, N Xia, W Liu
Molecular Therapy 2021
The Current and Future Role of Radiation Therapy in the Era of CAR T-cell Salvage
C DeSelm
British Journal of Radiology 2021
Pharmacologic Control of CAR T Cells
B Caulier, JM Enserink, S Wälchli
International journal of molecular sciences 2021
Biomarkers for Chimeric Antigen Receptor T Cell Therapy in Acute Lymphoblastic Leukemia: Prospects for Personalized Management and Prognostic Prediction
R Hong, Y Hu, H Huang
Frontiers in immunology 2021
Comparative analysis of TCR and CAR signaling informs CAR designs with superior antigen sensitivity and in vivo function
AI Salter, A Rajan, JJ Kennedy, RG Ivey, SA Shelby, I Leung, ML Templeton, V Muhunthan, V Voillet, D Sommermeyer, JR Whiteaker, R Gottardo, SL Veatch, AG Paulovich, SR Riddell
Science signaling 2021
CAR T-cell therapy in mature lymphoid malignancies: clinical opportunities and challenges
M Narkhede, A Mehta, SM Ansell, G Goyal
Annals of translational medicine 2021
Born to survive: how cancer cells resist CAR T cell therapy
J Lemoine, M Ruella, R Houot
Journal of Hematology & Oncology 2021
Engineering-enhanced CAR T cells for improved cancer therapy
MC Milone, J Xu, SJ Chen, MK Collins, J Zhou, DJ Powell, JJ Melenhorst
2021
CAR T-Cell Production Using Nonviral Approaches
V Lukjanov, I Koutná, P Šimara, LA Ponce-Soto
Journal of Immunology Research 2021
CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial
JY Spiegel, S Patel, L Muffly, NM Hossain, J Oak, JH Baird, MJ Frank, P Shiraz, B Sahaf, J Craig, M Iglesias, S Younes, Y Natkunam, MG Ozawa, E Yang, J Tamaresis, H Chinnasamy, Z Ehlinger, W Reynolds, R Lynn, MC Rotiroti, N Gkitsas, S Arai, L Johnston, R Lowsky, RG Majzner, E Meyer, RS Negrin, AR Rezvani, S Sidana, J Shizuru, WK Weng, C Mullins, A Jacob, I Kirsch, M Bazzano, J Zhou, S Mackay, SJ Bornheimer, L Schultz, S Ramakrishna, KL Davis, KA Kong, NN Shah, H Qin, T Fry, S Feldman, CL Mackall, DB Miklos
Nature Medicine 2021
Exploiting the CRISPR‐Cas9 gene‐editing system for human cancers and immunotherapy
LO Afolabi, MO Afolabi, MM Sani, WO Okunowo, D Yan, L Chen, Y Zhang, X Wan
IBMS BoneKEy 2021
Current Immunotherapies for Glioblastoma Multiforme
B Huang, X Li, Y Li, J Zhang, Z Zong, H Zhang
Frontiers in immunology 2021
Next Generation Imaging Techniques to Define Immune Topographies in Solid Tumors
V Pietrobon, A Cesano, F Marincola, JN Kather
Frontiers in immunology 2021
The role of small molecules in cell and gene therapy
LL Brayshaw, C Martinez-Fleites, T Athanasopoulos, T Southgate, L Jespers, C Herring
2021
Challenges and Clinical Strategies of CAR T-Cell Therapy for Acute Lymphoblastic Leukemia: Overview and Developments
X Xu, S Huang, X Xiao, Q Sun, X Liang, S Chen, Z Zhao, Z Huo, S Tu, Y Li
Frontiers in immunology 2021
Cas9 RNP transfection by vapor nanobubble photoporation for ex vivo cell engineering
L Raes, M Pille, A Harizaj, G Goetgeluk, JV Hoeck, S Stremersch, JC Fraire, T Brans, OG de Jong, R Maas-Bakker, E Mastrobattista, P Vader, SC Smedt, B Vandekerckhove, K Raemdonck, K Braeckmans
Molecular Therapy — Nucleic Acids 2021
Clonal expansion of T memory stem cells determines early anti-leukemic responses and long-term CAR T cell persistence in patients
L Biasco, N Izotova, C Rivat, S Ghorashian, R Richardson, A Guvenel, R Hough, R Wynn, B Popova, A Lopes, M Pule, AJ Thrasher, PJ Amrolia
2021
An overview of multiplexed analyses of CAR T-cell therapies: insights and potential
BP DePriest, N Vieira, A Bidgoli, S Paczesny
Expert Review of Proteomics 2021
Early Survival Prediction Framework in CD19-Specific CAR-T Cell Immunotherapy Using a Quantitative Systems Pharmacology Model
A Mueller-Schoell, N Puebla-Osorio, R Michelet, MR Green, A Künkele, W Huisinga, P Strati, B Chasen, SS Neelapu, C Yee, C Kloft
Cancers 2021
Optimizing the Clinical Impact of CAR-T Cell Therapy in B-Cell Acute Lymphoblastic Leukemia: Looking Back While Moving Forward
PS Kozani, PS Kozani, F Rahbarizadeh
Frontiers in immunology 2021
Targeting NK Cells to Enhance Melanoma Response to Immunotherapies
H Lee, IP Silva, U Palendira, RA Scolyer, GV Long, JS Wilmott
Cancers 2021
The Potential Role of the Intestinal Micromilieu and Individual Microbes in the Immunobiology of Chimeric Antigen Receptor T-Cell Therapy
ML Schubert, R Rohrbach, M Schmitt, CK Stein-Thoeringer
Frontiers in immunology 2021
Making Potent CAR T Cells Using Genetic Engineering and Synergistic Agents
CH Park
Cancers 2021
Immunogenicity of CAR T cells in cancer therapy
DL Wagner, E Fritsche, MA Pulsipher, N Ahmed, M Hamieh, M Hegde, M Ruella, B Savoldo, NN Shah, CJ Turtle, AS Wayne, M Abou-el-Enein
Nature Reviews Clinical Oncology 2021
CAR T-Cells for CNS Lymphoma: Driving into New Terrain?
P Karschnia, J Blobner, N Teske, F Schöberl, E Fitzinger, M Dreyling, JC Tonn, N Thon, M Subklewe, L von Baumgarten
Cancers 2021
The role of axicabtagene ciloleucel as a treatment option for patients with follicular/marginal zone lymphoma
J Sandoval-Sus, JC Chavez
Therapeutic Advances in Hematology 2021
Factors associated with treatment response to CD19 CAR-T therapy among a large cohort of B cell acute lymphoblastic leukemia
X Zhang, J Yang, J Li, W Li, D Song, X Lu, F Wu, J Li, D Chen, X Li, Z Xu, S Liu, Z Li, K Ying, P Lu
Cancer Immunology, Immunotherapy 2021
The antigen‐binding moiety in the driver's seat of CARs
H Hanssens, F Meeus, KD Veirman, K Breckpot, N Devoogdt
Medicinal Research Reviews 2021
Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy
M Abou-el-Enein, M Elsallab, SA Feldman, AD Fesnak, HE Heslop, P Marks, BG Till, G Bauer, B Savoldo
2021
Cytokine Release Syndrome Associated with T-Cell-Based Therapies for Hematological Malignancies: Pathophysiology, Clinical Presentation, and Treatment
M Cosenza, S Sacchi, S Pozzi
International journal of molecular sciences 2021
Genetically engineered myeloid cells rebalance the core immune suppression program in metastasis
S Kaczanowska, DW Beury, V Gopalan, AK Tycko, H Qin, ME Clements, J Drake, C Nwanze, M Murgai, Z Rae, W Ju, KA Alexander, J Kline, CF Contreras, KM Wessel, S Patel, S Hannenhalli, MC Kelly, RN Kaplan
Cell 2021
Befriending the Hostile Tumor Microenvironment in CAR T-Cell Therapy
L Lindo, LH Wilkinson, KA Hay
Frontiers in immunology 2021
Combination therapy with CAR T cells and oncolytic viruses: a new era in cancer immunotherapy
R Rezaei, HE Ghaleh, M Farzanehpour, R Dorostkar, R Ranjbar, M Bolandian, MM Nodooshan, AG Alvanegh
Cancer Gene Therapy 2021
Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies
X Xiao, S Huang, S Chen, Y Wang, Q Sun, X Xu, Y Li
Journal of Experimental & Clinical Cancer Research 2021
Hypoxia and the phenomenon of immune exclusion
V Pietrobon, FM Marincola
Journal of Translational Medicine 2021
Progress in the Application of Immune Checkpoint Inhibitor-Based Immunotherapy for Targeting Different Types of Colorectal Cancer
R He, Y Lao, W Yu, X Zhang, M Jiang, C Zhu
Frontiers in Oncology 2021
Cell Therapy With TILs: Training and Taming T Cells to Fight Cancer
A Kumar, R Watkins, AE Vilgelm
Frontiers in immunology 2021
In vivo CART cell imaging: Paving the way for success in CART cell therapy
R Sakemura, I Can, EL Siegler, SS Kenderian
Molecular Therapy — Oncolytics 2021
Enhancing Therapeutic Efficacy of Double Negative T Cells against Acute Myeloid Leukemia Using Idelalisib
H Kang, JB Lee, I Khatri, Y Na, C DSouza, A Arruda, MD Minden, L Zhang
Cancers 2021
Targeting Glioblastoma: The Current State of Different Therapeutic Approaches
I Khan, S Mahfooz, E Elbasan, B Karacam, M Oztanir, M Hatiboglu
Current neuropharmacology 2021
Bcl-2 Enhances Chimeric Antigen Receptor T Cell Persistence by Reducing Activation-Induced Apoptosis
H Wang, P Han, X Qi, F Li, M Li, L Fan, H Zhang, X Zhang, X Yang
Cancers 2021
Adoptive Immunotherapy beyond CAR T-Cells
A Titov, E Zmievskaya, I Ganeeva, A Valiullina, A Petukhov, A Rakhmatullina, R Miftakhova, M Fainshtein, A Rizvanov, E Bulatov
Cancers 2021
Realizing Innate Potential: CAR-NK Cell Therapies for Acute Myeloid Leukemia
M Gurney, M ODwyer
Cancers 2021
Remote controlling of CAR-T cells and toxicity management: Molecular switches and next generation CARs
E Moghanloo, H Mollanoori, M Talebi, S Pashangzadeh, F Faraji, F Hadjilooei, H Mahmoodzadeh
Translational oncology 2021
A broad and systematic approach to identify B cell malignancy-targeting TCRs for multi-antigen-based T cell therapy
MH Meeuwsen, AK Wouters, L Jahn, RS Hagedoorn, MG Kester, DF Remst, LT Morton, DM van der Steen, C Kweekel, AH de Ru, M Griffioen, PA van Veelen, JH Falkenburg, MH Heemskerk
Molecular Therapy 2021
In Like a Lamb; Out Like a Lion: Marching CAR T Cells Toward Enhanced Efficacy in B-ALL
PS Kozani, PS Kozani, RS O'Connor
Molecular cancer therapeutics 2021
Insights on Droplet Digital PCR–Based Cellular Kinetics and Biodistribution Assay Support for CAR-T Cell Therapy
H Sugimoto, S Chen, JP Minembe, J Chouitar, X He, H Wang, X Fang, MG Qian
The AAPS Journal 2021
Clinical experience of CAR T cells for B cell acute lymphoblastic leukemia
VA Fabrizio, KJ Curran
Best practice & research. Clinical haematology 2021
The rational development of CD5-targeting biepitopic CARs with fully human heavy-chain-only antigen recognition domains
Z Dai, W Mu, Y Zhao, X Jia, J Liu, Q Wei, T Tan, J Zhou
Molecular Therapy 2021
Anti-BCMA CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease: A Single Center Analysis of Two Clinical Trials
Y Que, M Xu, Y Xu, VD Almeida, L Zhu, Z Wang, Y Wang, X Liu, L Jiang, D Wang, C Li, J Zhou
Frontiers in immunology 2021
Efficacy and safety of humanized CD19 CAR‑T as a salvage therapy for recurrent CNSL of B‑ALL following murine CD19 CAR‑T cell therapy
X Li, MJ Liu, N Mou, ZX Yang, J Wang, J Mu, HB Zhu, Q Deng
Oncology Letters 2021
Preclinical and clinical advances in dual‐target chimeric antigen receptor therapy for hematological malignancies
Z Guo, S Tu, S Yu, L Wu, W Pan, N Chang, X Zhou, C Song, Y Li, Y He
Cancer Science 2021
CAR-T cells: Early successes in blood cancer and challenges in solid tumors
H Dana, GM Chalbatani, SA Jalali, HR Mirzaei, SA Grupp, ER Suarez, C Rapôso, TJ Webster
Acta pharmaceutica Sinica. B 2021
Does lineage plasticity enable escape from CAR-T cell therapy? Lessons from MLL-r leukemia
W Liao, ME Kohler, T Fry, P Ernst
Experimental Hematology 2021
Proceedings From the First International Workshop at Sidra Medicine: “Engineered Immune Cells in Cancer Immunotherapy (EICCI): From Discovery to Off-the-Shelf Development”, 15th–16th February 2019, Doha, Qatar
B Guerrouahen, M Elnaggar, A Al-Mohannadi, D Kizhakayil, C Bonini, R Benjamin, R Brentjens, CJ Buchholz, G Casorati, S Ferrone, FL Locke, F Martin, A Schambach, C Turtle, P Veys, HJ van der Vliet, C Maccalli
Frontiers in immunology 2021
Current Status of CAR T Cell Therapy for Leukemias
K Harris, JL LaBelle, MR Bishop
Current Treatment Options in Oncology 2021
Cellular networks controlling T cell persistence in adoptive cell therapy
JD Chan, J Lai, CY Slaney, A Kallies, PA Beavis, PK Darcy
Nature Reviews Immunology 2021
A Systematic Review of the Efforts and Hindrances of Modeling and Simulation of CAR T-cell Therapy
U Nukala, MR Messan, ON Yogurtcu, X Wang, H Yang
The AAPS Journal 2021
Bench‐to‐bedside translation of chimeric antigen receptor (CAR) T cells using a multiscale systems pharmacokinetic‐pharmacodynamic model: A case study with anti‐BCMA CAR‐T
AP Singh, W Chen, X Zheng, H Mody, TJ Carpenter, A Zong, DL Heald
CPT Pharmacometrics Syst. Pharmacol. 2021
Physiological Imaging Methods for Evaluating Response to Immunotherapies in Glioblastomas
S Chawla, V Shehu, PK Gupta, K Nath, H Poptani
International journal of molecular sciences 2021
Treatment-Related Adverse Events of Chimeric Antigen Receptor T-Cell (CAR T) in Clinical Trials: A Systematic Review and Meta-Analysis
W Lei, M Xie, Q Jiang, N Xu, P Li, A Liang, KH Young, W Qian
Cancers 2021
Melanoma reactive TCR-modified T cells generated without activation retain a less differentiated phenotype and mediate a superior in vivo response
SY Wang, TV Moore, AV Dalheim, GM Scurti, MI Nishimura
Scientific Reports 2021
Opening of the Blood–Brain Barrier Using Low-Intensity Pulsed Ultrasound Enhances Responses to Immunotherapy in Preclinical Glioma Models
A Sabbagh, K Beccaria, X Ling, A Marisetty, M Ott, H Caruso, E Barton, LY Kong, D Fang, K Latha, DY Zhang, J Wei, J DeGroot, MA Curran, G Rao, J Hu, C Desseaux, G Bouchoux, M Canney, A Carpentier, AB Heimberger
Clinical cancer research 2021
Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies
J Gauthier, ED Bezerra, AV Hirayama, S Fiorenza, A Sheih, CK Chou, EL Kimble, BS Pender, RM Hawkins, A Vakil, TD Phi, RN Steinmetz, AW Jamieson, M Bar, RD Cassaday, AG Chapuis, AJ Cowan, DJ Green, HP Kiem, F Milano, M Shadman, BG Till, SR Riddell, DG Maloney, CJ Turtle
Blood 2021
Characterization of the Therapeutic Effects of Novel Chimeric Antigen Receptor T Cells Targeting CD38 on Multiple Myeloma
X Li, Y Feng, F Shang, Z Yu, T Wang, J Zhang, Z Song, P Wang, B Shi, J Wang
Frontiers in Oncology 2021
Reactions Related to CAR-T Cell Therapy
L Miao, Z Zhang, Z Ren, Y Li
Frontiers in immunology 2021
Beyond the storm — subacute toxicities and late effects in children receiving CAR T cells
H Shalabi, J Gust, A Taraseviciute, PL Wolters, AB Leahy, C Sandi, TW Laetsch, L Wiener, RA Gardner, V Nussenblatt, JA Hill, KJ Curran, TS Olson, C Annesley, HW Wang, J Khan, MC Pasquini, CN Duncan, SA Grupp, MA Pulsipher, NN Shah
Nature Reviews Clinical Oncology 2021
CRS-related coagulopathy in BCMA targeted CAR-T therapy: a retrospective analysis in a phase I/II clinical trial
M Shao, Q Yu, X Teng, X Guo, G Wei, H Xu, J Cui, AH Chang, Y Hu, H Huang
Bone Marrow Transplantation 2021
CAR T-cell therapy in multiple myeloma: more room for improvement
PJ Teoh, WJ Chng
Blood Cancer Journal 2021
The Anticancer Potential of T Cell Receptor-Engineered T Cells
M Ecsedi, MS McAfee, AG Chapuis
Trends in Cancer 2021
Single-cell transcriptome analysis of CAR T-cell products reveals subpopulations, stimulation, and exhaustion signatures
X Wang, C Peticone, E Kotsopoulou, B Göttgens, FJ Calero-Nieto
OncoImmunology 2021
Cytolytic Activity of CAR T Cells and Maintenance of Their CD4+ Subset Is Critical for Optimal Antitumor Activity in Preclinical Solid Tumor Models
M Csaplár, J Szöllősi, S Gottschalk, G Vereb, Á Szöőr
Cancers 2021
Genome edited B cells: a new frontier in immune cell therapies
GL Rogers, PM Cannon
Molecular Therapy 2021
Single-cell Analysis Technologies for Immuno-oncology Research: From Mechanistic Delineation to Biomarker Discovery
Z Bai, G Su, R Fan
Genomics, proteomics & bioinformatics / Beijing Genomics Institute 2021
Interventions and outcomes of adult patients with B-ALL progressing after CD19 chimeric antigen receptor T-cell therapy
K Wudhikarn, JR Flynn, I Rivière, M Gönen, X Wang, B Senechal, KJ Curran, M Roshal, PG Maslak, MB Geyer, EF Halton, C Diamonte, ML Davila, M Sadelain, RJ Brentjens, JH Park
Blood 2021
Anti-CD19 CAR-T cell therapy bridge to HSCT decreases the relapse rate and improves the long-term survival of R/R B-ALL patients: a systematic review and meta-analysis
L Hu, A Charwudzi, Q Li, W Zhu, Q Tao, S Xiong, Z Zhai
Annals of Hematology 2021
Mutated GM‐CSF‐based CAR‐T cells targeting CD116/CD131 complexes exhibit enhanced anti‐tumor effects against acute myeloid leukaemia
A Hasegawa, S Saito, S Narimatsu, S Nakano, M Nagai, H Ohnota, Y Inada, H Morokawa, I Nakashima, D Morita, Y Ide, K Matsuda, H Tashiro, S Yagyu, M Tanaka, Y Nakazawa
IBMS BoneKEy 2021
A Prospective Investigation of Bispecific CD19/22 CAR T Cell Therapy in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
Y Zhang, J Li, X Lou, X Chen, Z Yu, L Kang, J Chen, J Zhou, X Zong, Z Yang, M Li, N Xu, S Jia, H Geng, G Chen, H Dai, X Tang, L Yu, D Wu, C Li
Frontiers in Oncology 2021
Absolute lymphocyte count proliferation kinetics after CAR T-cell infusion impact response and relapse
S Faude, J Wei, K Muralidharan, X Xu, G Wertheim, M Paessler, VG Bhoj, SA Grupp, SL Maude, SR Rheingold, V Pillai
Blood Advances 2021
The roles of T cell competition and stochastic extinction events in chimeric antigen receptor T cell therapy
GJ Kimmel, FL Locke, PM Altrock
Proceedings of the Royal Society B: Biological Sciences 2021
State-of-Art of Cellular Therapy for Acute Leukemia
JB Lee, D Vasic, H Kang, KK Fang, L Zhang
International journal of molecular sciences 2021
Human T cells engineered with a leukemia lipid-specific TCR enables donor-unrestricted recognition of CD1c-expressing leukemia
M Consonni, C Garavaglia, A Grilli, C de Lalla, A Mancino, L Mori, GD Libero, D Montagna, M Casucci, M Serafini, C Bonini, D Häussinger, F Ciceri, M Bernardi, S Mastaglio, S Bicciato, P Dellabona, G Casorati
Nature Communications 2021
Design and Assessment of Novel Anti-CD30 Chimeric Antigen Receptors with Human Antigen-Recognition Domains
S Choi, MA Pegues, N Lam, C Geldres, D Vanasse, JN Kochenderfer
Human Gene Therapy 2021
The impact of obesity and body weight on the outcome of patients with relapsed/refractory large B-cell lymphoma treated with axicabtagene ciloleucel
K Wudhikarn, R Bansal, A Khurana, MA Hathcock, NN Bennani, J Paludo, JC Villasboas, Y Wang, PB Johnston, SM Ansell, Y Lin
Blood Cancer Journal 2021
Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis
NA Vitanza, AJ Johnson, AL Wilson, C Brown, JK Yokoyama, A Künkele, CA Chang, S Rawlings-Rhea, W Huang, K Seidel, CM Albert, N Pinto, J Gust, LS Finn, JG Ojemann, J Wright, RJ Orentas, M Baldwin, RA Gardner, MC Jensen, JR Park
Nature Medicine 2021
Comparison of Three CD3-Specific Separation Methods Leading to Labeled and Label-Free T Cells
R Weiss, W Gerdes, R Berthold, U Sack, U Koehl, S Hauschildt, A Grahnert
Cells 2021
CAR-T Cell Therapy: Mechanism, Management, and Mitigation of Inflammatory Toxicities
JW Fischer, N Bhattarai
Frontiers in immunology 2021
Adding Help to an HLA-A*24:02 Tumor-Reactive γδTCR Increases Tumor Control
I Johanna, P Hernández-López, S Heijhuurs, W Scheper, L Bongiovanni, A de Bruin, DX Beringer, R Oostvogels, T Straetemans, Z Sebestyen, J Kuball
Frontiers in immunology 2021
CD19 CAR-T Cells With Membrane-Bound IL-15 for B-Cell Acute Lymphoblastic Leukemia After Failure of CD19 and CD22 CAR-T Cells: Case Report
Y Sun, Y Su, Y Wang, N Liu, Y Li, J Chen, Z Qiao, J Niu, J Hu, B Zhang, H Ning, L Hu
Frontiers in immunology 2021
CD19 and CD30 CAR T-Cell Immunotherapy for High-Risk Classical Hodgkin’s Lymphoma
YB Xue, X Lai, RL Li, CL Ge, BZ Zeng, Z Li, QF Fu, LF Zhao, SW Dong, JY Yang, JY Guo, QY Meng, QH Tan, ZH Li, HY Ding, YL Zhang, SH Liu, AH Chang, H Yao, RC Luo
Frontiers in Oncology 2021
NOT-Gated CD93 CAR T Cells Effectively Target AML with Minimized Endothelial Cross-Reactivity
RM Richards, F Zhao, KA Freitas, KR Parker, P Xu, A Fan, E Sotillo, M Daugaard, HZ Oo, J Liu, WJ Hong, PH Sorensen, HY Chang, AT Satpathy, RG Majzner, R Majeti, CL Mackall
2021
HSC and iPS cell‐derived CAR‐NK cells as reliable cell‐based therapy solutions
J Arias, J Yu, M Varshney, J Inzunza, I Nalvarte
Stem Cells Translational Medicine 2021
A Novel Peptide-MHC Targeted Chimeric Antigen Receptor T Cell Forms a T Cell-like Immune Synapse
SS Wang, K Luong, FM Gracey, S Jabar, B McColl, RS Cross, MR Jenkins
Biomedicines 2021
[Mechanism and prevention strategies of neurotoxicity in CAR-T treatment of B cell tumors]
Q Zhang, Y Xiao
Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 2021
What Happens to the Immune Microenvironment After PD-1 Inhibitor Therapy?
Q Wang, B Xie, S Liu, Y Shi, Y Tao, D Xiao, W Wang
Frontiers in immunology 2021
TRAIL-R1-Targeted CAR-T Cells Exhibit Dual Antitumor Efficacy
Y Nai, L Du, M Shen, T Li, J Huang, X Han, F Luo, W Wang, D Pang, A Jin
Frontiers in Molecular Biosciences 2021
Relapsed ALL: CAR T vs transplant vs novel therapies
N Frey
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program 2021
[Humanized BCMA CAR-T cell salvage therapy in two refractory multiple myeloma patients who progressed after their murine BCMA CAR-T cell therapy]
R Cui, P Li, Q Li, J Mu, Y L Jiang, Y Y Jiang, Q Deng
Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 2021
Successful BCMA CAR-T Therapy for Multiple Myeloma With Central Nervous System Involvement Manifesting as Cauda Equina Syndrome—A Wandering Road to Remission
Y Wang, L Wang, Y Zeng, R Hong, C Zu, ET Yin, H Zhao, G Wei, L Yang, A Jin, Y Hu, H Huang
Frontiers in Oncology 2021
T Cell Fitness and Autologous CAR T Cell Therapy in Haematologic Malignancy
PH Mehta, S Fiorenza, RM Koldej, A Jaworowski, DS Ritchie, KM Quinn
Frontiers in immunology 2021
A Review of Clinical Outcomes of CAR T-Cell Therapies for B-Acute Lymphoblastic Leukemia.
Martino M, Alati C, Canale FA, Musuraca G, Martinelli G, Cerchione C
International journal of molecular sciences 2021
Impact of bridging chemotherapy on clinical outcome of CD19 CAR T therapy in adult acute lymphoblastic leukemia.
Perica K, Flynn J, Curran KJ, Rivere I, Wang X, Senechal B, Halton E, Diamonte C, Pineda J, Bernal Y, Gonen M, Sadelain M, Brentjens RJ, Park JH
Leukemia 2021
Immune Effector Cell Associated Neurotoxicity (ICANS) in Pediatric and Young Adult Patients Following Chimeric Antigen Receptor (CAR) T-Cell Therapy: Can We Optimize Early Diagnosis?
Brown BD, Tambaro FP, Kohorst M, Chi L, Mahadeo KM, Tewari P, Petropoulos D, Slopis JM, Sadighi Z, Khazal S
Frontiers in Oncology 2021
Long-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults With B-ALL.
Shah NN, Lee DW, Yates B, Yuan CM, Shalabi H, Martin S, Wolters PL, Steinberg SM, Baker EH, Delbrook CP, Stetler-Stevenson M, Fry TJ, Stroncek DF, Mackall CL
Journal of Clinical Oncology 2021
CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: a post-hoc analysis of pooled data from five clinical trials.
Leahy AB, Newman H, Li Y, Liu H, Myers R, DiNofia A, Dolan JG, Callahan C, Baniewicz D, Devine K, Wray L, Aplenc R, June CH, Grupp SA, Rheingold SR, Maude SL
The Lancet Haematology 2021
CD19 CAR-T cell treatment conferred sustained remission in B-ALL patients with minimal residual disease.
Lu W, Wei Y, Cao Y, Xiao X, Li Q, Lyu H, Jiang Y, Zhang H, Li X, Jiang Y, Meng J, Yuan T, Zhu H, He X, Jin X, Sun R, Sui T, Liu K, Zhao M
Cancer Immunology, Immunotherapy 2021
Bispecific Antibodies: A Review of Development, Clinical Efficacy and Toxicity in B-Cell Lymphomas.
Salvaris R, Ong J, Gregory GP
Journal of Personalized Medicine 2021
Natural Receptor- and Ligand-Based Chimeric Antigen Receptors: Strategies Using Natural Ligands and Receptors for Targeted Cell Killing
Branella GM, Spencer HT
Cells 2021
Utility of a safety switch to abrogate CD19.CAR T-cell-associated neurotoxicity.
Foster MC, Savoldo B, Lau W, Rubinos C, Grover N, Armistead P, Coghill J, Hagan RS, Morrison K, Buchanan FB, Cheng C, Laing S, Ivanova A, West J, Foster A, Serody J, Dotti G
Blood 2021
[Preparation of a novel tri-specific T cell engager targeting CD19 antigen and its anti-leukemia effect exploration].
Chen ML, Peng N, Liu XY, Zhang T, Xu YX, Tian Z, Xing HY, Tang KJ, Rao Q, Wang JX, Wang M
Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 2021
Real-World Outcome in the pre-CAR-T Era of Myeloma Patients Qualifying for CAR-T Cell Therapy
Brechbühl S, Bacher U, Jeker B, Pabst T
Mediterranean journal of hematology and infectious diseases 2021
Emerging Monoclonal Antibody Therapy for the Treatment of Acute Lymphoblastic Leukemia
Abuasab T, Rowe J, Tvito A
Biologics : targets & therapy 2021
Tisagenlecleucel immunogenicity in relapsed/refractory acute lymphoblastic leukemia and diffuse large B-cell lymphoma
Thudium Mueller K, Grupp SA, Maude SL, Levine JE, Pulsipher MA, Boyer MW, August KJ, Myers GD, Tam CS, Jaeger U, Foley SR, Borchmann P, Schuster SJ, Waller EK, Awasthi R, Potthoff B, Warren A, Waldron ER, McBlane F, Chassot-Agostinho A, Laetsch TW
Blood Advances 2021
Enriching leukapheresis improves T cell activation and transduction efficiency during CAR T processing.
Noaks E, Peticone C, Kotsopoulou E, Bracewell DG
2021
Consolidative Hematopoietic Stem Cell Transplantation After CD19 CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: A Systematic Review and Meta-analysis.
Xu X, Chen S, Zhao Z, Xiao X, Huang S, Huo Z, Li Y, Tu S
Frontiers in Oncology 2021
POINT: CAR T cells better than BiTEs
Molina JC, Shah NN
Blood Advances 2021
Direct control of CAR T cells through small molecule-regulated antibodies
Park S, Pascua E, Lindquist KC, Kimberlin C, Deng X, Mak YS, Melton Z, Johnson TO, Lin R, Boldajipour B, Abraham RT, Pons J, Sasu BJ, Van Blarcom TJ, Chaparro-Riggers J
Nature Communications 2021
Successful Treatment of Refractory and Relapsed CNS Acute Lymphoblastic Leukemia With CD-19 CAR-T Immunotherapy: A Case Report
Htun KT, Gong Q, Ma L, Wang P, Tan Y, Wu G, Chen J
Frontiers in Oncology 2021
Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. II: CAR-T cell therapy for patients with CD19+ acute lymphoblastic leukemia
Seber A, de CastroJunior CG, Kerbauy LN, Hirayama AV, Bonfim C, Fernandes JF, Souza M, Schafell R, Nabhan S, Loggetto SR, Simões BP, Rocha V, de Lima M, Guerino-Cunha RL, Bittencourt H
2021
Culturing adequate CAR-T cells from less peripheral blood to treat B-cell malignancies
Han L, Zhou J, Li L, Zhou K, Zhao L, Zhu X, Yin Q, Li Y, You H, Zhang J, Song Y, Gao Q
Cancer biology & medicine 2021
Risk-Adapted Preemptive Tocilizumab to Prevent Severe Cytokine Release Syndrome After CTL019 for Pediatric B-Cell Acute Lymphoblastic Leukemia: A Prospective Clinical Trial.
Kadauke S, Myers RM, Li Y, Aplenc R, Baniewicz D, Barrett DM, Barz Leahy A, Callahan C, Dolan JG, Fitzgerald JC, Gladney W, Lacey SF, Liu H, Maude SL, McGuire R, Motley LS, Teachey DT, Wertheim GB, Wray L, DiNofia AM, Grupp SA
Journal of Clinical Oncology 2021
Current Management and New Developments in the Treatment of ALL.
Darrah J, Sun W
Cancer treatment and research 2021
Efficacy and Safety of Chimeric Antigen Receptor T Cells in Acute Lymphoblastic Leukemia With Post-Transplant Relapse
Ding L, Wang Y, Hong R, Zhao H, Zhou L, Wei G, Wu W, Xu H, Zhang Y, Luo Y, Shi J, Chang AH, Hu Y, Huang H
Frontiers in Oncology 2021
A novel CD34-derived hinge for rapid and efficient detection and enrichment of CAR T cells
Bister A, Ibach T, Haist C, Smorra D, Roellecke K, Wagenmann M, Scheckenbach K, Gattermann N, Wiek C, Hanenberg H
2021
Durable Responses and Low Toxicity After Fast Off-Rate CD19 Chimeric Antigen Receptor-T Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
Roddie C, Dias J, O'Reilly MA, Abbasian M, Cadinanos-Garai A, Vispute K, Bosshard-Carter L, Mitsikakou M, Mehra V, Roddy H, Hartley JA, Spanswick V, Lowe H, Popova B, Clifton-Hadley L, Wheeler G, Olejnik J, Bloor A, Irvine D, Wood L, Marzolini MA, Domning S, Farzaneh F, Lowdell MW, Linch DC, Pule MA, Peggs KS
Journal of Clinical Oncology 2021
EEG findings in CAR T-cell-associated neurotoxicity: Clinical and radiological correlations
Beuchat I, Danish HH, Rubin DB, Jacobson C, Robertson M, Vaitkevicius H, Lee JW
Neuro-Oncology 2021
Imagining the cell therapist: Future CAR T cell monitoring and intervention strategies to improve patient outcomes
Jain MD, Spiegel JY
2021
Impact of Bridging Chemotherapy on Clinical Outcomes of CD19-Specific CAR T Cell Therapy in Children/Young Adults with Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia
Shahid S, Ramaswamy K, Flynn J, Mauguen A, Perica K, Park JH, Forlenza CJ, Shukla NN, Steinherz PG, Margossian SP, Boelens JJ, Kernan NA, Curran KJ
2021
Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia.
Jetani H, Navarro-Bailón A, Maucher M, Frenz S, Verbruggen C, Yeguas A, Vidriales MB, González M, Rial Saborido J, Kraus S, Mestermann K, Thomas S, Bonig H, Luu M, Monjezi R, Mougiakakos D, Sauer M, Einsele H, Hudecek M
Blood 2021
Therapeutic Targeting of Mesothelin with Chimeric Antigen Receptor T Cells in Acute Myeloid Leukemia
Le Q, Castro S, Tang T, Loeb AM, Hylkema T, McKay CN, Perkins L, Srivastava S, Call L, Smith J, Leonti A, Ries R, Pardo L, Loken MR, Correnti C, Fiorenza S, Turtle CJ, Riddell S, Tarlock K, Meshinchi S
Clinical cancer research 2021
Combining a CAR and a chimeric costimulatory receptor enhances T cell sensitivity to low antigen density and promotes persistence
Katsarou A, Sjöstrand M, Naik J, Mansilla-Soto J, Kefala D, Kladis G, Nianias A, Ruiter R, Poels R, Sarkar I, Patankar YR, Merino E, Reijmers RM, Frerichs KA, Yuan H, de Bruijn J, Stroopinsky D, Avigan D, van de Donk NW, Zweegman S, Mutis T, Sadelain M, Groen RW, Themeli M
Science Translational Medicine 2021
Humanized CD19-Targeted Chimeric Antigen Receptor (CAR) T Cells in CAR-Naive and CAR-Exposed Children and Young Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia
Myers RM, Li Y, Barz Leahy A, Barrett DM, Teachey DT, Callahan C, Fasano CC, Rheingold SR, DiNofia A, Wray L, Aplenc R, Baniewicz D, Liu H, Shaw PA, Pequignot E, Getz KD, Brogdon JL, Fesnak AD, Siegel DL, Davis MM, Bartoszek C, Lacey SF, Hexner EO, Chew A, Wertheim GB, Levine BL, June CH, Grupp SA, Maude SL
Journal of Clinical Oncology 2021
KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results
Shah BD, Bishop MR, Oluwole OO, Logan AC, Baer MR, Donnellan WB, O'Dwyer KM, Holmes H, Arellano ML, Ghobadi A, Pagel JM, Lin Y, Cassaday RD, Park JH, Abedi M, Castro JE, DeAngelo DJ, Malone AK, Mawad R, Schiller GJ, Rossi JM, Bot A, Shen T, Goyal L, Jain RK, Vezan R, Wierda WG
Blood 2021
A Subset of Cytotoxic Effector Memory T cells Enhances CAR T cell Efficacy in a Model of Pancreatic Ductal Adenocarcinoma
Konduri V, Joseph SK, Byrd TT, Nawas Z, Vazquez-Perez J, Hofferek CJ, Halpert MM, Liu D, Liang Z, Baig Y, Salsman VS, Oyewole-Said D, Tsimelzon A, Burns BA, Chen C, Levitt JM, Yao Q, Ahmed NM, Hegde M, Decker WK
Science Translational Medicine 2021
KTE-X19 for relapsed/refractory adult B-cell acute lymphoblastic leukemia: phase 2 results from the single-arm, multicenter ZUMA-3 study
Shah BD, Ghobadi A, Oluwole OO, Logan AC, Boissel N, Cassaday RD, Leguay T, Bishop MR, Topp MS, Tzachanis D, O\u2019Dwyer KM, Arellano ML, Lin Y, Baer MR, Schiller GJ, Park JH, Subklewe M, Abedi M, Minnema MC, Wierda WG, DeAngelo DJ, Stiff P, Jeyakumar D, Feng C, Dong J, Shen T, Milletti F, Rossi JM, Vezan R, Masouleh BK, Houot R
Lancet (London, England) 2021
Sleeping Beauty-engineered CAR T cells achieve anti-leukemic activity without severe toxicities
Chiara F. Magnani, Giuseppe Gaipa, Federico Lussana, Daniela Belotti, Giuseppe Gritti, Sara Napolitano, Giada Matera, Benedetta Cabiati, Chiara Buracchi, Gianmaria Borleri, Grazia Fazio, Silvia Zaninelli, Sarah Tettamanti, Stefania Cesana, Valentina Colombo, Michele Quaroni, Giovanni Cazzaniga, Attilio Rovelli, Ettore Biagi, Stefania Galimberti, Andrea Calabria, Fabrizio Benedicenti, Eugenio Montini, Silvia Ferrari, Martino Introna, Adriana Balduzzi, Maria Grazia Valsecchi, Giuseppe Dastoli, Alessandro Rambaldi, Andrea Biondi
Journal of Clinical Investigation 2020
Immunotherapy of lymphomas
Stephen Ansell, Yi Lin
Journal of Clinical Investigation 2020
State of the art in CAR T-cell therapy for CD19+ B-cell malignancies
Matthew J. Frigault, Marcela V. Maus
Journal of Clinical Investigation 2020
Successful application of anti-CD19 CAR-T therapy with IL-6 knocking down to patients with central nervous system B-cell acute lymphocytic leukemia
LY Chen, LQ Kang, HX Zhou, HQ Gao, XF Zhu, N Xu, L Yu, DP Wu, SL Xue, AN Sun
Translational oncology 2020
EGFR‐targeted CAR‐T cells are potent and specific in suppressing triple‐negative breast cancer both in vitro and in vivo
L Xia, Z Zheng, J Liu, Y Chen, J Ding, N Xia, W Luo, W Liu
IBMS BoneKEy 2020
Engineering T cells for immunotherapy of primary human hepatocellular carcinoma
LD Galva, L Cai, Y Shao, Y He
Journal of genetics and genomics = Yi chuan xue bao 2020
Engineering Solutions for Mitigation of Chimeric Antigen Receptor T-Cell Dysfunction
A Gavriil, M Barisa, E Halliwell, J Anderson
Cancers 2020
Immunotherapy for the Treatment of Acute Lymphoblastic Leukemia
V Barsan, S Ramakrishna, KL Davis
Current Oncology Reports 2020
Hematopoeitic Cell Transplantation and CAR T-Cell Therapy: Complements or Competitors?
SR Goldsmith, A Ghobadi, JF DiPersio
Frontiers in Oncology 2020
Overcoming Chimeric Antigen Receptor (CAR) Modified T-Cell Therapy Limitations in Multiple Myeloma
E García-Guerrero, B Sierro-Martínez, JA Pérez-Simón
Frontiers in immunology 2020
Persistent STAT5 activation reprograms the epigenetic landscape in CD4 + T cells to drive polyfunctionality and antitumor immunity
ZC Ding, H Shi, NS Aboelella, K Fesenkova, EJ Park, Z Liu, L Pei, J Li, RA McIndoe, H Xu, GA Piazza, BR Blazar, DH Munn, G Zhou
Science Immunology 2020
TCR Redirected T Cells for Cancer Treatment: Achievements, Hurdles, and Goals
F Manfredi, BC Cianciotti, A Potenza, E Tassi, M Noviello, A Biondi, F Ciceri, C Bonini, E Ruggiero
Frontiers in immunology 2020
The Emerging Landscape of Immune Cell Therapies
E Weber, M Maus, C Mackall
Cell 2020
How to Combine the Two Landmark Treatment Methods—Allogeneic Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Together to Cure High-Risk B Cell Acute Lymphoblastic Leukemia?
M Zhang, H Huang
Frontiers in immunology 2020
Chimeric Antigen Receptor T-Cell Therapy for Colorectal Cancer
D Sur, A Havasi, C Cainap, G Samasca, C Burz, O Balacescu, I Lupan, D Deleanu, A Irimie
Journal of Clinical Medicine 2020
Prolonged Persistence of Chimeric Antigen Receptor (CAR) T Cell in Adoptive Cancer Immunotherapy: Challenges and Ways Forward
L Jafarzadeh, E Masoumi, K Fallah-Mehrjardi, HR Mirzaei, J Hadjati
Frontiers in immunology 2020
The Advent of CAR T-Cell Therapy for Lymphoproliferative Neoplasms: Integrating Research Into Clinical Practice
M Cerrano, M Ruella, MA Perales, C Vitale, DG Faraci, L Giaccone, M Coscia, M Maloy, M Sanchez-Escamilla, H Elsabah, A Fadul, E Maffini, G Pittari, B Bruno
Frontiers in immunology 2020
In Vivo Generation of CAR T Cells Selectively in Human CD4+ Lymphocytes
S Agarwal, JD Hanauer, AM Frank, V Riechert, FB Thalheimer, CJ Buchholz
Molecular Therapy 2020
The Great War of Today: Modifications of CAR-T Cells to Effectively Combat Malignancies
A Zhylko, M Winiarska, A Graczyk-Jarzynka
Cancers 2020
Clinical CAR-T Cell and Oncolytic Virotherapy for Cancer Treatment
N Watanabe, MK McKenna, AR Shaw, M Suzuki
Molecular Therapy 2020
Engineering better chimeric antigen receptor T cells
H Zhang, P Zhao, H Huang
Experimental Hematology and Oncology 2020
The Role of Immunological Synapse in Predicting the Efficacy of Chimeric Antigen Receptor (CAR) Immunotherapy
D Liu, S Badeti, G Dotti, JJ, H Wang, J Dermody, P Soteropoulos, D Streck, RB Birge, C Liu
Cell Communication and Signaling 2020
Targeted Cellular Micropharmacies: Cells Engineered for Localized Drug Delivery
TJ Gardner, CM Bourne, MM Dacek, K Kurtz, M Malviya, L Peraro, PC Silberman, KC Vogt, MJ Unti, R Brentjens, D Scheinberg
Cancers 2020
Advancing CAR T-Cell Therapy for Solid Tumors: Lessons Learned from Lymphoma Treatment
A Titov, A Valiullina, E Zmievskaya, E Zaikova, A Petukhov, R Miftakhova, E Bulatov, A Rizvanov
Cancers 2020
Gene Modified CAR-T Cellular Therapy for Hematologic Malignancies
WY Lin, HH Wang, YW Chen, CF Lin, HC Fan, YY Lee
International journal of molecular sciences 2020
Consolidative allogeneic hematopoietic stem cell transplantation after chimeric antigen receptor T-cell therapy for relapsed/refractory B-cell acute lymphoblastic leukemia: who? When? Why?
H Jiang, Y Hu, H Mei
Biomarker Research 2020
Chimeric Antigen Receptor (CAR)-Modified Immune Effector Cell Therapy for Acute Myeloid Leukemia (AML)
UH Acharya, RB Walter
Cancers 2020
The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19
P Braendstrup, BL Levine, M Ruella
Cytotherapy 2020
[Mechanisms and countermeasures in relapse of relapsed/refractory non-Hodgkin lymphoma after treatment of CD19 chimeric antigen receptor T cells]
S Y Wang, J Cao, K L Xu
Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 2020
A narrative review of critical factors for better efficacy of CD19 chimeric antigen receptor T cell therapy in the treatment of B cell malignancies
J Liu, L Wang, H Yang, M Xing, S Liu, Z Yu, L Ma
Translational cancer research 2020
Rapid and Effective Generation of Nanobody Based CARs using PCR and Gibson Assembly
SD Munter, AV Parys, L Bral, J Ingels, G Goetgeluk, S Bonte, M Pille, L Billiet, K Weening, A Verhee, JV der Heyden, T Taghon, G Leclercq, T Kerre, J Tavernier, B Vandekerckhove
International journal of molecular sciences 2020
Chimeric Antigen Receptor Cell Therapy: Overcoming Obstacles to Battle Cancer
AJ Petty, B Heyman, Y Yang
Cancers 2020
Systematically optimized BCMA/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma
E Zah, E Nam, V Bhuvan, U Tran, BY Ji, SB Gosliner, X Wang, CE Brown, YY Chen
Nature Communications 2020
CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression
K Fousek, J Watanabe, SK Joseph, A George, X An, TT Byrd, JS Morris, A Luong, MA Martínez-Paniagua, K Sanber, SA Navai, AZ Gad, VS Salsman, PR Mathew, HN Kim, DL Wagner, L Brunetti, A Jang, ML Baker, N Varadarajan, M Hegde, YM Kim, N Heisterkamp, H Abdel-Azim, N Ahmed
Leukemia 2020
Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia
H Dai, Z Wu, H Jia, C Tong, Y Guo, D Ti, X Han, Y Liu, W Zhang, C Wang, Y Zhang, M Chen, Q Yang, Y Wang, W Han
Journal of Hematology & Oncology 2020
Evaluation of piggyBac ‐mediated anti‐CD19 CAR‐T cells after ex vivo expansion with aAPCs or magnetic beads
LR Yang, L Li, MY Meng, WJ Wang, SL Yang, YY Zhao, RQ Wang, H Gao, WW Tang, Y Yang, LL Yang, LW Liao, ZL Hou
Journal of Cellular and Molecular Medicine 2020
Neurotoxicity and Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy: Insights Into Mechanisms and Novel Therapies
EL Siegler, SS Kenderian
Frontiers in immunology 2020
Chimeric Antigen Receptor T Cell Therapy Comes to Clinical Practice
DA Wall, J Krueger
Current Oncology 2020
CD3xCD19 DART molecule treatment induces non-apoptotic killing and is efficient against high-risk chemotherapy and venetoclax-resistant chronic lymphocytic leukemia cells
AW Martens, SR Janssen, IA Derks, HC Adams, L Izhak, R van Kampen, SH Tonino, E Eldering, GJ van der Windt, AP Kater
Journal for ImmunoTherapy of Cancer 2020
Humanized Mice Are Precious Tools for Preclinical Evaluation of CAR T and CAR NK Cell Therapies
R Mhaidly, E Verhoeyen
Cancers 2020
Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia
R Gu, F Liu, D Zou, Y Xu, Y Lu, B Liu, W Liu, X Chen, K Liu, Y Guo, X Gong, R Lv, X Chen, C Zhou, M Zhong, H Wang, H Wei, Y Mi, L Qiu, L Lv, M Wang, Y Wang, X Zhu, J Wang
Journal of Hematology & Oncology 2020
T-cells with a single tumor antigen-specific T-cell receptor can be generated in vitro from clinically relevant stem cell sources
S Bonte, SD Munter, G Goetgeluk, J Ingels, M Pille, L Billiet, T Taghon, G Leclercq, B Vandekerckhove, T Kerre
OncoImmunology 2020
Excessive Costimulation Leads to Dysfunction of Adoptively Transferred T Cells
D Wijewarnasuriya, C Bebernitz, AV Lopez, S Rafiq, RJ Brentjens
Cancer immunology research 2020
Harnessing neoantigen specific CD4 T cells for cancer immunotherapy
SE Brightman, MS Naradikian, AM Miller, SP Schoenberger
Journal of leukocyte biology 2020
To Remember or to Forget: The Role of Good and Bad Memories in Adoptive T Cell Therapy for Tumors
A Mondino, T Manzo
Frontiers in immunology 2020
Reactive Myelopoiesis and the Onset of Myeloid-Mediated Immune Suppression: Implications for Adoptive Cell Therapy
P Innamarato, S Pilon-Thomas
Cellular Immunology 2020
Clinical practice: chimeric antigen receptor (CAR) T cells: a major breakthrough in the battle against cancer
S Lundh, IY Jung, A Dimitri, A Vora, JJ Melenhorst, JK Jadlowsky, JA Fraietta
Clinical and Experimental Medicine 2020
CARs: Beyond T Cells and T Cell-Derived Signaling Domains
NM Sievers, J Dörrie, N Schaft
International journal of molecular sciences 2020
The Role of Circulating Tumor Cells in the Metastatic Cascade: Biology, Technical Challenges, and Clinical Relevance
H Dianat-Moghadam, M Azizi, Z Eslami-S, LE Cortés-Hernández, M Heidarifard, M Nouri, C Alix-Panabières
Cancers 2020
Dual Targeting of Mesothelin and CD19 with Chimeric Antigen Receptor-Modified T Cells in Patients with Metastatic Pancreatic Cancer
AH Ko, AC Jordan, E Tooker, SF Lacey, RB Chang, Y Li, AP Venook, M Tempero, L Damon, L Fong, MH OHara, BL Levine, JJ Melenhorst, G Plesa, CH June, GL Beatty
Molecular Therapy 2020
Clonal kinetics and single-cell transcriptional profiling of CAR-T cells in patients undergoing CD19 CAR-T immunotherapy
A Sheih, V Voillet, LA Hanafi, HA DeBerg, M Yajima, R Hawkins, V Gersuk, SR Riddell, DG Maloney, ME Wohlfahrt, D Pande, MR Enstrom, HP Kiem, JE Adair, R Gottardo, PS Linsley, CJ Turtle
Nature Communications 2020
The Art and Science of Selecting a CD123-Specific Chimeric Antigen Receptor for Clinical Testing
JM Riberdy, S Zhou, F Zheng, YI Kim, J Moore, A Vaidya, RE Throm, A Sykes, N Sahr, CL Bonifant, B Ryu, S Gottschalk, MP Velasquez
Molecular Therapy — Methods & Clinical Development 2020
GP130 Cytokines in Breast Cancer and Bone
T Omokehinde, RW Johnson
Cancers 2020
A Critical Role for Fas-Mediated Off-Target Tumor Killing in T-cell Immunotherapy
R Upadhyay, JA Boiarsky, G Pantsulaia, J Svensson-Arvelund, MJ Lin, A Wroblewska, S Bhalla, N Scholler, A Bot, JM Rossi, N Sadek, S Parekh, A Lagana, A Baccarini, M Merad, BD Brown, JD Brody
Cancer Discovery 2020
Targeting Cancer Stem Cells by Genetically Engineered Chimeric Antigen Receptor T Cells
RY Alhabbab
Frontiers in Genetics 2020
Mechanisms of resistance to CAR T cell therapies
N Singh, E Orlando, J Xu, J Xu, Z Binder, MK Collins, DM ORourke, JJ Melenhorst
Seminars in Cancer Biology 2020
Management of toxicities associated with novel immunotherapy agents in acute lymphoblastic leukemia
T Jain, MR Litzow
Therapeutic Advances in Hematology 2020
The Role of Immune Checkpoints after Cellular Therapy
F Schmitz, D Wolf, TA Holderried
International journal of molecular sciences 2020
Single-Cell Analyses Identify Brain Mural Cells Expressing CD19 as Potential Off-Tumor Targets for CAR-T Immunotherapies
KR Parker, D Migliorini, E Perkey, KE Yost, A Bhaduri, P Bagga, M Haris, NE Wilson, F Liu, K Gabunia, J Scholler, TJ Montine, VG Bhoj, R Reddy, S Mohan, I Maillard, AR Kriegstein, CH June, HY Chang, AD Posey, AT Satpathy
Cell 2020
A Cross-Reactive Small Protein Binding Domain Provides a Model to Study Off-Tumor CAR-T Cell Toxicity
JA Hammill, JM Kwiecien, A Dvorkin-Gheva, VW Lau, C Baker, Y Wu, K Bezverbnaya, C Aarts, CW Heslen, GF Denisova, H Derocher, K Milne, BH Nelson, JL Bramson
Molecular Therapy — Oncolytics 2020
4-1BB costimulation promotes CAR T cell survival through noncanonical NF-κB signaling
BI Philipson, RS OConnor, MJ May, CH June, SM Albelda, MC Milone
Science signaling 2020
Combining Oncolytic Viruses With Cancer Immunotherapy: Establishing a New Generation of Cancer Treatment
T Shi, X Song, Y Wang, F Liu, J Wei
Frontiers in immunology 2020
Advances in the development of chimeric antigen receptor-T-cell therapy in B-cell acute lymphoblastic leukemia:
X Zhang, JJ Li, PH Lu
Chinese Medical Journal 2020
HIV-Resistant and HIV-Specific CAR-Modified CD4+ T Cells Mitigate HIV Disease Progression and Confer CD4+ T Cell Help In Vivo
CR Maldini, K Gayout, RS Leibman, DL Dopkin, JP Mills, X Shan, JA Glover, JL Riley
Molecular Therapy 2020
Potential strategies against resistance to CAR T-cell therapy in haematological malignancies
Q Cai, M Zhang, Z Li
Therapeutic advances in medical oncology 2020
The Influence of Chimeric Antigen Receptor Structural Domains on Clinical Outcomes and Associated Toxicities
AS Davey, ME Call, MJ Call
Cancers 2020
The Application of CAR-T Cells in Haematological Malignancies
K Skorka, K Ostapinska, A Malesa, K Giannopoulos
Archivum Immunologiae et Therapiae Experimentalis 2020
Efficacy and safety of chimeric antigen receptor-T cells in the treatment of B cell lymphoma: a systematic review and meta-analysis
XH Zheng, , QQ Dong, F Chen, SB Yang, WB Li
Chinese Medical Journal 2020
Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia
T Badar, NN Shah
Current Treatment Options in Oncology 2020
A Novel Siglec-4 Derived Spacer Improves the Functionality of CAR T Cells Against Membrane-Proximal Epitopes
D Schäfer, J Henze, R Pfeifer, A Schleicher, J Brauner, N Mockel-Tenbrinck, C Barth, D Gudert, WA Rawashdeh, IC Johnston, O Hardt
Frontiers in immunology 2020
Strategies for having a more effective and less toxic CAR T-cell therapy for acute lymphoblastic leukemia
MH Boroojerdi, F Rahbarizadeh, PS Kozani, E Kamali, PS Kozani
Medical Oncology 2020
Cytokines in CAR T Cell–Associated Neurotoxicity
J Gust, R Ponce, WC Liles, GA Garden, CJ Turtle
Frontiers in immunology 2020
Peripheral inflammation and blood–brain barrier disruption: effects and mechanisms
X Huang, B Hussain, J Chang
CNS Neuroscience & Therapeutics 2020
CAR T cell therapy: newer approaches to counter resistance and cost
RK Yadav, A Ali, S Kumar, A Sharma, B Baghchi, P Singh, S Das, C Singh, S Sharma
Heliyon 2020
Emerging immunotherapies for malignant glioma: from immunogenomics to cell therapy
GP Dunn, TF Cloughesy, MV Maus, RM Prins, DA Reardon, AM Sonabend
Neuro-Oncology 2020
Mechanisms underlying CD19-positive ALL relapse after anti-CD19 CAR T cell therapy and associated strategies
Y Nie, W Lu, D Chen, H Tu, Z Guo, X Zhou, M Li, S Tu, Y Li
Biomarker Research 2020
T-Cell Dependent Immunogenicity of Protein Therapeutics Pre-clinical Assessment and Mitigation–Updated Consensus and Review 2020
V Jawa, F Terry, J Gokemeijer, S Mitra-Kaushik, BJ Roberts, S Tourdot, AS Groot
Frontiers in immunology 2020
Use of Cell and Genome Modification Technologies to Generate Improved “Off-the-Shelf” CAR T and CAR NK Cells
MA Morgan, H Büning, M Sauer, A Schambach
Frontiers in immunology 2020
Antitumor Potency of an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, Lisocabtagene Maraleucel in Combination With Ibrutinib or Acalabrutinib:
JS Qin, TG Johnstone, A Baturevych, RJ Hause, SP Ragan, CR Clouser, JC Jones, R Ponce, CM Krejsa, RA Salmon, MO Ports
Journal of immunotherapy (Hagerstown, Md. : 1997) 2020
Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure
J Gauthier, AV Hirayama, J Purushe, KA Hay, J Lymp, DH Li, CC Yeung, A Sheih, BS Pender, RM Hawkins, A Vakil, TD Phi, RN Steinmetz, M Shadman, SR Riddell, DG Maloney, CJ Turtle
Blood 2020
CAR T and CAR NK cells in multiple myeloma: Expanding the targets
UA Shah, S Mailankody
Best practice & research. Clinical haematology 2020
CAR T-cell immunotherapy of B-cell malignancy: the story so far
L Halim, J Maher
2020
Transposon-Based CAR T Cells in Acute Leukemias: Where Are We Going?
CF Magnani, S Tettamanti, G Alberti, I Pisani, A Biondi, M Serafini, G Gaipa
Cells 2020
Immunotherapy in Pediatric B-Cell Acute Lymphoblastic Leukemia: Advances and Ongoing Challenges
S Jasinski, FA Reyes, GC Yametti, J Pierro, E Raetz, WL Carroll
Pediatric Drugs 2020
Immune Literacy: Reading, Writing, and Editing Adaptive Immunity
L Csepregi, RA Ehling, B Wagner, ST Reddy
iScience 2020
4-1BB Signaling Boosts the Anti-Tumor Activity of CD28-Incorporated 2nd Generation Chimeric Antigen Receptor-Modified T Cells
Q Dai, P Han, X Qi, F Li, M Li, L Fan, H Zhang, X Zhang, X Yang
Frontiers in immunology 2020
Chimeric Antigen Receptor T Cell Therapy Targeting ICAM-1 in Gastric Cancer
M Jung, Y Yang, JE McCloskey, M Zaman, Y Vedvyas, X Zhang, D Stefanova, KD Gray, IM Min, R Zarnegar, YY Choi, JH Cheong, SH Noh, SY Rha, HC Chung, MM Jin
Molecular Therapy — Oncolytics 2020
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events
MV Maus, S Alexander, MR Bishop, JN Brudno, C Callahan, ML Davila, C Diamonte, J Dietrich, JC Fitzgerald, MJ Frigault, TJ Fry, JL Holter-Chakrabarty, KV Komanduri, DW Lee, FL Locke, SL Maude, PL McCarthy, E Mead, SS Neelapu, TG Neilan, BD Santomasso, EJ Shpall, DT Teachey, CJ Turtle, T Whitehead, SA Grupp
Journal for ImmunoTherapy of Cancer 2020
convertibleCARs: A chimeric antigen receptor system for flexible control of activity and antigen targeting
KE Landgraf, SR Williams, D Steiger, D Gebhart, S Lok, DW Martin, KT Roybal, KC Kim
2020
Rapidly Switchable Universal CAR-T Cells for Treatment of CD123-Positive Leukemia
S Loff, J Dietrich, JE Meyer, J Riewaldt, J Spehr, M von Bonin, C Gründer, M Swayampakula, K Franke, A Feldmann, M Bachmann, G Ehninger, A Ehninger, M Cartellieri
Molecular Therapy — Oncolytics 2020
Biomarkers in individualized management of chimeric antigen receptor T cell therapy
M Du, P Hari, Y Hu, H Mei
Biomarker Research 2020
A comprehensive analysis of the fatal toxic effects associated with CD19 CAR-T cell therapy
C Cai, D Tang, Y Han, E Shen, OA Ahmed, C Guo, H Shen, S Zeng
Aging 2020
Case Report: Humanized Selective CD19CAR-T Treatment Induces MRD-Negative Remission in a Pediatric B-ALL Patient With Primary Resistance to Murine-Based CD19CAR-T Therapy
K Wang, Y Zhao, X Wang, B Wang, M Qin, G Zhu, H Wu, Z Liu, X Zheng, H Zheng, Z Chen
Frontiers in immunology 2020
Is Hematopoietic Stem Cell Transplantation Required to Unleash the Full Potential of Immunotherapy in Acute Myeloid Leukemia?
E Abadir, RE Gasiorowski, PA Silveira, S Larsen, GJ Clark
Journal of Clinical Medicine 2020
Late Events after Treatment with CD19-Targeted Chimeric Antigen Receptor Modified T Cells
A Cordeiro, ED Bezerra, AV Hirayama, JA Hill, QV Wu, J Voutsinas, ML Sorror, CJ Turtle, DG Maloney, M Bar
Biology of Blood and Marrow Transplantation 2020
CAR T Cell Generation by piggyBac Transposition from Linear Doggybone DNA Vectors Requires Transposon DNA-Flanking Regions
DC Bishop, L Caproni, K Gowrishankar, M Legiewicz, K Karbowniczek, J Tite, DJ Gottlieb, KP Micklethwaite
Molecular Therapy — Methods & Clinical Development 2020
Identification of human CD4 + T cell populations with distinct antitumor activity
MH Nelson, HM Knochelmann, SR Bailey, LW Huff, JS Bowers, K Majchrzak-Kuligowska, MM Wyatt, MP Rubinstein, S Mehrotra, MI Nishimura, KE Armeson, PG Giresi, MJ Zilliox, HE Broxmeyer, CM Paulos
Science Advances 2020
Triggers, Timescales, and Treatments for Cytokine-Mediated Tissue Damage
D McBride, M Kerr, N Dorn, D Ogbonna, E Santos, N Shah
2020
Influence of patient characteristics on chimeric antigen receptor T cell therapy in B-cell acute lymphoblastic leukemia
F An, H Wang, Z Liu, F Wu, J Zhang, Q Tao, Y Li, Y Shen, Y Ruan, Q Zhang, Y Pan, W Zhu, H Qin, Y Wang, Y Fu, Z Feng, Z Zhai
Nature Communications 2020
Bispecific Antibodies: A New Era of Treatment for Multiple Myeloma
X Zhou, H Einsele, S Danhof
Journal of Clinical Medicine 2020
Real-Time Killing Assays to Assess the Potency of a New Anti-Simian Immunodeficiency Virus Chimeric Antigen Receptor T Cell
F Haeseleer, K Eichholz, SU Tareen, N Iwamoto, M Roederer, F Kirchhoff, H Park, AA Okoye, L Corey
AIDS Research and Human Retroviruses 2020
Better Epitope Discovery, Precision Immune Engineering, and Accelerated Vaccine Design Using Immunoinformatics Tools
AS Groot, L Moise, F Terry, AH Gutierrez, P Hindocha, G Richard, DF Hoft, TM Ross, AR Noe, Y Takahashi, V Kotraiah, SE Silk, CM Nielsen, AM Minassian, R Ashfield, M Ardito, SJ Draper, WD Martin
Frontiers in immunology 2020
A Functional Screening Strategy for Engineering Chimeric Antigen Receptors with Reduced On-Target, Off-Tumor Activation
RB Roberto, R Castellanos-Rueda, S Frey, D Egli, R Vazquez-Lombardi, E Kapetanovic, J Kucharczyk, ST Reddy
Molecular Therapy 2020
Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL
R Awasthi, L Pacaud, E Waldron, CS Tam, U Jäger, P Borchmann, S Jaglowski, SR Foley, K van Besien, ND Wagner-Johnston, MJ Kersten, SJ Schuster, G Salles, RT Maziarz, Ö Anak, C del Corral, J Chu, I Gershgorin, I Pruteanu-Malinici, A Chakraborty, KT Mueller, EK Waller
Blood Advances 2020
Chimeric Antigen Receptor T-Cells in B-Acute Lymphoblastic Leukemia: State of the Art and Future Directions
U Greenbaum, KM Mahadeo, P Kebriaei, EJ Shpall, NY Saini
Frontiers in Oncology 2020
Secondary donor-derived humanized CD19-modified CAR-T cells induce remission in relapsed/refractory mixed phenotype acute leukemia after allogeneic hematopoietic stem cell transplantation: a case report
MY Li, ZH Lin, MM Hu, LQ Kang, X Wu, Q Chen, X Kong, J Zhang, HY Qiu, DP Wu
Biomarker Research 2020
Chimeric antigen receptor T cells for mature B-cell lymphoma and Burkitt lymphoma
EM Hsieh, RH Rouce
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program 2020
Taming the beast: CRS and ICANS after CAR T-cell therapy for ALL
VS Sheth, J Gauthier
Bone Marrow Transplantation 2020
The model of cytokine release syndrome in CAR T-cell treatment for B-cell non-Hodgkin lymphoma
J Wei, Y Liu, C Wang, Y Zhang, C Tong, G Dai, W Wang, JE Rasko, JJ Melenhorst, W Qian, A Liang, W Han
Signal Transduction and Targeted Therapy 2020
Chimeric antigen receptor–T cells with cytokine neutralizing capacity
AH Tan, N Vinanica, D Campana
Blood Advances 2020
Toxicity Induced by a Bispecific T Cell–Redirecting Protein Is Mediated by Both T Cells and Myeloid Cells in Immunocompetent Mice
C Godbersen-Palmer, TA Coupet, Z Grada, SC Zhang, CL Sentman
Journal of immunology (Baltimore, Md. : 1950) 2020

Low Level Donor Chimerism of CD19 CAR-T Cells Returned to Complete Donor Chimerism in Patients with Relapse After Allo-Hematopoietic Stem Cell Transplant


Q Li, J Mu, J Yuan, Z Yang, J Wang, Q Deng
OncoTargets and therapy 2020
Using apelin-based synthetic Notch receptors to detect angiogenesis and treat solid tumors
Z Wang, F Wang, J Zhong, T Zhu, Y Zheng, T Zhao, Q Xie, F Ma, R Li, Q Tang, F Xu, X Tian, J Zhu
Nature Communications 2020
PD-L1 chimeric costimulatory receptor improves the efficacy of CAR-T cells for PD-L1-positive solid tumors and reduces toxicity in vivo
Q Liao, Y Mao, H He, X Ding, X Zhang, J Xu
Biomarker Research 2020
Phase II trial of co‐administration of CD19‐ and CD20‐targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma
W Sang, M Shi, J Yang, J Cao, L Xu, D Yan, M Yao, H Liu, W Li, B Zhang, K Sun, X Song, C Sun, J Jiao, Y Qin, T Sang, Y Ma, M Wu, X Gao, H Cheng, Z Yan, D Li, H Sun, F Zhu, Y Wang, L Zeng, Z Li, J Zheng, K Xu
Cancer Medicine 2020
Lymphodepletion chemotherapy revitalizes chimeric antigen receptor T cells contributing to regression of relapsed B-cell lymphoma: A case report
Z Liang, H Zhang, M Shao, Q Cui, Z Wu, L Xiao, H Huang, Y Hu
Medicine 2020
Preclinical development of a humanized chimeric antigen receptor against B cell maturation antigen for multiple myeloma
L Perez-Amill, G Suñe, A Antoñana-Vildosola, M Castella, A Najjar, J Bonet, N Fernández-Fuentes, S Inogés, A López, C Bueno, M Juan, Á Urbano-Ispizua, B Martín-Antonio
Haematologica 2020
GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma
JA Park, NK Cheung
Journal of Hematology & Oncology 2020
Advances in Developing CAR T-Cell Therapy for HIV Cure
J Qi, C Ding, X Jiang, Y Gao
Frontiers in immunology 2020
Tumor Interferon Signaling Is Regulated by a lncRNA INCR1 Transcribed from the PD-L1 Locus
M Mineo, SM Lyons, M Zdioruk, N von Spreckelsen, R Ferrer-Luna, H Ito, QA Alayo, P Kharel, AG Larsen, WY Fan, S Auduong, K Grauwet, C Passaro, JK Khalsa, K Shah, DA Reardon, KL Ligon, R Beroukhim, H Nakashima, P Ivanov, PJ Anderson, SE Lawler, EA Chiocca
Molecular Cell 2020
Mass spectrometry-based identification of a B-cell maturation antigen-derived T-cell epitope for antigen-specific immunotherapy of multiple myeloma
T Bilich, A Nelde, J Bauer, S Walz, M Roerden, HR Salih, K Weisel, B Besemer, A Marcu, M Lübke, J Schuhmacher, MC Neidert, HG Rammensee, S Stevanović, JS Walz
Blood Cancer Journal 2020
Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma
FL Locke, JM Rossi, SS Neelapu, CA Jacobson, DB Miklos, A Ghobadi, OO Oluwole, PM Reagan, LJ Lekakis, Y Lin, M Sherman, M Better, WY Go, JS Wiezorek, A Xue, A Bot
Blood Advances 2020
Efficacy and Safety of CAR-Modified T Cell Therapy in Patients with Relapsed or Refractory Multiple Myeloma: A Meta-Analysis of Prospective Clinical Trials
X Xiang, Q He, Y Ou, W Wang, Y Wu
Frontiers in pharmacology 2020
Tuning the Antigen Density Requirement for CAR T-cell Activity
RG Majzner, SP Rietberg, E Sotillo, R Dong, VT Vachharajani, L Labanieh, JH Myklebust, M Kadapakkam, EW Weber, AM Tousley, RM Richards, S Heitzeneder, SM Nguyen, V Wiebking, J Theruvath, RC Lynn, P Xu, AR Dunn, RD Vale, CL Mackall
Cancer Discovery 2020
Chimeric antigen receptor T‐cell therapies: Optimising the dose
N Dasyam, P George, R Weinkove
British Journal of Clinical Pharmacology 2020
Improving CAR T cell therapy by optimizing critical quality attributes
OL Reddy, DF Stroncek, SR Panch
Seminars in Hematology 2020
Efficacy and Safety of CD28- or 4-1BB-Based CD19 CAR-T Cells in B Cell Acute Lymphoblastic Leukemia
X Zhao, J Yang, X Zhang, XA Lu, M Xiong, J Zhang, X Zhou, F Qi, T He, Y Ding, X Hu, FD Smet, P Lu, X Huang
Molecular Therapy — Oncolytics 2020
Immuntherapien zur Behandlung der chronischen Hepatitis-B-Virusinfektion – eine Übersicht unter besonderer Berücksichtigung von CAR-T-Zellen
Z Ivics, M Amberger, T Zahn, E Hildt
Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz 2020
Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes
L Schultz
Frontiers in immunology 2020
Chimeric antigen receptor T cell therapy for pediatric and young adult B cell acute lymphoblastic leukemia
RM Myers, J Dolan, DT Teachey
Expert Review of Clinical Immunology 2020
Cluster of differentiation 19 chimeric antigen receptor T‑cell therapy in pediatric acute lymphoblastic leukemia (Review)
Z Fu, J Zhou, R Chen, Y Jin, T Ni, L Qian, C Xiao
Oncology Letters 2020
CART Cell Toxicities: New Insight into Mechanisms and Management:
A Zahid, EL Siegler, SS Kenderian
2020
CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial.
Shah NN, Highfill SL, Shalabi H, Yates B, Jin J, Wolters PL, Ombrello A, Steinberg SM, Martin S, Delbrook C, Hoffman L, Little L, Ponduri A, Qin H, Qureshi H, Dulau-Florea A, Salem D, Wang HW, Yuan C, Stetler-Stevenson M, Panch S, Tran M, Mackall CL, Stroncek DF, Fry TJ
Journal of Clinical Oncology 2020
[Chimeric antigen receptors T cells for treatment of B-cell acute lymphoblastic leukemia previously infected with hepatitis B virus: two cases report and literatures review].
Han L, Zhou J, Zhu XH, Fu YW, Li LL, Gao QL, Song YP
Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 2020
Factors Associated with Costs in Chimeric Antigen Receptor T-Cell Therapy for Patients with Relapsed/Refractory B-Cell Malignancies.
Zhu F, Wei G, Zhang M, Zhao H, Wu W, Yang L, Hu Y, Huang H
Cell transplantation 2020
Pre-clinical assessment of chimeric antigen receptor t cell therapy targeting CD19+ B cell malignancy.
Hu SI, Ko MC, Dai YH, Lin HA, Chen LC, Huang KY, Pang TL, Kuo CY, Lin HC
Annals of translational medicine 2020
Allogeneic haematopoietic stem cell transplantation improves outcome of adults with relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia entering remission following CD19 chimeric antigen receptor T cells.
Gu B, Shi BY, Zhang X, Zhou SY, Chu JH, Wu XJ, Fu CC, Qiu HY, Han Y, Chen SN, Yu L, Ma X, Wu DP
Bone Marrow Transplantation 2020
How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies.
Hill JA, Seo SK
Blood 2020
Acute Kidney Injury and Electrolyte Abnormalities After Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Diffuse Large B-Cell Lymphoma.
Gupta S, Seethapathy H, Strohbehn IA, Frigault MJ, O'Donnell EK, Jacobson CA, Motwani SS, Parikh SM, Curhan GC, Reynolds KL, Leaf DE, Sise ME
American journal of kidney diseases : the official journal of the National Kidney Foundation 2020
A computationally designed chimeric antigen receptor provides a small-molecule safety switch for T-cell therapy.
Giordano-Attianese G, Gainza P, Gray-Gaillard E, Cribioli E, Shui S, Kim S, Kwak MJ, Vollers S, Corria Osorio AJ, Reichenbach P, Bonet J, Oh BH, Irving M, Coukos G, Correia BE
Nature Biotechnology 2020
A VHH-Based Anti-MUC1 Chimeric Antigen Receptor for Specific Retargeting of Human Primary T Cells to MUC1-Positive Cancer Cells.
Rajabzadeh A, Rahbarizadeh F, Ahmadvand D, Kabir Salmani M, Hamidieh AA
2020
Inefficient CAR-proximal signaling blunts antigen sensitivity.
Gudipati V, Rydzek J, Doel-Perez I, Gonçalves VDR, Scharf L, Königsberger S, Lobner E, Kunert R, Einsele H, Stockinger H, Hudecek M, Huppa JB
Nature Immunology 2020
[Maintenance therapy following CD19 CAR-T treatment for relapsed B-cell acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation].
Jiang YL, Li Q, Pu YD, Jiang YY, Yuan T, Deng Q, Li YM, Han MZ, Zhai WH
Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 2020
Infectious Complications Following CD19 Chimeric Antigen Receptor T-cell Therapy for Children, Adolescents, and Young Adults.
Vora SB, Waghmare A, Englund JA, Qu P, Gardner RA, Hill JA
Open Forum Infectious Diseases 2020
Efficacy and safety of anti-CD19 CAR T-cell therapy in 110 patients with B-cell acute lymphoblastic leukemia with high-risk features.
Zhang X, Lu XA, Yang J, Zhang G, Li J, Song L, Su Y, Shi Y, Zhang M, He J, Song D, Lv F, Li W, Wu Y, Wang H, Liu H, Zhou X, He T, Lu P
Blood Advances 2020
Recognizing and Grading CAR T-Cell Toxicities: An Advanced Practitioner Perspective.
Sievers S, Watson G, Johncy S, Adkins S
Frontiers in Oncology 2020
A nanoparticle vaccine that targets neoantigen peptides to lymphoid tissues elicits robust antitumor T cell responses.
Arbelaez CA, Estrada J, Gessner MA, Glaus C, Morales AB, Mohn D, Phee H, Lipford JR, Johnston JA
npj Vaccines 2020
Acute Graft-Versus-Host Disease After Humanized Anti-CD19-CAR T Therapy in Relapsed B-ALL Patients After Allogeneic Hematopoietic Stem Cell Transplant
Liu P, Liu M, Lyu C, Lu W, Cui R, Wang J, Li Q, Mou N, Deng Q, Yang D
Frontiers in Oncology 2020
Management of adverse effects of new monoclonal antibody treatments in acute lymphoblastic leukemia
Conde-Royo D, Juárez-Salcedo LM, Dalia S
Drugs in Context 2020
CAR-T细胞桥接异基因造血干细胞移植治疗复发/难治急性B淋巴细胞白血病的临床分析
2020
Bispecific T-cell engaging antibodies in B-cell precursor acute lymphoblastic leukemias: focus on blinatumomab.
Ribera JM, Genescà E, Ribera J
Therapeutic Advances in Hematology 2020
Interleukin-6-knockdown of chimeric antigen receptor-modified T cells significantly reduces IL-6 release from monocytes.
Kang L, Tang X, Zhang J, Li M, Xu N, Qi W, Tan J, Lou X, Yu Z, Sun J, Wang Z, Dai H, Chen J, Lin G, Wu D, Yu L
Experimental Hematology and Oncology 2020
Non-genetic mechanisms of therapeutic resistance in cancer.
Marine JC, Dawson SJ, Dawson MA
Nature reviews. Cancer 2020
CAR T cells vs allogeneic HSCT for poor-risk ALL.
Diorio C, Maude SL
Hematology 2020
Relmacabtagene autoleucel (relma-cel) CD19 CAR-T therapy for adults with heavily pretreated relapsed/refractory large B-cell lymphoma in China.
Ying Z, Yang H, Guo Y, Li W, Zou D, Zhou D, Wang Z, Zhang M, Wu J, Liu H, Zhang P, Yang S, Zhou Z, Zheng H, Song Y, Zhu J
Cancer Medicine 2020
Spotlight on Tocilizumab in the Treatment of CAR-T-Cell-Induced Cytokine Release Syndrome: Clinical Evidence to Date
Si S, Teachey DT
Therapeutics and Clinical Risk Management 2020
Clinical Predictors of Neurotoxicity After Chimeric Antigen Receptor T-Cell Therapy
Rubin DB, Al Jarrah A, Li K, LaRose S, Monk AD, Ali AB, Spendley LN, Nikiforow S, Jacobson C, Vaitkevicius H
JAMA neurology 2020
Hematopoietic stem cell transplantation and chimeric antigen receptor T cell for relapsed or refractory diffuse large B-cell lymphoma
Wang T, Gao L, Wang Y, Zhu W, Xu L, Wang Y, Yue W, Tang G, Chen L, Chen J, Zhang W, Yu X, Feng D, Yang J
Immunotherapy 2020
Potential lung attack and lethality generated by EpCAM-specific CAR-T cells in immunocompetent mouse models.
Qin D, Li D, Zhang B, Chen Y, Liao X, Li X, Alexander PB, Wang Y, Li QJ
OncoImmunology 2020
Humanized anti‐CD19 chimeric antigen receptor‐T cell therapy is safe and effective in lymphoma and leukemia patients with chronic and resolved hepatitis B virus infection
Cui R, Lyu C, Li Q, Jiang Y, Mou N, Yang Z, Liu X, Deng Q, Li L
Hematological Oncology 2020
Efficacy and safety of humanized anti-CD19-CAR-T therapy following intensive lymphodepleting chemotherapy for refractory/relapsed B acute lymphoblastic leukaemia.
Wang J, Mou N, Yang Z, Li Q, Jiang Y, Meng J, Liu X, Deng Q
British Journal of Haematology 2020
Different sites of extranodal involvement may affect the survival of patients with relapsed or refractory non-Hodgkin lymphoma after chimeric antigen receptor T cell therapy.
Zhou L, Li P, Ye S, Tang X, Wang J, Liu J, Liang A
Frontiers of Medicine 2020
Glypican-3-Specific CAR T Cells Coexpressing IL15 and IL21 Have Superior Expansion and Antitumor Activity against Hepatocellular Carcinoma.
Batra SA, Rathi P, Guo L, Courtney AN, Fleurence J, Balzeau J, Shaik RS, Nguyen TP, Wu MF, Bulsara S, Mamonkin M, Metelitsa LS, Heczey A
Cancer immunology research 2020
Navigating the Fas Lane to Improved Cellular Therapy of Cancer
Madhav Dhodapkar
Journal of Clinical Investigation 2019
Systematic testing and specificity mapping of alloantigen-specific chimeric antigen receptors in T regulatory cells
Nicholas AJ Dawson, Caroline Lamarche, Romy Hoeppli, Peter Bergqvist, Vivian Fung, Emma McIver, Qing Huang, Jana Gillies, Madeleine Speck, Paul Orban, Jonathan Bush, Majid Mojibian, Megan Levings
JCI Insight 2019
Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T-cells for relapsed/refractory CLL
Mark B Geyer, Isabelle Rivière, Brigitte Sénéchal, Xiuyan Wang, Yongzeng Wang, Terence Purdon, Meier Hsu, Sean M Devlin, Lia Palomba, Elizabeth Halton, Yvette Bernal, Michel Sadelain, Jae Park, Renier J. Brentjens
JCI Insight 2019
ROR1-CAR T-cells are effective against lung and breast cancer in advanced microphysiologic 3D tumor models
Lars Wallstabe, Claudia Göttlich, Lena Nelke, Johanna Kühnemundt, Thomas Schwarz, Thomas Nerreter, Hermann Einsele, Heike Walles, Gudrun Dandekar, Sarah Nietzer, Michael Hudecek
JCI Insight 2019
Mutated nucleophosmin 1 as immunotherapy target in acute myeloid leukemia.
Dyantha I. van der Lee, Rogier M. Reijmers, M. Wilhelmina Honders, Renate S. Hagedoorn, Rob de Jong, Michel D.G. Kester, Dirk M. van der Steen, Arnoud H. de Ru, Christiaan Kweekel, Helena M Bijen, Inge Jedema, Hendrik Veelken, Peter A. van Veelen, Mirjam H.M. Heemskerk, J.H.Frederik Falkenburg, Marieke Griffioen
Journal of Clinical Investigation 2019
CD19 CAR T cell product and disease attributes predict leukemia remission durability
Olivia C. Finney, Hannah M Brakke, Stephanie Rawlings-Rhea, Roxana Hicks, Danielle Doolittle, Marisa Lopez, Robert B. Futrell, Rimas J. Orentas, Daniel Li, Rebecca A Gardner, Michael C Jensen
Journal of Clinical Investigation 2019
B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma
Adam D Cohen, Alfred L. Garfall, Edward Stadtmauer, Jan Melenhorst, Simon F Lacey, Eric Lancaster, Dan T. Vogl, Brendan Weiss, Karen Dengel, Anne Marie Nelson, Gabriela Plesa, Fang Chen, Megan M Davis, Wei-Ting Hwang, Regina Young, Jennifer L. Brogdon, Randi Isaacs, Iulian Pruteanu-Malinici, Don L Siegel, Bruce L Levine, Carl H. June, Michael C. Milone
Journal of Clinical Investigation 2019
T-Cell Receptor–Based Immunotherapy for Hematologic Malignancies:
MA Biernacki, M Brault, M Bleakley
The Cancer Journal 2019
Emerging Cellular Therapies for Cancer
S Guedan, M Ruella, CH June
Annual Review of Immunology 2019
T cell receptor‐based cancer immunotherapy: Emerging efficacy and pathways of resistance
SS Chandran, CA Klebanoff
Immunological Reviews 2019
Optimizing Manufacturing Protocols of Chimeric Antigen Receptor T Cells for Improved Anticancer Immunotherapy
S Stock, M Schmitt, L Sellner
International journal of molecular sciences 2019
CAR T-cell therapy for B-cell lymphomas: clinical trial results of available products
JC Chavez, C Bachmeier, MA Kharfan-Dabaja
Therapeutic Advances in Hematology 2019
Single-cell Analysis of CAR-T Cell Activation Reveals A Mixed TH1/TH2 Response Independent of Differentiation
I Xhangolli, B Dura, GH Lee, D Kim, Y Xiao, R Fan
Genomics, proteomics & bioinformatics / Beijing Genomics Institute 2019
The making and function of CAR cells
M Zabel, PA Tauber, WF Pickl
Immunology Letters 2019
Mechanisms of resistance to CAR T cell therapy
NN Shah, TJ Fry
Nature Reviews Clinical Oncology 2019
Limitations in the Design of Chimeric Antigen Receptors for Cancer Therapy
S Stoiber, BL Cadilha, MR Benmebarek, S Lesch, S Endres, S Kobold
Cells 2019
CAR-T Cells: Future Perspectives
S Charrot, S Hallam
2019
CAR Talk: How Cancer-Specific CAR T Cells Can Instruct How to Build CAR T Cells to Cure HIV
GB Kim, K Hege, JL Riley
Frontiers in immunology 2019
Genetically engineered T cells for cancer immunotherapy
D Li, X Li, WL Zhou, Y Huang, X Liang, L Jiang, X Yang, J Sun, Z Li, WD Han, W Wang
Signal Transduction and Targeted Therapy 2019
Engineering strategies to overcome the current roadblocks in CAR T cell therapy
S Rafiq, CS Hackett, RJ Brentjens
Nature Reviews Clinical Oncology 2019
[PD-1 expression, mRNA level and cytotoxicity changes in CD19CAR-T cells]
Y D Pu, J Wang, Q Deng, H B Zhu, Y Y Jiang, J X Meng, Y M Li
Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 2019
Engineering and Design of Chimeric Antigen Receptors
S Guedan, H Calderon, AD Posey, MV Maus
Molecular Therapy — Methods & Clinical Development 2019
CAR T cells for brain tumors: Lessons learned and road ahead
D Akhavan, D Alizadeh, D Wang, MR Weist, JK Shepphird, CE Brown
Immunological Reviews 2019
Resistance Mechanisms to CAR T-Cell Therapy and Overcoming Strategy in B-Cell Hematologic Malignancies
MK Song, BB Park, JE Uhm
International journal of molecular sciences 2019
Gene editing for immune cell therapies
SR Bailey, MV Maus
Nature Biotechnology 2019
Multispecific Targeting with Synthetic Ankyrin Repeat Motif Chimeric Antigen Receptors
A Balakrishnan, A Rajan, AI Salter, PL Kosasih, Q Wu, J Voutsinas, MC Jensen, A Plückthun, SR Riddell
Clinical cancer research 2019
Clinical lessons learned from the first leg of the CAR T cell journey
R Majzner, C Mackall
Nature Medicine 2019
NKT Cells Coexpressing a GD2-Specific Chimeric Antigen Receptor and IL15 Show Enhanced In Vivo Persistence and Antitumor Activity against Neuroblastoma
X Xu, W Huang, A Heczey, D Liu, L Guo, M Wood, J Jin, AN Courtney, B Liu, EJ Pierro, J Hicks, GA Barragan, H Ngai, Y Chen, B Savoldo, G Dotti, LS Metelitsa
Clinical cancer research 2019
Cytotoxic Activity and Memory T Cell Subset Distribution of in vitro-Stimulated CD8+ T Cells Specific for HER2/neu Epitopes
M Kuznetsova, J Lopatnikova, J Shevchenko, A Silkov, A Maksyutov, S Sennikov
Frontiers in immunology 2019
Neuroendocrine Regulation of Tumor-Associated Immune Cells
CB Colon-Echevarria, R Lamboy-Caraballo, AN Aquino-Acevedo, GN Armaiz-Pena
Frontiers in Oncology 2019
Switching on the green light for chimeric antigen receptor T-cell therapy
S Mardiana, J Lai, IG House, PA Beavis, PK Darcy
IBMS BoneKEy 2019
Overcoming Challenges in Process Development of Cellular Therapies
SL Highfill, DF Stroncek
Current Hematologic Malignancy Reports 2019
Tumor infiltrating lymphocytes expanded from pediatric neuroblastoma display heterogeneity of phenotype and function
MO Hurtado, J Wolbert, J Fisher, B Flutter, S Stafford, J Barton, N Jain, G Barone, Y Majani, J Anderson, PA Beavis
PloS one 2019
Chimeric Antigen Receptor T-Cells: The Future is Now
W Mchayleh, P Bedi, R Sehgal, M Solh
Journal of Clinical Medicine 2019
CAR T Cells: A Snapshot on the Growing Options to Design a CAR
A Holzinger, H Abken
2019
Large-scale expansion and characterization of CD3+ T-cells in the Quantum® Cell Expansion System
C Coeshott, B Vang, M Jones, B Nankervis
Journal of Translational Medicine 2019
Human Platelet Lysate Media Supplement Supports Lentiviral Transduction and Expansion of Human T Lymphocytes While Maintaining Memory Phenotype
E Canestrari, HR Steidinger, B McSwain, SJ Charlebois, CT Dann
Journal of Immunology Research 2019
Two-Dimensional Regulation of CAR-T Cell Therapy with Orthogonal Switches
ML Duong, MR Collinson-Pautz, E Morschl, A Lu, SP Szymanski, M Zhang, ME Brandt, WC Chang, KL Sharp, SM Toler, KM Slawin, AE Foster, DM Spencer, JH Bayle
Molecular Therapy — Oncolytics 2019
Chimeric Antigen Receptor (CAR) T Cell Therapy in Acute Myeloid Leukemia (AML)
S Hofmann, ML Schubert, L Wang, B He, B Neuber, P Dreger, C Müller-Tidow, M Schmitt
Journal of Clinical Medicine 2019
CAR T Cell Immunotherapy in Human and Veterinary Oncology: Changing the Odds Against Hematological Malignancies
JP Mochel, SC Ekker, CM Johannes, AE Jergens, K Allenspach, A Bourgois-Mochel, M Knouse, S Benzekry, W Wierson, AK LeBlanc, SS Kenderian
The AAPS Journal 2019
Regulation of CAR T cell-mediated cytokine release syndrome-like toxicity using low molecular weight adapters
YG Lee, H Chu, Y Lu, CP Leamon, M Srinivasarao, KS Putt, PS Low
Nature Communications 2019
Target selection for CAR-T therapy
J Wei, X Han, J Bo, W Han
Journal of Hematology & Oncology 2019
Current Advances in Immunotherapy for Acute Leukemia: An Overview of Antibody, Chimeric Antigen Receptor, Immune Checkpoint, and Natural Killer
Y Shang, F Zhou
Frontiers in Oncology 2019
Mechanisms of Relapse After CD19 CAR T-Cell Therapy for Acute Lymphoblastic Leukemia and Its Prevention and Treatment Strategies
X Xu, Q Sun, X Liang, Z Chen, X Zhang, X Zhou, M Li, H Tu, Y Liu, S Tu, Y Li
Frontiers in immunology 2019
Peripheral immune-based biomarkers in cancer immunotherapy: can we realize their predictive potential?
AB Nixon, KA Schalper, I Jacobs, S Potluri, IM Wang, C Fleener
Journal for ImmunoTherapy of Cancer 2019
Chimeric antigen receptor T cell targeting B cell maturation antigen immunotherapy is promising for multiple myeloma
T Ma, J Shi, H Liu
Annals of Hematology 2019
Understanding the Mechanisms of Resistance to CAR T-Cell Therapy in Malignancies
J Cheng, L Zhao, Y Zhang, Y Qin, Y Guan, T Zhang, C Liu, J Zhou
Frontiers in Oncology 2019
Robust Selections of Various Hematopoietic Cell Fractions on the CliniMACS Plus Instrument
SR Panch, OL Reddy, K Li, T Bikkani, A Rao, S Yarlagadda, S Highfill, D Fowler, RW Childs, M Battiwalla, J Barrett, A Larochelle, C Mackall, N Shah, DF Stroncek
2019
Chimeric Antigen Receptor T-cell (CAR T) Therapy for Hematologic and Solid Malignancies: Efficacy and Safety—A Systematic Review with Meta-Analysis
WL Yu, ZC Hua
Cancers 2019
Factors affecting lymphocyte collection efficiency for the manufacture of chimeric antigen receptor T cells in adults with B‐cell malignancies
SA Tuazon, A Li, T Gooley, TW Eunson, DG Maloney, CJ Turtle, ML Linenberger, LS ConnellySmith
Transfusion 2019
Immunoglobulin Gamma-Like Therapeutic Bispecific Antibody Formats for Tumor Therapy
S Chen, L Li, F Zhang, Y Wang, Y Hu, L Zhao
Journal of Immunology Research 2019
Cytokine Release Syndrome With the Novel Treatments of Acute Lymphoblastic Leukemia: Pathophysiology, Prevention, and Treatment
I Aldoss, SK Khaled, E Budde, AS Stein
Current Oncology Reports 2019
Pharmacologic control of CAR-T cell function using dasatinib
EW Weber, RC Lynn, E Sotillo, J Lattin, P Xu, CL Mackall
Blood Advances 2019

Targeting the A3 adenosine receptor to treat cytokine release syndrome in cancer immunotherapy


S Cohen, P Fishman
Drug design, development and therapy 2019
Evaluation of a Fully Human, Hepatitis B Virus-Specific Chimeric Antigen Receptor in an Immunocompetent Mouse Model
MM Festag, J Festag, SP Fräßle, T Asen, J Sacherl, S Schreiber, MA Mück-Häusl, DH Busch, K Wisskirchen, U Protzer
Molecular Therapy 2019
Chimeric Antigen Receptors for T-Cell Malignancies
LD Scherer, MK Brenner, M Mamonkin
Frontiers in Oncology 2019
Antigen Targets for the Development of Immunotherapies in Leukemia
J Bauer, A Nelde, T Bilich, J Walz
International journal of molecular sciences 2019
Preclinical Evaluation of Bispecific Adaptor Molecule Controlled Folate Receptor CAR-T Cell Therapy With Special Focus on Pediatric Malignancies
YJ Lu, H Chu, LW Wheeler, M Nelson, E Westrick, JF Matthaei, II Cardle, A Johnson, J Gustafson, N Parker, M Vetzel, LC Xu, EZ Wang, MC Jensen, PJ Klein, PS Low, CP Leamon
Frontiers in Oncology 2019
CD40 Ligand-Modified Chimeric Antigen Receptor T Cells Enhance Antitumor Function by Eliciting an Endogenous Antitumor Response
NF Kuhn, TJ Purdon, DG van Leeuwen, AV Lopez, KJ Curran, AF Daniyan, RJ Brentjens
Cancer Cell 2019

Current approaches in the grading and management of cytokine release syndrome after chimeric antigen receptor T-cell therapy


LL Riegler, GP Jones, DW Lee
Therapeutics and Clinical Risk Management 2019
In the Eye of the Storm: Immune-mediated Toxicities Associated With CAR-T Cell Therapy
JG Borrega, P Gödel, MA Rüger, ÖA Onur, A Shimabukuro-Vornhagen, M Kochanek, B Böll
2019
Clinical chimeric antigen receptor‐T cell therapy: a new and promising treatment modality for glioblastoma
MP Brown, LM Ebert, T Gargett
IBMS BoneKEy 2019
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
N Raje, J Berdeja, Y Lin, D Siegel, S Jagannath, D Madduri, M Liedtke, J Rosenblatt, MV Maus, A Turka, LP Lam, RA Morgan, K Friedman, M Massaro, J Wang, G Russotti, Z Yang, T Campbell, K Hege, F Petrocca, MT Quigley, N Munshi, JN Kochenderfer
New England Journal of Medicine 2019
Emerging therapies for non-small cell lung cancer
C Zhang, NB Leighl, YL Wu, WZ Zhong
Journal of Hematology & Oncology 2019
CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape
M Hamieh, A Dobrin, A Cabriolu, SJ van der Stegen, T Giavridis, J Mansilla-Soto, J Eyquem, Z Zhao, BM Whitlock, MM Miele, Z Li, KM Cunanan, M Huse, RC Hendrickson, X Wang, I Rivière, M Sadelain
Nature 2019
Escape From ALL-CARTaz: Leukemia Immunoediting in the Age of Chimeric Antigen Receptors
S Zheng, M Asnani, A Thomas-Tikhonenko
The Cancer Journal 2019
The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells
AV Hirayama, J Gauthier, KA Hay, JM Voutsinas, Q Wu, T Gooley, D Li, S Cherian, X Chen, BS Pender, RM Hawkins, A Vakil, RN Steinmetz, UH Acharya, RD Cassaday, AG Chapuis, TM Dhawale, PC Hendrie, HP Kiem, RC Lynch, J Ramos, M Shadman, BG Till, SR Riddell, DG Maloney, CJ Turtle
Blood 2019
Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)–an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT)
AJ Kansagra, NV Frey, M Bar, TW Laetsch, PA Carpenter, BN Savani, HE Heslop, CM Bollard, KV Komanduri, DA Gastineau, C Chabannon, MA Perales, M Hudecek, M Aljurf, L Andritsos, JA Barrett, V Bachanova, C Bonini, A Ghobadi, SI Gill, JA Hill, S Kenderian, P Kebriaei, A Nagler, D Maloney, HD Liu, NN Shah, MA Kharfan-Dabaja, EJ Shpall, GJ Mufti, L Johnston, E Jacoby, A Bazarbachi, JF DiPersio, SZ Pavletic, DL Porter, SA Grupp, M Sadelain, MR Litzow, M Mohty, SK Hashmi
Bone Marrow Transplantation 2019
Analysis of the function of MAGE-A in esophageal carcinoma by bioinformatics:
X Chen, S Cai, L Wang, X Zhang, W Li, X Cao
Medicine 2019
Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy
KA Hay, J Gauthier, AV Hirayama, JM Voutsinas, Q Wu, D Li, TA Gooley, S Cherian, X Chen, BS Pender, RM Hawkins, A Vakil, RN Steinmetz, G Schoch, AG Chapuis, BG Till, HP Kiem, JD Ramos, M Shadman, RD Cassaday, UH Acharya, SR Riddell, DG Maloney, CJ Turtle
Blood 2019
A safe and potent anti-CD19 CAR T cell therapy
Z Ying, XF Huang, X Xiang, Y Liu, , Y Song, X Guo, H Liu, N Ding, T Zhang, P Duan, Y Lin, W Zheng, X Wang, N Lin, M Tu, Y Xie, C Zhang, W Liu, L Deng, S Gao, L Ping, X Wang, N Zhou, J Zhang, Y Wang, S Lin, M Mamuti, X Yu, L Fang, S Wang, H Song, G Wang, L Jones, J Zhu, SY Chen
Nature Medicine 2019

Decitabine enhances cytotoxic effect of T cells with an anti-CD19 chimeric antigen receptor in treatment of lymphoma


S Li, L Xue, M Wang, P Qiang, H Xu, X Zhang, W Kang, F You, H Xu, Y Wang, X Liu, L Yang, X Wang
OncoTargets and therapy 2019
Super-resolution microscopy reveals ultra-low CD19 expression on myeloma cells that triggers elimination by CD19 CAR-T
T Nerreter, S Letschert, R Götz, S Doose, S Danhof, H Einsele, M Sauer, M Hudecek
Nature Communications 2019
Imaging CAR T cell therapy with PSMA-targeted positron emission tomography
I Minn, DJ Huss, HH Ahn, TM Chinn, A Park, J Jones, M Brummet, SP Rowe, P Sysa-Shah, Y Du, HI Levitsky, MG Pomper
Science Advances 2019
Adverse Events of Oncologic Immunotherapy and Their Management
FD Barber
Asia-Pacific Journal of Oncology Nursing 2019
Clinical Approach to the Patient in Critical State Following Immunotherapy and/or Stem Cell Transplantation: Guideline for the On-Call Physician
Constantinescu, Bodolea, Pasca, Teodorescu, Dima, Rus, Tat, AC, Tanase, Tomuleasa, Einsele
Journal of Clinical Medicine 2019
Chimeric antigen receptor T-cell therapy for acute myeloid leukemia: how close to reality?
KD Cummins, S Gill
Haematologica 2019
Haploidentical CD19/CD22 bispecific CAR-T cells induced MRD-negative remission in a patient with relapsed and refractory adult B-ALL after haploidentical hematopoietic stem cell transplantation
H Jia, Z Wang, Y Wang, Y Liu, H Dai, C Tong, Y Guo, B Guo, D Ti, X Han, Q Yang, Z Wu, W Han
Journal of Hematology & Oncology 2019
Effect of Cryopreservation on Autologous Chimeric Antigen Receptor T Cell Characteristics
SR Panch, SK Srivastava, N Elavia, A McManus, S Liu, P Jin, SL Highfill, X Li, P Dagur, JN Kochenderfer, TJ Fry, CL Mackall, D Lee, NN Shah, DF Stroncek
Molecular Therapy 2019

Delayed remission following sequential infusion of humanized CD19- and CD22-modified CAR-T cells in a patient with relapsed/refractory acute lymphoblastic leukemia and prior exposure to murine-derived CD19-directed CAR-T cells


F Yang, J Zhang, X Zhang, M Tian, J Wang, L Kang, H Qiu, D Wu
OncoTargets and therapy 2019
Preservation of cell-based immunotherapies for clinical trials
R Li, R Johnson, G Yu, DA Mckenna, A Hubel
Cytotherapy 2019
Human CD4 + T Cells Specific for Merkel Cell Polyomavirus Localize to Merkel Cell Carcinomas and Target a Required Oncogenic Domain
NV Longino, J Yang, JG Iyer, D Ibrani, IT Chow, KJ Laing, VL Campbell, KG Paulson, RM Kulikauskas, CD Church, EA James, P Nghiem, WW Kwok, DM Koelle
Cancer immunology research 2019
Traceless aptamer-mediated isolation of CD8+ T cells for chimeric antigen receptor T-cell therapy
N Kacherovsky, II Cardle, EL Cheng, JL Yu, ML Baldwin, SJ Salipante, MC Jensen, SH Pun
Nature Biomedical Engineering 2019
High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy
AV Hirayama, J Gauthier, KA Hay, JM Voutsinas, Q Wu, BS Pender, RM Hawkins, A Vakil, RN Steinmetz, SR Riddell, DG Maloney, CJ Turtle
Blood 2019
CAR-T – and a side order of IgG, to go? – Immunoglobulin replacement in patients receiving CAR-T cell therapy
JA Hill, S Giralt, TR Torgerson, HM Lazarus
Blood Reviews 2019
Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma
I Ramachandran, DE Lowther, R Dryer-Minnerly, R Wang, S Fayngerts, D Nunez, G Betts, N Bath, AJ Tipping, L Melchiori, JM Navenot, J Glod, CL Mackall, SP DAngelo, DM Araujo, WA Chow, GD Demetri, M Druta, BA Tine, SA Grupp, AR Razak, B Wilky, M Iyengar, T Trivedi, EV Winkle, K Chagin, R Amado, GK Binder, S Basu
Journal for ImmunoTherapy of Cancer 2019
Engineered T Cell Therapy for Cancer in the Clinic
L Zhao, YJ Cao
Frontiers in immunology 2019
Recent updates on CAR T clinical trials for multiple myeloma
Q Lin, J Zhao, Y Song, D Liu
Molecular Cancer 2019
Chimeric Antigen Receptor T-Cell Therapy Clinical Results in Pediatric and Young Adult B-ALL:
AM DiNofia, SL Maude
2019
Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma
A Schmidts, M Ormhøj, BD Choi, AO Taylor, AA Bouffard, I Scarfò, RC Larson, MJ Frigault, K Gallagher, AP Castano, LS Riley, ML Cabral, AC Boroughs, RM Cárdenas, W Schamel, J Zhou, S Mackay, YT Tai, KC Anderson, MV Maus
Blood Advances 2019
Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapy
M Shadman, J Gauthier, KA Hay, JM Voutsinas, F Milano, A Li, AV Hirayama, ML Sorror, S Cherian, X Chen, RD Cassaday, BG Till, AK Gopal, BM Sandmaier, DG Maloney, CJ Turtle
Blood Advances 2019
Immune-Based Therapies in Acute Leukemia
MT Witkowski, A Lasry, WL Carroll, I Aifantis
Trends in Cancer 2019
Durable preservation of antiviral antibodies after CD19-directed chimeric antigen receptor T-cell immunotherapy
JA Hill, EM Krantz, KA Hay, S Dasgupta, T Stevens-Ayers, RA Ignacio, M Bar, J Maalouf, S Cherian, X Chen, G Pepper, SR Riddell, DG Maloney, MJ Boeckh, CJ Turtle
Blood Advances 2019
Chimeric Antigen Receptor T Cell-Related Neurotoxicity: Mechanisms, Clinical Presentation, and Approach to Treatment
J Rice, S Nagle, J Randall, HE Hinson
Current Treatment Options in Neurology 2019
Bispecific Antibodies Enable Synthetic Agonistic Receptor-Transduced T Cells for Tumor Immunotherapy
CH Karches, MR Benmebarek, ML Schmidbauer, M Kurzay, R Klaus, M Geiger, F Rataj, BL Cadilha, S Lesch, C Heise, R Murr, J vom Berg, M Jastroch, D Lamp, J Ding, P Duewell, G Niederfellner, C Sustmann, S Endres, C Klein, S Kobold
Clinical cancer research 2019
Mechanisms of and approaches to overcoming resistance to immunotherapy
L Schultz, R Gardner
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program 2019
A highly soluble Sleeping Beauty transposase improves control of gene insertion
I Querques, A Mades, C Zuliani, C Miskey, M Alb, E Grueso, M Machwirth, T Rausch, H Einsele, Z Ivics, M Hudecek, O Barabas
Nature Biotechnology 2019
Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy
RA Gardner, F Ceppi, J Rivers, C Annesley, C Summers, A Taraseviciute, J Gust, KJ Leger, K Tarlock, TM Cooper, OC Finney, H Brakke, DH Li, JR Park, MC Jensen
Blood 2019
Development of a quantitative relationship between CAR-affinity, antigen abundance, tumor cell depletion and CAR-T cell expansion using a multiscale systems PK-PD model
AP Singh, X Zheng, X Lin-Schmidt, W Chen, TJ Carpenter, A Zong, W Wang, DL Heald
mAbs 2019
CD19 CAR T Cells for the Treatment of Pediatric Pre-B Cell Acute Lymphoblastic Leukemia
HL Pacenta, TW Laetsch, S John
Pediatric Drugs 2019
Evidence of long‐lasting anti‐CD19 activity of engrafted CD19 chimeric antigen receptor–modified T cells in a phase I study targeting pediatrics with acute lymphoblastic leukemia
F Ma, JY Ho, H Du, F Xuan, X Wu, Q Wang, L Wang, Y Liu, M Ba, Y Wang, J Luo, J Li
Hematological Oncology 2019
Current status and hurdles for CAR-T cell immune therapy
R Zhao, Y Cui, S Li, L Qin, P Li
2019
Next Generation of Cancer Treatments: Chimeric Antigen Receptor T-Cell Therapy and Its Related Toxicities
G Echeverry, GW Fischer, E Mead
Anesthesia & Analgesia 2019
Molecular Design, Optimization, and Genomic Integration of Chimeric B Cell Receptors in Murine B Cells
T Pesch, L Bonati, W Kelton, C Parola, RA Ehling, L Csepregi, D Kitamura, ST Reddy
Frontiers in immunology 2019
Adult peripheral blood and umbilical cord blood NK cells are good sources for effective CAR therapy against CD19 positive leukemic cells
L Herrera, S Santos, MA Vesga, J Anguita, I Martin-Ruiz, T Carrascosa, M Juan, C Eguizabal
Scientific Reports 2019
Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Transplantation and Cellular Therapy
AJ Kansagra, NV Frey, M Bar, TW Laetsch, PA Carpenter, BN Savani, HE Heslop, CM Bollard, KV Komanduri, DA Gastineau, C Chabannon, MA Perales, M Hudecek, M Aljurf, L Andritsos, JA Barrett, V Bachanova, C Bonini, A Ghobadi, SI Gill, J Hill, S Kenderian, P Kebriaei, A Nagler, D Maloney, HD Liu, NN Shah, MA Kharfan-Dabaja, EJ Shpall, GJ Mufti, L Johnston, E Jacoby, A Bazarbachi, JF DiPersio, SZ Pavletic, DL Porter, SA Grupp, M Sadelain, MR Litzow, M Mohty, SK Hashmi
Biology of Blood and Marrow Transplantation 2019
Beat pediatric ALL MRD: CD28 CAR T and transplant.
Ruella M, Locke FL
Blood 2019
Donor-Derived CD123-Targeted CAR T Cell Serves as a RIC Regimen for Haploidentical Transplantation in a Patient With FUS-ERG+ AML
Yao S, Jianlin C, Yarong L, Botao L, Qinghan W, Hongliang F, Lu Z, Hongmei N, Pin W, Hu C, Liangding H, Bin Z
Frontiers in Oncology 2019
Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL
Curran KJ, Margossian SP, Kernan NA, Silverman LB, Williams DA, Shukla N, Kobos R, Forlenza CJ, Steinherz P, Prockop S, Boulad F, Spitzer B, Cancio MI, Boelens JJ, Kung AL, Szenes V, Park JH, Sauter CS, Heller G, Wang X, Senechal B, O\u2019Reilly RJ, Riviere I, Sadelain M, Brentjens RJ
Blood 2019
CAR-T在造血干细胞移植中的作用
2019
T-Cell Receptor Stimulation Enhances the Expansion and Function of CD19 Chimeric Antigen Receptor-Expressing T Cells.
Lapteva N, Gilbert M, Diaconu I, Rollins LA, Al-Sabbagh M, Naik S, Krance RA, Tripic T, Hiregange M, Raghavan D, Dakhova O, Rouce RH, Liu H, Omer B, Savoldo B, Dotti G, Cruz CR, Sharpe K, Gates M, Orozco A, Durett A, Pacheco E, Gee AP, Ramos CA, Heslop HE, Brenner MK, Rooney CM
Clinical cancer research 2019
Management of cytokine release syndrome related to CAR-T cell therapy.
Chen H, Wang F, Zhang P, Zhang Y, Chen Y, Fan X, Cao X, Liu J, Yang Y, Wang B, Lei B, Gu L, Bai J, Wei L, Zhang R, Zhuang Q, Zhang W, Zhao W, He A
Frontiers of Medicine 2019
Hemophagocytic Lymphohistiocytosis and Other Culture Negative Sepsis-Like Syndromes in the ICU
Denstaedt SJ, Singer BH
2019
Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia
Frey NV, Shaw PA, Hexner EO, Pequignot E, Gill S, Luger SM, Mangan JK, Loren AW, Perl AE, Maude SL, Grupp SA, Shah NN, Gilmore J, Lacey SF, Melenhorst JJ, Levine BL, June CH, Porter DL
Journal of Clinical Oncology 2019
Driving the CAR to the Bone Marrow Transplant Program.
Dave H, Jerkins L, Hanley PJ, Bollard CM, Jacobsohn D
Current Hematologic Malignancy Reports 2019
Relapse and Resistance to CAR-T Cells and Blinatumomab in Hematologic Malignancies.
Jacoby E
2019
Treatment of Adult Patients with Relapsed/Refractory B-Cell Philadelphia-Negative Acute Lymphoblastic Leukemia.
Maffini E, Saraceni F, Lanza F
2019
Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation
Sonia Guedan, Avery D. Posey, Jr., Carolyn Shaw, Anna Wing, Tong Da, Prachi Patel, Shannon McGettigan, Victoria Casado-Medrano, Omkar U. Kawalekar, Mireia Uribe-Herranz, J. Joseph Melenhorst, Simon Lacey, Decheng Song, John Scholler, Brian Keith, Regina Young, Carl June
JCI Insight 2018
Glioblastoma-Targeted CD4+ CAR-T cells outperform CD8+ cells for Sustained Effector Function and Superior Antitumor Activity
Dongrui Wang, Brenda Aguilar, Renate Starr, Darya Alizadeh, Alfonso Brito, Aniee Sarkissian, Julie Ostberg, Stephen J. Forman, Christine Brown
JCI Insight 2018
4-1BB enhancement of CAR T function requires NF-κB and TRAFs
Gongbo Li, Justin C Boucher, Bishwas Shrestha, Hiroshi Kotani, Kyungho Park, Yongliang Zhang, Xuefeng Wang, Lawrence Guan, Nolan J Beatty, Daniel Abate-Daga, Marco L Davila
JCI Insight 2018
CAR T Cells in Solid Tumors: Blueprints for Building Effective Therapies
HM Knochelmann, AS Smith, CJ Dwyer, MM Wyatt, S Mehrotra, CM Paulos
Frontiers in immunology 2018
Chimeric Antigen Receptor T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia
C Tomuleasa, S Fuji, C Berce, A Onaciu, S Chira, B Petrushev, WT Micu, V Moisoiu, C Osan, C Constantinescu, S Pasca, A Jurj, L Pop, I Berindan-Neagoe, D Dima, S Kitano
Frontiers in immunology 2018
Beyond Cell Death: New Functions for TNF Family Cytokines in Autoimmunity and Tumor Immunotherapy
F Yi, N Frazzette, AC Cruz, CA Klebanoff, RM Siegel
Trends in Molecular Medicine 2018
Critical factors in chimeric antigen receptor-modified T-cell (CAR-T) therapy for solid tumors
LL Yan, BN Liu
OncoTargets and therapy 2018
Differences in Expansion Potential of Naive Chimeric Antigen Receptor T Cells from Healthy Donors and Untreated Chronic Lymphocytic Leukemia Patients
JM Hoffmann, ML Schubert, L Wang, A Hückelhoven, L Sellner, S Stock, A Schmitt, C Kleist, U Gern, A Loskog, P Wuchter, S Hofmann, AD Ho, C Müller-Tidow, P Dreger, M Schmitt
Frontiers in immunology 2018
Posttransplant chimeric antigen receptor therapy
M Smith, J Zakrzewski, S James, M Sadelain
Blood 2018
CAR T cell therapy for B-cell lymphomas
JC Chavez, FL Locke
Best practice & research. Clinical haematology 2018
Scaffolds that mimic antigen-presenting cells enable ex vivo expansion of primary T cells
AS Cheung, DK Zhang, ST Koshy, DJ Mooney
Nature Biotechnology 2018
CART Immunotherapy: Development, Success, and Translation to Malignant Gliomas and Other Solid Tumors
AC Filley, M Henriquez, M Dey
Frontiers in Oncology 2018
TGF-β-responsive CAR-T cells promote anti-tumor immune function
AJ Hou, ZN Chang, MH Lorenzini, E Zah, YY Chen
Bioengineering & Translational Medicine 2018
CAR T cells for infection, autoimmunity and allotransplantation
CR Maldini, GI Ellis, JL Riley
Nature Reviews Immunology 2018
Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T Cell Responses
JH Cho, JJ Collins, WW Wong
Cell 2018
Induction of a central memory and stem cell memory phenotype in functionally active CD4+ and CD8+ CAR T cells produced in an automated good manufacturing practice system for the treatment of CD19+ acute lymphoblastic leukemia
F Blaeschke, D Stenger, T Kaeuferle, S Willier, R Lotfi, AD Kaiser, M Assenmacher, M Döring, J Feucht, T Feuchtinger
Cancer Immunology, Immunotherapy 2018
Clinical translation and regulatory aspects of CAR/TCR-based adoptive cell therapies—the German Cancer Consortium approach
AM Krackhardt, B Anliker, M Hildebrandt, M Bachmann, SB Eichmüller, DM Nettelbeck, M Renner, L Uharek, G Willimsky, M Schmitt, WS Wels, M Schüssler-Lenz
Cancer Immunology, Immunotherapy 2018
Immunotherapy with CAR-Modified T Cells: Toxicities and Overcoming Strategies
S Sun, H Hao, G Yang, Y Zhang, Y Fu
Journal of Immunology Research 2018
The Pharmacology of T Cell Therapies
MC Milone, VG Bhoj
Molecular Therapy — Methods & Clinical Development 2018
Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function
AI Salter, RG Ivey, JJ Kennedy, V Voillet, A Rajan, EJ Alderman, UJ Voytovich, C Lin, D Sommermeyer, L Liu, JR Whiteaker, R Gottardo, AG Paulovich, SR Riddell
Science signaling 2018
Dawn of chimeric antigen receptor T cell therapy in non-Hodgkin Lymphoma
K Perica, ML Palomba, RJ Brentjens
2018
Teaching an old dog new tricks: next-generation CAR T cells
N Tokarew, J Ogonek, S Endres, M von Bergwelt-Baildon, S Kobold
British Journal of Cancer 2018
Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells
R Elahi, E Khosh, S Tahmasebi, A Esmaeilzadeh
Frontiers in immunology 2018
Nanobody Based Dual Specific CARs
SD Munter, J Ingels, G Goetgeluk, S Bonte, M Pille, K Weening, T Kerre, H Abken, B Vandekerckhove
International journal of molecular sciences 2018
Role of Chimeric Antigen Receptor T Cell Therapy in Glioblastoma Multiforme
V Jindal
Molecular Neurobiology 2018
Optimization of IL13Rα2-Targeted Chimeric Antigen Receptor T Cells for Improved Anti-tumor Efficacy against Glioblastoma
CE Brown, B Aguilar, R Starr, X Yang, WC Chang, L Weng, B Chang, A Sarkissian, A Brito, JF Sanchez, JR Ostberg, M DApuzzo, B Badie, ME Barish, SJ Forman
Molecular Therapy 2018
The development of CAR design for tumor CAR-T cell therapy
D Xu, G Jin, D Chai, X Zhou, W Gu, Y Chong, J Song, J Zheng
Oncotarget 2018
CAR-T Cells and Oncolytic Viruses: Joining Forces to Overcome the Solid Tumor Challenge
S Guedan, R Alemany
Frontiers in immunology 2018
Anti-BCMA CAR-T cells for treatment of plasma cell dyscrasia: case report on POEMS syndrome and multiple myeloma
J Xu, Q Wang, H Xu, C Gu, L Jiang, J Wang, D Wang, B Xu, X Mao, J Wang, Z Wang, Y Xiao, Y Zhang, C Li, J Zhou
Journal of Hematology & Oncology 2018
Current development of chimeric antigen receptor T-cell therapy
J Wang, Y Hu, H Huang
Stem Cell Investigation 2018
Chimeric antigen receptor–modified T cells: CD19 and the road beyond
AI Salter, MJ Pont, SR Riddell
Blood 2018
In Vivo Expansion and Antitumor Activity of Coinfused CD28- and 4-1BB-Engineered CAR-T Cells in Patients with B Cell Leukemia
Z Cheng, R Wei, Q Ma, L Shi, F He, Z Shi, T Jin, R Xie, B Wei, J Chen, H Fang, X Han, JA Rohrs, P Bryson, Y Liu, QJ Li, B Zhu, P Wang
Molecular Therapy 2018
Defining success with cellular therapeutics: the current landscape for clinical end point and toxicity analysis:
LS Kean
Blood 2018
Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy
KM Mahadeo, SJ Khazal, H Abdel-Azim, JC Fitzgerald, A Taraseviciute, CM Bollard, P Tewari, C Duncan, C Traube, D McCall, ME Steiner, IM Cheifetz, LE Lehmann, R Mejia, JM Slopis, R Bajwa, P Kebriaei, PL Martin, J Moffet, J McArthur, D Petropoulos, JO Curry, S Featherston, J Foglesong, B Shoberu, A Gulbis, ME Mireles, L Hafemeister, C Nguyen, N Kapoor, K Rezvani, SS Neelapu, EJ Shpall
Nature Reviews Clinical Oncology 2018
Modulation of immune responses in lentiviral vector-mediated gene transfer
A Annoni, S Gregori, L Naldini, A Cantore
Cellular Immunology 2018
mRNA as novel technology for passive immunotherapy
T Schlake, A Thess, M Thran, I Jordan
Cellular and Molecular Life Sciences 2018
Autologous CD19-Targeted CAR T Cells in Patients with Residual CLL following Initial Purine Analog-Based Therapy
MB Geyer, I Rivière, B Sénéchal, X Wang, Y Wang, TJ Purdon, M Hsu, SM Devlin, E Halton, N Lamanna, J Rademaker, M Sadelain, RJ Brentjens, JH Park
Molecular Therapy 2018
CD19 Chimeric Antigen Receptor T Cells From Patients With Chronic Lymphocytic Leukemia Display an Elevated IFN-γ Production Profile:
I Magalhaes, I Kalland, JN Kochenderfer, A Österborg, M Uhlin, J Mattsson
Journal of immunotherapy (Hagerstown, Md. : 1997) 2018
Preclinical Optimization of a CD20-specific Chimeric Antigen Receptor Vector and Culture Conditions:
SY Lee, P Olsen, DH Lee, AL Kenoyer, LE Budde, S OSteen, DJ Green, S Heimfeld, MC Jensen, SR Riddell, OW Press, BG Till
Journal of immunotherapy (Hagerstown, Md. : 1997) 2018
Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia
JA Fraietta, SF Lacey, EJ Orlando, I Pruteanu-Malinici, M Gohil, S Lundh, AC Boesteanu, Y Wang, RS OConnor, WT Hwang, E Pequignot, DE Ambrose, C Zhang, N Wilcox, F Bedoya, C Dorfmeier, F Chen, L Tian, H Parakandi, M Gupta, RM Young, FB Johnson, I Kulikovskaya, L Liu, J Xu, SH Kassim, MM Davis, BL Levine, NV Frey, DL Siegel, AC Huang, EJ Wherry, H Bitter, JL Brogdon, DL Porter, CH June, JJ Melenhorst
Nature Medicine 2018
Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1c259T cells in Synovial Sarcoma
SP D'Angelo, L Melchiori, MS Merchant, DB Bernstein, J Glod, RN Kaplan, SA Grupp, WD Tap, K Chagin, GK Binder, S Basu, DE Lowther, R Wang, N Bath, A Tipping, G Betts, I Ramachandran, JM Navenot, H Zhang, DK Wells, EV Winkle, G Kari, T Trivedi, T Holdich, LN Pandite, R Amado, CL Mackall
Cancer Discovery 2018
Design considerations for early-phase clinical trials of immune-oncology agents
NA Wages, C Chiuzan, KS Panageas
Journal for ImmunoTherapy of Cancer 2018
CAR T cell therapy for breast cancer: harnessing the tumor milieu to drive T cell activation
P Bajgain, S Tawinwung, L DElia, S Sukumaran, N Watanabe, V Hoyos, P Lulla, MK Brenner, AM Leen, JF Vera
Journal for ImmunoTherapy of Cancer 2018
Chimeric Antigen Receptor T Cell Therapy: Challenges to Bench-to-Bedside Efficacy
S Srivastava, SR Riddell
Journal of immunology (Baltimore, Md. : 1950) 2018
Cell‐Templated Silica Microparticles with Supported Lipid Bilayers as Artificial Antigen‐Presenting Cells for T Cell Activation
BR Olden, CR Perez, AL Wilson, II Cardle, YS Lin, B Kaehr, JA Gustafson, MC Jensen, SH Pun
Advanced Healthcare Materials 2018
CTL019 (tisagenlecleucel): CAR-T therapy for relapsed and refractory B-cell acute lymphoblastic leukemia
S Vairy, JL Garcia, P Teira, H Bittencourt
Drug design, development and therapy 2018
Animal Models for Preclinical Development of Allogeneic Hematopoietic Cell Transplantation
SS Graves, MH Parker, R Storb
ILAR journal / National Research Council, Institute of Laboratory Animal Resources 2018
Chimeric Antigen Receptor Therapy
CH June, M Sadelain
New England Journal of Medicine 2018
T-cell Immunotherapies and the Role of Nonclinical Assessment: The Balance between Efficacy and Pathology
ME Sharpe
Toxicologic pathology 2018
Clinical use of lentiviral vectors
MC Milone, U ODoherty
Leukemia 2018
CAR T Cell Therapy for Neuroblastoma
RM Richards, E Sotillo, RG Majzner
Frontiers in immunology 2018
Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells
JA Fraietta, CL Nobles, MA Sammons, S Lundh, SA Carty, TJ Reich, AP Cogdill, JJ Morrissette, JE DeNizio, S Reddy, Y Hwang, M Gohil, I Kulikovskaya, F Nazimuddin, M Gupta, F Chen, JK Everett, KA Alexander, E Lin-Shiao, MH Gee, X Liu, RM Young, D Ambrose, Y Wang, J Xu, MS Jordan, KT Marcucci, BL Levine, KC Garcia, Y Zhao, M Kalos, DL Porter, RM Kohli, SF Lacey, SL Berger, FD Bushman, CH June, JJ Melenhorst
Nature 2018
Enhancing the potency and specificity of engineered T cells for cancer treatment
S Sukumaran, N Watanabe, P Bajgain, K Raja, S Mohammed, WE Fisher, MK Brenner, AM Leen, JF Vera
Cancer Discovery 2018
Cytokine release syndrome
A Shimabukuro-Vornhagen, P Gödel, M Subklewe, HJ Stemmler, HA Schlößer, M Schlaak, M Kochanek, B Böll, MS von Bergwelt-Baildon
Journal for ImmunoTherapy of Cancer 2018
Extracellular NGFR Spacers Allow Efficient Tracking and Enrichment of Fully Functional CAR-T Cells Co-Expressing a Suicide Gene
M Casucci, L Falcone, B Camisa, M Norelli, S Porcellini, A Stornaiuolo, F Ciceri, C Traversari, C Bordignon, C Bonini, A Bondanza
Frontiers in immunology 2018
The application of CAR-T cell therapy in hematological malignancies: advantages and challenges
Z Zhao, Y Chen, NM Francisco, Y Zhang, M Wu
Acta pharmaceutica Sinica. B 2018
Genetically enhanced T lymphocytes and the intensive care unit
T Tat, H Li, CS Constantinescu, A Onaciu, S Chira, C Osan, S Pasca, B Petrushev, V Moisoiu, WT Micu, C Berce, S Tranca, D Dima, I Berindan-Neagoe, J Shen, C Tomuleasa, L Qian
Oncotarget 2018
Chimeric antigen receptor modified T-cells for cancer treatment
X Han, Y Wang, WD Han
Chronic Diseases and Translational Medicine 2018
Chimeric antigen receptor-modified T cell therapy in chronic lymphocytic leukemia
Y Zou, W Xu, J Li
Journal of Hematology & Oncology 2018
Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management
JN Brudno, JN Kochenderfer
Blood Reviews 2018
Mechanisms and Management of Chimeric Antigen Receptor T-Cell Therapy-Related Toxicities
BR Dholaria, CA Bachmeier, F Locke
BioDrugs 2018
Carbohydrate Targets for CAR T Cells in Solid Childhood Cancers
C Rossig, S Kailayangiri, S Jamitzky, B Altvater
Frontiers in Oncology 2018
Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma
CM Bollard, T Tripic, CR Cruz, G Dotti, S Gottschalk, V Torrano, O Dakhova, G Carrum, CA Ramos, H Liu, MF Wu, AN Marcogliese, C Barese, Y Zu, DY Lee, O OConnor, AP Gee, MK Brenner, HE Heslop, CM Rooney
Journal of Clinical Oncology 2018
Delayed Terminal Ileal Perforation in a Relapsed/refractory B-Cell Lymphoma Patient with Rapid Remission Following Chimeric Antigen Receptor T-Cell Therapy
Y Hu, J Wang, C Pu, K Zhao, Q Cui, G Wei, W Wu, L Xiao, Y Xiao, J Wang, Z Wu, H Huang
Cancer Research and Treatment 2018
Cytokine Release Syndrome Grade is a Predictive Marker for Infections in Relapsed or Refractory B-cell All Patients Treated with CAR T Cells
JH Park, FA Romero, Y Taur, M Sadelain, RJ Brentjens, TM Hohl, SK Seo
Clinical Infectious Diseases 2018
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
JH Park, I Rivière, M Gonen, X Wang, B Sénéchal, KJ Curran, C Sauter, Y Wang, B Santomasso, E Mead, M Roshal, P Maslak, M Davila, RJ Brentjens, M Sadelain
New England Journal of Medicine 2018
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
SL Maude, TW Laetsch, J Buechner, S Rives, M Boyer, H Bittencourt, P Bader, MR Verneris, HE Stefanski, GD Myers, M Qayed, BD Moerloose, H Hiramatsu, K Schlis, KL Davis, PL Martin, ER Nemecek, GA Yanik, C Peters, A Baruchel, N Boissel, F Mechinaud, A Balduzzi, J Krueger, CH June, BL Levine, P Wood, T Taran, M Leung, KT Mueller, Y Zhang, K Sen, D Lebwohl, MA Pulsipher, SA Grupp
New England Journal of Medicine 2018
Absence of Replication-Competent Lentivirus in the Clinic: Analysis of Infused T Cell Products
K Cornetta, L Duffy, CJ Turtle, M Jensen, S Forman, G Binder-Scholl, T Fry, A Chew, DG Maloney, CH June
Molecular Therapy 2018
Engineered T lymphocytes eliminate lung metastases in models of pancreatic cancer
Q Sun, S Zhou, J Zhao, C Deng, R Teng, Y Zhao, J Chen, J Dong, M Yin, Y Bai, H Deng, J Wen
Oncotarget 2018
T Cells Genetically Modified to Express an Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma
JN Brudno, I Maric, SD Hartman, JJ Rose, M Wang, N Lam, M Stetler-Stevenson, D Salem, C Yuan, S Pavletic, JA Kanakry, SA Ali, L Mikkilineni, SA Feldman, DF Stroncek, BG Hansen, J Lawrence, R Patel, F Hakim, RE Gress, JN Kochenderfer
Journal of Clinical Oncology 2018
Clinical and Biologic Correlates of Neurotoxicity Associated with CAR T Cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia (B-ALL)
BD Santomasso, JH Park, D Salloum, I Rivière, J Flynn, E Mead, E Halton, X Wang, B Senechal, T Purdon, JR Cross, H Liu, B Vachha, , LM DeAngelis, D Li, Y Bernal, M Gonen, HG Wendel, M Sadelain, RJ Brentjens
Cancer Discovery 2018
Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML
S Haubner, F Perna, T Köhnke, C Schmidt, S Berman, C Augsberger, FM Schnorfeil, C Krupka, FS Lichtenegger, X Liu, P Kerbs, S Schneider, KH Metzeler, K Spiekermann, W Hiddemann, PA Greif, T Herold, M Sadelain, M Subklewe
Leukemia 2018
Current Status of Gene Engineering Cell Therapeutics
A Saudemont, L Jespers, T Clay
Frontiers in immunology 2018
Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy
Z Wang, W Han
Biomarker Research 2018
Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia
MY Kim, KR Yu, SS Kenderian, M Ruella, S Chen, TH Shin, AA Aljanahi, D Schreeder, M Klichinsky, O Shestova, MS Kozlowski, KD Cummins, X Shan, M Shestov, A Bagg, JJ Morrissette, P Sekhri, CR Lazzarotto, KR Calvo, DB Kuhns, RE Donahue, GK Behbehani, SQ Tsai, CE Dunbar, S Gill
Cell 2018
CARs and other T cell therapies for MM: The clinical experience
S Danhof, M Hudecek, EL Smith
Best practice & research. Clinical haematology 2018
Acute myeloid leukemia chimeric antigen receptor T-cell immunotherapy: how far up the road have we traveled?
SK Tasian
Therapeutic Advances in Hematology 2018
CD19 CAR-T cell therapy for relapsed/refractory acute lymphoblastic leukemia: factors affecting toxicities and long-term efficacies
LN Zhang, Y Song, D Liu
Journal of Hematology & Oncology 2018
Chimeric Antigen Receptor-T Cell Therapy: Practical Considerations for Implementation in Europe
J Buechner, MJ Kersten, M Fuchs, F Salmon, U Jäger
2018
Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel
D Porter, N Frey, PA Wood, Y Weng, SA Grupp
Journal of Hematology & Oncology 2018
Chimeric antigen receptor T cells form nonclassical and potent immune synapses driving rapid cytotoxicity
AJ Davenport, RS Cross, KA Watson, Y Liao, W Shi, HM Prince, PA Beavis, JA Trapani, MH Kershaw, DS Ritchie, PK Darcy, PJ Neeson, MR Jenkins
Proceedings of the National Academy of Sciences 2018
Enhanced Expression of Anti-CD19 Chimeric Antigen Receptor in piggyBac Transposon-Engineered T Cells
D Morita, N Nishio, S Saito, M Tanaka, N Kawashima, Y Okuno, S Suzuki, K Matsuda, Y Maeda, MH Wilson, G Dotti, CM Rooney, Y Takahashi, Y Nakazawa
Molecular Therapy — Methods & Clinical Development 2018
Producing proT cells to promote immunotherapies
J Singh, JC Zúñiga-Pflücker
International Immunology 2018
The biological basis and clinical symptoms of CAR-T therapy-associated toxicites
A Titov, A Petukhov, A Staliarova, D Motorin, E Bulatov, O Shuvalov, SM Soond, M Piacentini, G Melino, A Zaritskey, NA Barlev
Cell Death and Disease 2018
Principles of adoptive T cell therapy in cancer
Ö Met, KM Jensen, CA Chamberlain, M Donia, IM Svane
Seminars in Immunopathology 2018
CD70 as a target for chimeric antigen receptor T cells in head and neck squamous cell carcinoma
YP Park, L Jin, KB Bennett, D Wang, KM Fredenburg, JE Tseng, LJ Chang, J Huang, EK Chan
Oral Oncology 2018
Influence of various medium environment to in vitro human T cell culture
H Xu, N Wang, W Cao, L Huang, J Zhou, L Sheng
In vitro cellular & developmental biology. Animal 2018
Diagnosis and management of pulmonary toxicity associated with cancer immunotherapy
S Rashdan, JD Minna, DE Gerber
The lancet. Respiratory medicine 2018
Human CD19-Targeted Mouse T Cells Induce B Cell Aplasia and Toxicity in Human CD19 Transgenic Mice
CA Pennell, JL Barnum, CS McDonald-Hyman, A Panoskaltsis-Mortari, MJ Riddle, Z Xiong, M Loschi, G Thangavelu, HM Campbell, MD Storlie, Y Refaeli, SN Furlan, MC Jensen, LS Kean, JS Miller, J Tolar, MJ Osborn, BR Blazar
Molecular Therapy 2018
Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Acute Lymphoblastic Leukemia; Current Evidence, and Improving Outcomes Going Forward
JT Leonard, B Hayes-Lattin
Current Hematologic Malignancy Reports 2018
The promise of CAR T-cell therapy in aggressive B-cell lymphoma
R Nair, SS Neelapu
Best practice & research. Clinical haematology 2018
Development and Evaluation of an Optimal Human Single-Chain Variable Fragment-Derived BCMA-Targeted CAR T Cell Vector
EL Smith, M Staehr, R Masakayan, IJ Tatake, TJ Purdon, X Wang, P Wang, H Liu, Y Xu, SC Garrett-Thomson, SC Almo, I Riviere, C Liu, RJ Brentjens
Molecular Therapy 2018
Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy
J Gauthier, CJ Turtle
Current Research in Translational Medicine 2018
Selection of Tumor-Specific Cytotoxic T Lymphocytes in Acute Myeloid Leukemia Patients Through the Identification of T-Cells Capable to Establish Stable Interactions With the Leukemic Cells: “Doublet Technology”
E García-Guerrero, LI Sánchez-Abarca, E Domingo, TL Ramos, JA Bejarano-García, JA Gonzalez-Campos, T Caballero-Velázquez, JA Pérez-Simón
Frontiers in immunology 2018
Single-cell technologies for profiling T cells to enable monitoring of immunotherapies
X An, N Varadarajan
Current Opinion in Chemical Engineering 2018
PiggyBac-Engineered T Cells Expressing CD19-Specific CARs that Lack IgG1 Fc Spacers Have Potent Activity against B-ALL Xenografts
DC Bishop, N Xu, B Tse, TA OBrien, DJ Gottlieb, A Dolnikov, KP Micklethwaite
Molecular Therapy 2018
PD1-CD28 Fusion Protein Enables CD4+ T Cell Help for Adoptive T Cell Therapy in Models of Pancreatic Cancer and Non-hodgkin Lymphoma
F Rataj, FB Kraus, M Chaloupka, S Grassmann, C Heise, BL Cadilha, P Duewell, S Endres, S Kobold
Frontiers in immunology 2018
Cancer Immunotherapy in Diffuse Large B-Cell Lymphoma
J Zhang, LJ Medeiros, KH Young
Frontiers in Oncology 2018
CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease
KC Pehlivan, BB Duncan, DW Lee
Current Hematologic Malignancy Reports 2018
Engineering a Dual Small Molecule Gated ZAP70 Switch in T Cells
NM Wong, WW Wong
ACS Synthetic Biology 2018
Selection of a novel CD19 aptamer for targeted delivery of doxorubicin to lymphoma cells
Y Hu, X Li, Y An, J Duan, XD Yang
Oncotarget 2018
Chimeric Antigen Receptor T-Cells (CAR T-Cells) for Cancer Immunotherapy – Moving Target for Industry?
P Salmikangas, N Kinsella, P Chamberlain
Pharmaceutical Research 2018
Neurologic adverse events in patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab: management and mitigating factors
AS Stein, G Schiller, R Benjamin, C Jia, A Zhang, M Zhu, Z Zimmerman, MS Topp
Annals of Hematology 2018
CAR T cells find strength in polyfunction
ML Davila
Blood 2018
Hematopoietic Stem Cell Transplantation in the Era of Engineered Cell Therapy
JS Appelbaum, F Milano
Current Hematologic Malignancy Reports 2018
A fifty-year odyssey: prospects for a cytomegalovirus vaccine in transplant and congenital infection
DJ Diamond, CL Rosa, F Chiuppesi, H Contreras, S Dadwal, F Wussow, S Bautista, R Nakamura, JA Zaia
Expert Review of Vaccines 2018
Neurotoxicity Associated with CD19-Targeted CAR-T Cell Therapies
J Gust, A Taraseviciute, CJ Turtle
CNS Drugs 2018
The Modified Vaccination Technique
A Barabas, C Cole, Z Kovacs, E Kovacs, R Lafreniere
Human vaccines 2018
No free rides: management of toxicities of novel immunotherapies in ALL, including financial
T Jain, MR Litzow
Blood Advances 2018
Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance
MM Boyiadzis, MV Dhodapkar, RJ Brentjens, JN Kochenderfer, SS Neelapu, MV Maus, DL Porter, DG Maloney, SA Grupp, CL Mackall, CH June, MR Bishop
Journal for ImmunoTherapy of Cancer 2018
CAR T cells targeting α v β 3 integrin are effective against advanced cancer in preclinical models
L Wallstabe, A Mades, S Frenz, H Einsele, C Rader, M Hudecek
2018
No free rides: management of toxicities of novel immunotherapies in ALL, including financial
T Jain, MR Litzow
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program 2018
Are CAR T cells better than antibody or HCT therapy in B-ALL?
MA Pulsipher
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program 2018
Biological Consequences of MHC-II Expression by Tumor Cells in Cancer
ML Axelrod, RS Cook, DB Johnson, JM Balko
Clinical cancer research 2018
Recent advances in the biology and treatment of B-cell acute lymphoblastic leukemia
M Hefazi, MR Litzow
Blood and Lymphatic Cancer: Targets and Therapy 2018
A novel method to generate T-cell receptor–deficient chimeric antigen receptor T cells
T Kamiya, D Wong, YT Png, D Campana
Blood Advances 2018
Treatment of Older Patients with Acute Lymphoblastic Leukaemia.
Gökbuget N
Drugs & Aging 2018
[Anti-CD19 chimeric antigen receptors T cells for treatment of relapsed or refractory E2A-PBX1 positive acute lymphoblastic leukemia: three cases report and literatures review].
Yang F, Zhang J, Qiu HY, Wu Q, Kong DQ, Han JJ, Qi JQ, Han Y, Wu DP
Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 2018
CAR T cells: The future is already present.
Sánchez-Escamilla M, Yáñez San Segundo L, Urbano-Ispizua Á, Perales MÁ
2018
[Safety and efficacy of chimeric antigen receptor T cell in the treatment of elderly patients with hematological malignancies].
Liu D, Ke P, Huo L, Hu XH, Fu CC, Li CX, Huang HW, Xue SL, Qiu HY, Wu DP, Ma X
Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 2018
[An experimental study of CD4 targeted chimeric antigen receptor modified T cell with anti-lymphoma activity].
Chen GH, Huang HW, Wang Y, Liu HW, Xu LJ, Ma X, Xue SL, He XF, Wang Y, Gu B, Li CX, Qiu HY, Tang XW, Jin ZM, Miao M, Sun AN, Wu DP
Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 2018
我如何诊疗CAR-T细胞治疗相关细胞因子释放综合征
2018
一种新的高亲和力的人源化抗CD19 CAR-T细胞的构建及体外功能验证
2018
Effect of transplant status in CD19-targeted CAR T-cell therapy: a systematic review and meta-analysis.
Nagle K, Tafuto B, Palladino Kim L, Parrott JS
Medical Oncology 2018
Tisagenlecleucel for the treatment of B-cell acute lymphoblastic leukemia
Leahy AB, Elgarten CW, Grupp SA, Maude SL, Teachey DT
Expert Review of Anticancer Therapy 2018
Recent progress in improving the safety and efficacy of chimeric antigen receptor T cell therapy
Yang Y, Hu Y, Wang J, Huang H
2018
A dynamical systems perspective on chimeric antigen receptor T-cell dosing.
Toor AA, Chesney A, Zweit J, Reed J, Hashmi SK
Bone marrow transplantation 2018
Clinical and Immunological Responses after CD30-specific Chimeric Antigen Receptor redirected Lymphocytes
Carlos Ramos, Brandon Ballard, Huimin Zhang, Olga Dakhova, Adrian Gee, Zhuyong Mei, Mrinalini Bilgi, Meng-Fen Wu, Hao Liu, Bambi Grilley, Catherine M. Bollard, Bill Chang, Cliona Rooney, Malcolm Brenner, Helen Heslop, Gianpietro Dotti, Barbara Savoldo
Journal of Clinical Investigation 2017
Inhibition of AKT-signaling uncouples T-cell differentiation from expansion for receptor-engineered adoptive immunotherapy
Christopher Klebanoff, Joseph G. Crompton, Anthony Leonardi, Tori Yamamoto, Smita Chandran, Robert Eil, Madhusudhanan Sukumar, Suman Kumar Vodnala, Jinhui Hu, Yun Ji, David Clever, Mary Black, Devikala Gurusamy, Michael Kruhlak, Ping Jin, David Stroncek, Luca Gattinoni, Steven A. Feldman, Nicholas Restifo
JCI Insight 2017
Fine-tuning the CAR spacer improves T-cell potency
N Watanabe, P Bajgain, S Sukumaran, S Ansari, HE Heslop, CM Rooney, MK Brenner, AM Leen, JF Vera
OncoImmunology 2017
Trial Watch: Adoptively transferred cells for anticancer immunotherapy
C Fournier, F Martin, L Zitvogel, G Kroemer, L Galluzzi, L Apetoh
OncoImmunology 2017
Novel Immunotherapies for Multiple Myeloma
M DAgostino, M Boccadoro, EL Smith
Current Hematologic Malignancy Reports 2017
T memory stem cells in health and disease
L Gattinoni, DE Speiser, M Lichterfeld, C Bonini
Nature Medicine 2017
CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma
A Heczey, CU Louis, B Savoldo, O Dakhova, A Durett, B Grilley, H Liu, MF Wu, Z Mei, A Gee, B Mehta, H Zhang, N Mahmood, H Tashiro, HE Heslop, G Dotti, CM Rooney, MK Brenner
Molecular Therapy 2017
Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels
JN Kochenderfer, RP Somerville, T Lu, V Shi, A Bot, J Rossi, A Xue, SL Goff, JC Yang, RM Sherry, CA Klebanoff, US Kammula, M Sherman, A Perez, CM Yuan, T Feldman, JW Friedberg, MJ Roschewski, SA Feldman, L McIntyre, MA Toomey, SA Rosenberg
Journal of Clinical Oncology 2017
CAR T-cell therapy for pancreatic cancer
CJ DeSelm, ZE Tano, AM Varghese, PS Adusumilli
Journal of Surgical Oncology 2017
Chimeric Antigen Receptors: A Cell and Gene Therapy Perspective
I Rivière, M Sadelain
Molecular Therapy 2017
Immunotherapy in hematologic malignancies: past, present, and future
A Im, SZ Pavletic
Journal of Hematology & Oncology 2017
Therapeutic T cell engineering
M Sadelain, I Rivière, S Riddell
Nature 2017
Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains
L Alabanza, M Pegues, C Geldres, V Shi, JJ Wiltzius, SA Sievers, S Yang, JN Kochenderfer
Molecular Therapy 2017
Chimeric antigen receptor T-cell therapies for lymphoma
JN Brudno, JN Kochenderfer
Nature Reviews Clinical Oncology 2017
Integrating Proteomics and Transcriptomics for Systematic Combinatorial Chimeric Antigen Receptor Therapy of AML
F Perna, SH Berman, RK Soni, J Mansilla-Soto, J Eyquem, M Hamieh, RC Hendrickson, CW Brennan, M Sadelain
Cancer Cell 2017
Stop and go: hematopoietic cell transplantation in the era of chimeric antigen receptor T cells and checkpoint inhibitors
A Ghosh, I Politikos, MA Perales
Current Opinion in Oncology 2017
CAR T cell therapy for multiple myeloma: where are we now and where are we headed?
A Ghosh, S Mailankody, SA Giralt, CO Landgren, EL Smith, RJ Brentjens
Leukemia & Lymphoma 2017
CARs: Synthetic Immunoreceptors for Cancer Therapy and Beyond
ZN Chang, YY Chen
Trends in Molecular Medicine 2017
Chimeric Antigen Receptor (CAR) T Cells: Lessons Learned from Targeting of CD19 in B-Cell Malignancies
KA Hay, CJ Turtle
Drugs 2017
An Update on the Use of Immunotherapy in the Treatment of Lymphoma
TU Marron, M Kalac, J Brody
Current Hematologic Malignancy Reports 2017
Adoptive T-Cell Therapy for Solid Tumors
O Yeku, X Li, RJ Brentjens
American Society of Clinical Oncology Educational Book 2017
A CD200R-CD28 fusion protein appropriates an inhibitory signal to enhance T-cell function and therapy of murine leukemia
SK Oda, AW Daman, NM Garcia, F Wagener, TM Schmitt, X Tan, AG Chapuis, PD Greenberg
Blood 2017
New development in CAR-T cell therapy
Z Wang, Z Wu, Y Liu, W Han
Journal of Hematology & Oncology 2017
Incorporation of a hinge domain improves the expansion of chimeric antigen receptor T cells
L Qin, Y Lai, R Zhao, X Wei, J Weng, P Lai, B Li, S Lin, S Wang, Q Wu, Q Liang, Y Li, X Zhang, Y Wu, P Liu, Y Yao, D Pei, X Du, P Li
Journal of Hematology & Oncology 2017
Current status and perspectives of chimeric antigen receptor modified T cells for cancer treatment
Z Wang, Y Guo, W Han
Protein & Cell 2017
Building upon the success of CART19: chimeric antigen receptor T cells for hematologic malignancies
A Rotolo, A Karadimitris, M Ruella
Leukemia & Lymphoma 2017
Tonic 4-1BB Costimulation in Chimeric Antigen Receptors Impedes T Cell Survival and Is Vector-Dependent
D Gomes-Silva, M Mukherjee, M Srinivasan, G Krenciute, O Dakhova, Y Zheng, JM Cabral, CM Rooney, JS Orange, MK Brenner, M Mamonkin
Cell Reports 2017
Development of T cell immunotherapy for hematopoietic stem cell transplantation recipients at risk of leukemia relapse
RG Dossa, T Cunningham, D Sommermeyer, I Medina-Rodriguez, MA Biernacki, K Foster, M Bleakley
Blood 2017
Restoring Natural Killer Cell Immunity against Multiple Myeloma in the Era of New Drugs
G Pittari, L Vago, M Festuccia, C Bonini, D Mudawi, L Giaccone, B Bruno
Frontiers in immunology 2017
Ex vivo Akt inhibition promotes the generation of potent CD19CAR T cells for adoptive immunotherapy
R Urak, M Walter, L Lim, CL Wong, LE Budde, S Thomas, SJ Forman, X Wang
Journal for ImmunoTherapy of Cancer 2017
TCR engagement negatively affects CD8 but not CD4 CAR T cell expansion and leukemic clearance
Y Yang, ME Kohler, CD Chien, CT Sauter, E Jacoby, C Yan, Y Hu, K Wanhainen, H Qin, TJ Fry
Science Translational Medicine 2017
The Principles of Engineering Immune Cells to Treat Cancer
WA Lim, CH June
Cell 2017
Considerations in T Cell Therapy Product Development for B Cell Leukemia and Lymphoma Immunotherapy
AD Fesnak, PJ Hanley, BL Levine
Current Hematologic Malignancy Reports 2017
Preclinical and clinical advances in transposon-based gene therapy
J Tipanee, YC Chai, T VandenDriessche, MK Chuah
Bioscience Reports 2017
Integration of a CD19 CAR into the TCR Alpha Chain Locus Streamlines Production of Allogeneic Gene-Edited CAR T Cells
DT MacLeod, J Antony, AJ Martin, RJ Moser, A Hekele, KJ Wetzel, AE Brown, MA Triggiano, JA Hux, CD Pham, VV Bartsevich, CA Turner, J Lape, S Kirkland, CW Beard, J Smith, ML Hirsch, MG Nicholson, D Jantz, B McCreedy
Molecular Therapy 2017
Chimeric antigen receptor engineered stem cells: a novel HIV therapy
A Zhen, MA Carrillo, SG Kitchen
Immunotherapy 2017
T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas: Sarcoma Immune Microenvironment
SM Pollack, Q He, JH Yearley, R Emerson, M Vignali, Y Zhang, MW Redman, KK Baker, S Cooper, B Donahue, ET Loggers, LD Cranmer, MB Spraker, YD Seo, VG Pillarisetty, RW Ricciotti, BL Hoch, TK McClanahan, E Murphy, WM Blumenschein, SM Townson, S Benzeno, SR Riddell, RL Jones
Cancer 2017
Obstacles Posed by the Tumor Microenvironment to T cell Activity: A Case for Synergistic Therapies
KG Anderson, IM Stromnes, PD Greenberg
Cancer Cell 2017
Fully human CD19-specific chimeric antigen receptors for T-cell therapy
D Sommermeyer, T Hill, SM Shamah, AI Salter, Y Chen, KM Mohler, SR Riddell
Leukemia 2017
Chimeric Antigen Receptor Therapy in Acute Lymphoblastic Leukemia Clinical Practice
MR Luskin, DJ DeAngelo
Current Hematologic Malignancy Reports 2017
Intent to treat leukemia remission by CD19CAR T cells of defined formulation and dose in children and young adults
RA Gardner, O Finney, C Annesley, H Brakke, C Summers, K Leger, M Bleakley, C Brown, S Mgebroff, K Spratt, V Hoglund, C Lindgren, AP Oron, D Li, SR Riddell, JR Park, MC Jensen
Blood 2017
Chimeric-antigen receptor T (CAR-T) cell therapy for solid tumors: challenges and opportunities
AL Xia, XC Wang, YJ Lu, XJ Lu, B Sun
Oncotarget 2017
Reversible Transgene Expression Reduces Fratricide and Permits 4-1BB Costimulation of CAR T Cells Directed to T-cell Malignancies
M Mamonkin, M Mukherjee, M Srinivasan, S Sharma, D Gomes-Silva, F Mo, G Krenciute, JS Orange, MK Brenner
Cancer immunology research 2017
Next-Generation Chimeric Antigen Receptor T-Cell Therapy: Going off the Shelf
M Ruella, SS Kenderian
BioDrugs 2017
Antigen receptor-redirected T cells derived from hematopoietic precursor cellslack expression of the endogenous TCR/CD3 receptor and exhibit specific antitumor capacities
YV Caeneghem, SD Munter, P Tieppo, G Goetgeluk, K Weening, G Verstichel, S Bonte, T Taghon, G Leclercq, T Kerre, R Debets, D Vermijlen, H Abken, B Vandekerckhove
OncoImmunology 2017
Cells to prevent/treat relapse following allogeneic stem cell transplantation
AC Dietz, AS Wayne
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program 2017
Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma
FL Locke, SS Neelapu, NL Bartlett, T Siddiqi, JC Chavez, CM Hosing, A Ghobadi, LE Budde, A Bot, JM Rossi, Y Jiang, AX Xue, M Elias, J Aycock, J Wiezorek, WY Go
Molecular Therapy 2017
Cocktail treatment with EGFR-specific and CD133-specific chimeric antigen receptor-modified T cells in a patient with advanced cholangiocarcinoma
K Feng, Y Guo, Y Liu, H Dai, Y Wang, H Lv, J Huang, Q Yang, W Han
Journal of Hematology & Oncology 2017
CARs in the Lead Against Multiple Myeloma
M Ormhøj, F Bedoya, MJ Frigault, MV Maus
Current Hematologic Malignancy Reports 2017
Masked Chimeric Antigen Receptor for Tumor-Specific Activation
X Han, PD Bryson, Y Zhao, GE Cinay, S Li, Y Guo, N Siriwon, P Wang
Molecular Therapy 2017
Overall survival among older US adults with ALL remains low despite modest improvement since 1980: SEER analysis
MB Geyer, M Hsu, SM Devlin, MS Tallman, D Douer, JH Park
Blood 2017
Advances of CD19-directed chimeric antigen receptor-modified T cells in refractory/relapsed acute lymphoblastic leukemia
G Wei, L Ding, J Wang, Y Hu, H Huang
Experimental Hematology and Oncology 2017
The Why, what, and How of the New FACT standards for immune effector cells
MV Maus, S Nikiforow
Journal for ImmunoTherapy of Cancer 2017
Genome variation across cancers scales with tissue stiffness – An invasion-mutation mechanism and implications for immune cell infiltration
CR Pfeifer, CM Alvey, J Irianto, DE Discher
Current Opinion in Systems Biology 2017
Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia
SK Tasian, SS Kenderian, F Shen, M Ruella, O Shestova, M Kozlowski, Y Li, A Schrank-Hacker, JJ Morrissette, M Carroll, CH June, SA Grupp, S Gill
Blood 2017
Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor–Modified T Cells After Failure of Ibrutinib
CJ Turtle, KA Hay, LA Hanafi, D Li, S Cherian, X Chen, B Wood, A Lozanski, JC Byrd, S Heimfeld, SR Riddell, DG Maloney
Journal of Clinical Oncology 2017
CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies
D Gomes-Silva, M Srinivasan, S Sharma, CM Lee, DL Wagner, TH Davis, RH Rouce, G Bao, MK Brenner, M Mamonkin
Blood 2017
A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma
DM ORourke, ML Nasrallah, A Desai, JJ Melenhorst, K Mansfield, JJ Morrissette, M Martinez-Lage, S Brem, E Maloney, A Shen, R Isaacs, S Mohan, G Plesa, SF Lacey, JM Navenot, Z Zheng, BL Levine, H Okada, CH June, JL Brogdon, MV Maus
Science Translational Medicine 2017
Recent developments in immunotherapy of acute myeloid leukemia
FS Lichtenegger, C Krupka, S Haubner, T Köhnke, M Subklewe
Journal of Hematology & Oncology 2017
Chimeric antigen receptor T-cell therapy — assessment and management of toxicities
SS Neelapu, S Tummala, P Kebriaei, W Wierda, C Gutierrez, FL Locke, KV Komanduri, Y Lin, N Jain, N Daver, J Westin, AM Gulbis, ME Loghin, JF de Groot, S Adkins, SE Davis, K Rezvani, P Hwu, EJ Shpall
Nature Reviews Clinical Oncology 2017
Adnectin-Based Design of Chimeric Antigen Receptor for T Cell Engineering
X Han, GE Cinay, Y Zhao, Y Guo, X Zhang, P Wang
Molecular Therapy 2017
Engineering Synthetic Signaling Pathways with Programmable dCas9-Based Chimeric Receptors
TA Baeumler, AA Ahmed, TA Fulga
Cell Reports 2017
Novel immunotherapies for adult patients with B-lineage acute lymphoblastic leukemia
G Wei, J Wang, H Huang, Y Zhao
Journal of Hematology & Oncology 2017
Clinical development of CAR T cells—challenges and opportunities in translating innovative treatment concepts
J Hartmann, M SchüßlerLenz, A Bondanza, CJ Buchholz
EMBO Molecular Medicine 2017
Concurrent therapy of chronic lymphocytic leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia utilizing CD19-targeted CAR T-cells
MB Geyer, SH Manjunath, AG Evans, JH Park, ML Davila, CS Cutler, X Wang, Y Wang, B Senechal, I Rivière, M Sadelain, JL Liesveld, RJ Brentjens
Leukemia & Lymphoma 2017
Clinical trials of CAR-T cells in China
B Liu, Y Song, D Liu
Journal of Hematology & Oncology 2017
Phase I Escalating-Dose Trial of CAR-T Therapy Targeting CEA + Metastatic Colorectal Cancers
C Zhang, Z Wang, Z Yang, M Wang, S Li, Y Li, R Zhang, Z Xiong, Z Wei, J Shen, Y Luo, Q Zhang, L Liu, H Qin, W Liu, F Wu, W Chen, F Pan, X Zhang, P Bie, H Liang, G Pecher, C Qian
Molecular Therapy 2017
Overcoming the Immunosuppressive Tumor Microenvironment of Hodgkin Lymphoma Using Chimeric Antigen Receptor T Cells
M Ruella, M Klichinsky, SS Kenderian, O Shestova, A Ziober, DO Kraft, M Feldman, MA Wasik, CH June, S Gill
Cancer Discovery 2017
Driving better and safer HER2-specific CARs for cancer therapy
X Liu, N Zhang, H Shi
Oncotarget 2017
Cancer Immunotherapy Using CAR-T Cells: From the Research Bench to the Assembly Line
D Gomes-Silva, CA Ramos
Biotechnology Journal 2017
Integrating a 19F MRI Tracer Agent into the Clinical Scale Manufacturing of a T-Cell Immunotherapy
CF OHanlon, T Fedczyna, S Eaker, WD Shingleton, BM Helfer
Contrast Media & Molecular Imaging 2017
Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor–modified T-cell therapy
KA Hay, LA Hanafi, D Li, J Gust, WC Liles, MM Wurfel, JA López, J Chen, D Chung, S Harju-Baker, S Cherian, X Chen, SR Riddell, DG Maloney, CJ Turtle
Blood 2017
Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia
KT Mueller, SL Maude, DL Porter, N Frey, P Wood, X Han, E Waldron, A Chakraborty, R Awasthi, BL Levine, JJ Melenhorst, SA Grupp, CH June, SF Lacey
Blood 2017
Blockade of CD7 expression in T cells for effective chimeric antigen receptor targeting of T-cell malignancies
YT Png, N Vinanica, T Kamiya, N Shimasaki, E Coustan-Smith, D Campana
Blood Advances 2017
Study protocol for THINK: a multinational open-label phase I study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumour types
C Lonez, B Verma, A Hendlisz, P Aftimos, A Awada, EV Neste, G Catala, JP Machiels, F Piette, JB Brayer, DA Sallman, T Kerre, K Odunsi, ML Davila, DE Gilham, FF Lehmann
BMJ Open 2017
Endothelial Activation and Blood–Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells
J Gust, KA Hay, LA Hanafi, D Li, D Myerson, LF Gonzalez-Cuyar, C Yeung, WC Liles, M Wurfel, JA Lopez, J Chen, D Chung, S Harju-Baker, T Özpolat, KR Fink, SR Riddell, DG Maloney, CJ Turtle
Cancer Discovery 2017
Fluorine-19 nuclear magnetic resonance of chimeric antigen receptor T cell biodistribution in murine cancer model
F Chapelin, S Gao, H Okada, TG Weber, K Messer, ET Ahrens
Scientific Reports 2017
Development of novel target modules for retargeting of UniCAR T cells to GD2 positive tumor cells
N Mitwasi, A Feldmann, R Bergmann, N Berndt, C Arndt, S Koristka, A Kegler, J Jureczek, A Hoffmann, A Ehninger, M Cartellieri, S Albert, C Rossig, G Ehninger, J Pietzsch, J Steinbach, M Bachmann
Oncotarget 2017
Hematopoietic stem cell involvement in BCR-ABL1– positive ALL as a potential mechanism of resistance to blinatumomab therapy
I Nagel, M Bartels, J Duell, HH Oberg, S Ussat, H Bruckmueller, O Ottmann, H Pfeifer, H Trautmann, N Gökbuget, A Caliebe, D Kabelitz, M Kneba, HA Horst, D Hoelzer, MS Topp, I Cascorbi, R Siebert, M Brüggemann
Blood 2017
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
SS Neelapu, FL Locke, NL Bartlett, LJ Lekakis, DB Miklos, CA Jacobson, I Braunschweig, OO Oluwole, T Siddiqi, Y Lin, JM Timmerman, PJ Stiff, JW Friedberg, IW Flinn, A Goy, BT Hill, MR Smith, A Deol, U Farooq, P McSweeney, J Munoz, I Avivi, JE Castro, JR Westin, JC Chavez, A Ghobadi, KV Komanduri, R Levy, ED Jacobsen, TE Witzig, P Reagan, A Bot, J Rossi, L Navale, Y Jiang, J Aycock, M Elias, D Chang, J Wiezorek, WY Go
New England Journal of Medicine 2017
Infectious complications of CD19-targeted chimeric antigen receptor-modified T cell immunotherapy
JA Hill, D Li, KA Hay, ML Green, S Cherian, X Chen, SR Riddell, DG Maloney, M Boeckh, CJ Turtle
Blood 2017
Progress in adult ALL: incorporation of new agents to frontline treatment
J Leonard, W Stock
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program 2017
儿童急性髓系白血病靶向治疗进展
2017
Understanding cytokine release syndrome.
Gödel P, Shimabukuro-Vornhagen A, von Bergwelt-Baildon M
Intensive Care Medicine 2017
Adoptive T-Cell Therapy for Solid Tumors.
Yeku O, Li X, Brentjens RJ
2017
Is Disease-Specific Immunotherapy a Potential Reality for MDS?
Sallman DA, Davila ML
Clinical Lymphoma, Myeloma & Leukemia 2017
A Novel Strategy for Preventing Antigen-Loss Relapses after CD19-directed Immunotherapies
Marco Ruella, David Barrett, Saad S. Kenderian, Olga Shestova, Ted Hofmann, Jessica Perazzelli, Michael Klichinsky, Vania Aikawa, Farzana Nazimuddin, Miroslaw Kozlowski, John Scholler, Simon Lacey, Jan Melenhorst, Jennifer J.D. Morrissette, David A. Christian, Christopher A. Hunter, Michael Kalos, David Porter, Carl June, Stephan A. Grupp, Saar Gill
Journal of Clinical Investigation 2016
Targeted antibody-mediated depletion of CD19 CAR-T cells permanently reverses B cell aplasia
Paulina Paszkiewicz, Simon Fräßle, Shivani Srivastava, Daniel Sommermeyer, Michael Hudecek, Ingo Drexler, Michel Sadelain, Lingfeng Liu, Michael Jensen, Stanley R. Riddell, Dirk Busch
Journal of Clinical Investigation 2016
Longitudinal PET imaging demonstrates biphasic CAR-T cell responses in survivors
Yogindra Vedvyas, Enda Shevlin, Marjan Zaman, Irene Min, Alejandro Amor-Coarasa, Spencer Park, Susan Park, Keon-Woo Kwon, Turner Smith, Yonghua Luo, Dohyun Kim, Young Kim, Benedict Law, Richard Ting, John Babich, Moonsoo Jin
JCI Insight 2016
Recent advances in T-cell immunotherapy for haematological malignancies
RH Rouce, S Sharma, M Huynh, HE Heslop
British Journal of Haematology 2016
Generation of clinical-grade CD19-specific CAR-modified CD8+ memory stem cells for the treatment of human B-cell malignancies
M Sabatino, J Hu, M Sommariva, S Gautam, V Fellowes, JD Hocker, S Dougherty, H Qin, CA Klebanoff, TJ Fry, RE Gress, JN Kochenderfer, DF Stroncek, Y Ji, L Gattinoni
Blood 2016
Interleukin-15 enhances the proliferation, stimulatory phenotype, and antitumor effector functions of human gamma delta T cells
HH van Acker, S Anguille, Y Willemen, JM van Bergh, ZN Berneman, E Lion, EL Smits, VF van Tendeloo
Journal of Hematology & Oncology 2016
A Rapid Cell Expansion Process for Production of Engineered Autologous CAR-T Cell Therapies
TL Lu, O Pugach, R Somerville, SA Rosenberg, JN Kochenderfer, M Better, SA Feldman
Human Gene Therapy Methods 2016
Improving Adoptive T Cell Therapy: The Particular Role of T Cell Costimulation, Cytokines, and Post-Transfer Vaccination
A Redeker, R Arens
Frontiers in immunology 2016
Catch me if you can: Leukemia Escape after CD19-Directed T Cell Immunotherapies
M Ruella, MV Maus
Computational and Structural Biotechnology Journal 2016
Engineered T cells: the promise and challenges of cancer immunotherapy
AD Fesnak, CH June, BL Levine
Nature Reviews Cancer 2016
Does it make sense to target one tumor cell chemotactic factor or its receptor when several chemotactic axes are involved in metastasis of the same cancer?
MZ Ratajczak, M Suszynska, M Kucia
Clinical and Translational Medicine 2016
Review: Current clinical applications of chimeric antigen receptor (CAR) modified T cells
MB Geyer, RJ Brentjens
Cytotherapy 2016
Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease
CT Ellebrecht, VG Bhoj, A Nace, EJ Choi, X Mao, MJ Cho, GD Zenzo, A Lanzavecchia, JT Seykora, G Cotsarelis, MC Milone, AS Payne
Science 2016
Immunotherapy of non-Hodgkins lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells
CJ Turtle, LA Hanafi, C Berger, M Hudecek, B Pender, E Robinson, R Hawkins, C Chaney, S Cherian, X Chen, L Soma, B Wood, D Li, S Heimfeld, SR Riddell, DG Maloney
Science Translational Medicine 2016
Third-generation CD28/4-1BB chimeric antigen receptor T cells for chemotherapy relapsed or refractory acute lymphoblastic leukaemia: a non-randomised, open-label phase I trial protocol
XY Tang, Y Sun, A Zhang, GL Hu, W Cao, DH Wang, B Zhang, H Chen
BMJ Open 2016
Chimeric Antigen Receptor T Cells and Hematopoietic Cell Transplantation: How Not to Put the CART before the Horse
SS Kenderian, DL Porter, S Gill
Biology of Blood and Marrow Transplantation 2016
Toxicities of chimeric antigen receptor T cells: recognition and management
JN Brudno, JN Kochenderfer
Blood 2016
Chimeric Antigen Receptor T cells for B Cell Neoplasms: Choose the Right CAR for You
M Ruella, CH June
Current Hematologic Malignancy Reports 2016
Immunotherapy for acute lymphoblastic leukemia: from famine to feast
KL Davis, CL Mackall
Blood Advances 2016
Recent advances in T-cell engineering for use in immunotherapy
P Sharma, DM Kranz
F1000Research 2016
Immunotherapy for opportunistic infections: Current status and future perspectives
S Fuji, J Löffler, H Einsele, M Kapp
Virulence 2016
Prospects for chimeric antigen receptor (CAR) γδ T cells: A potential game changer for adoptive T cell cancer immunotherapy
HR Mirzaei, H Mirzaei, SY Lee, J Hadjati, BG Till
Cancer Letters 2016
Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy
Y Hu, J Sun, Z Wu, J Yu, Q Cui, C Pu, B Liang, Y Luo, J Shi, A Jin, L Xiao, H Huang
Journal of Hematology & Oncology 2016
Enhanced CAR T-cell engineering using non-viral Sleeping Beauty transposition from minicircle vectors
R Monjezi, C Miskey, T Gogishvili, M Schleef, M Schmeer, H Einsele, Z Ivics, M Hudecek
Leukemia 2016
Forecasting Cytokine Storms with New Predictive Biomarkers
RH Rouce, HE Heslop
Cancer Discovery 2016
Making urothelial carcinomas less immune to immunotherapy
JD Ramos, EY Yu
Urologic Oncology: Seminars and Original Investigations 2016
Redirecting T cells to eradicate B-cell acute lymphoblastic leukemia: bispecific T-cell engagers and chimeric antigen receptors
I Aldoss, RC Bargou, D Nagorsen, GR Friberg, PA Baeuerle, SJ Forman
Leukemia 2016
BCR-ABL–specific T-cell therapy in Ph + ALL patients on tyrosine-kinase inhibitors
P Comoli, S Basso, G Riva, P Barozzi, I Guido, A Gurrado, G Quartuccio, L Rubert, I Lagreca, D Vallerini, F Forghieri, M Morselli, P Bresciani, A Cuoghi, A Paolini, E Colaci, R Marasca, A Cuneo, L Iughetti, T Trenti, F Narni, R Foà, M Zecca, M Luppi, L Potenza
Blood 2016
New insights into effective targeted therapy for the treatment of adult acute lymphoblastic leukemia
X Thomas
International Journal of Hematologic Oncology 2016
Human Vaccines & Immunotherapeutics: News
Human Vaccines & Immunotherapeutics 2016
Pulmonary surfactant: an immunological perspective
ZC Chroneos, Z Sever-Chroneos, VL Shepherd
Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 2009

← Previous 1 2 3 … 46 47 Next →

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Picked up by 20 news outlets
Blogged by 3
Referenced in 1 policy sources
Posted by 34 X users
Referenced in 146 patents
On 5 Facebook pages
Referenced in 3 Wikipedia pages
Mentioned in 1 Google+ posts
Referenced in 3 clinical guideline sources
1538 readers on Mendeley
See more details